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ABSTRACT
The theonellamides are a family of compounds distinguished by their crosslinking τhistidinoalanine (τ-HAL) residue. Part one of this dissertation details the synthesis of an
orthogonally protected τ-HAL building block that will be incorporated into a total synthesis of
theonellamide C. Selective deprotection of each amine and acid of this orthogonally protected
building block is also demonstrated.
Various reaction partners for the assembly of τ-histidinoalanine were explored. One
approach involved the coupling of N-Fmoc-β-iodoalanine benzyl ester and (Nπim)-blocked
histidine nucleophiles including a fused bicyclic urea and a Boc-His(Nπ-Pac)-OMe. While the
imidazolium salts were identified by mass spectrometry, elimination of the iodide group was a
major side reaction.
Successful nucleophilic opening of a five-membered ring sulfamidate (derived from
Fmoc-D-Ser-OH) by Boc-L-His-OTCE led to preparation

of

a regiochemically and

stereochemically pure τ-HAL derivative. Thus, a new set of orthogonal protecting groups have
been identified: Fluorenylmethyloxycarbonyl (Fmoc), 2,2,2-trichloroethylester (TCE), tert-butyl
carbamate (Boc), and benzyl (Bn) ester.
Part two of this dissertation outlines the synthesis of a trimethyl lock-based prodrug
model system, wherein photothermal activation of a salt containing a cationic near-IR dye and
an anionic prodrug, releases a paclitaxel side-chain fragment via a tandem aryl Claisen
rearrangement and lactonization.
The prodrug model system was prepared via coupling of the paclitaxel sidechain alcohol
to an acid with a pendant substrate for the rearrangement-lactonization. Claisen
xx

rearrangement studies in various solvent systems on the release of the paclitaxel fragment
demonstrated that aqueous alcoholic solutions of allyl aryl ethers accelerated the
rearrangement relative to hydrocarbon solvents, temperatures achieved were still too high to
be feasible in biological systems. The 1,1-dimethylallyl group was identified for its rateaccelerating properties. Studies of the Claisen rearrangement in aqueous methanol
demonstrated that the aryl dimethylallyl ether derivatives rearranged significantly faster than
the unsubstituted allyl ethers. Moreover, electron donating groups facilitated the reaction.
A salt was formed from a cationic near-IR laser dye (IR-780) and 1-(1,1-dimethylallyl
ether)-4-benzoic acid, then suspended as nanoparticles in water. Photothermal studies of these
aggregated species are underway.
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CHAPTER 1: τ-HISTIDINOALANINE AND CHALLENGES ASSOCIATED WITH ITS SYNTHESIS IN A
TETRAORTHOGONALLY PROTECTED FORMAT
1.1 Introduction: Occurrence and Origin
Fujimoto and co-workers first isolated histidinoalanine (HAL) in 1982 from the
hydrolyzate of human dentin.1 This bis-amino acid cross-link can exist as two regioisomers, τHAL and π-HAL (Figure 1.1). HAL is derived from the covalent linkage formed between a
dehydroalanine residue coupling to the τ- or π-nitrogen on the imidazole of the histidine side
chain.

Figure 1.1: τ-Histidinoalanine and π-Histidinoalanine
Since its initial isolation, HAL has been identified from numerous sources.2
Histidinoalanine is produced in milk products that have been heated and/or treated with alkali,
and although the nutritional consequences are unknown, their stability to enzymes and
subsequent increase in protein crosslinks suggests some nutritional consequences.3

τ-

Histidinoalanine also occurs naturally in human tissues including dentin,4 eye cataracts,5 and
connective tissue. The connective tissue that is responsible for the elasticity in the aorta, which
is important for blood pressure, loses its elasticity over time. This has been attributed to
production of bis-amino acids like τ-HAL.1 Furthermore, HALs have been identified in
phosphoproteins of bivalve mollusks where they are integral to the process of mineralization.6

1

Although the biosynthetic mechanism of the formation of HAL is not known, it is
structurally similar to lanthionine and lysinoalanine crosslinks whose biosynthesis has been
studied extensively.7 Presumably, serine is phosphorylated to give phosphoserine that readily
undergoes β-elimination to yield dehydroalanine. By analogy to the formation of lanthionine
and lysinoalanine, in which thiol and ε-amino nucleophiles add to dehydroalanine, a histidine
residue is conjugated to dehydroalanine, giving histidinoalanine (Scheme 1.1).

Scheme 1.1: Formation of HAL by serine phosphorylation followed by β-elimination; then
conjugate addition
1.2 HAL in Theonellamides
Theonellamide C is bicyclic peptide from the genus Theonella, and is part of a family of
cyclic peptides, theonellamides A-F (Figure 1.2). These bis-macrocyclic peptides are
characterized by structurally interesting amino acid residues, such as (2S,4R)-α-amino--hydroxy
adipic

acid

(Ahad),

(3S,4S,5E,7E)-3-amino-8-(4-bromophenyl)-4-hydroxy-6-methyl-5,7-

octadienoic acid (Aboa), and erythro-β-hydroxyasparagine (eHyAsn). To-date, there has been no
reported total synthesis of a theonellamide, and there has been only one partial synthesis of
theonellamide F.8 Therefore, most bioactivity studies have been conducted using
theonellamide F obtained from isolation which has demonstrated moderate cytotoxic activity
towards P388 leukemia cells with IC50 values ranging from 0.9-5.0 µg/mL.9
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1-Theonellamide A
2-Theonellamide B
3-Theonellamide C
4-Theonellamide D
5-Theonellamide E
6-Theonellamide F
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Figure 1.2: Theonellamides A-F
Other natural products originating from the genus Theonella have shown promising
therapeutic potential.10 These marine natural products include theopalauamide,11 and
theonegramide.12 Biological and mechanistic studies of the structurally-related theopalauamide
have helped shed light on the mode of action of the theonellamides. Theonellamides have been
shown to recognize lipid bilayers containing cholesterol and other 3β-hydroxysterols and induce
1,3-β-D-glucan biosynthesis13 – both of which likely play a role in the compound’s antifungal
and cytotoxic effects. To understand how theonellamides recognize and bind to lipid bilayers
containing 3β-hydroxysterols, the Yoshida group conducted surface plasmon resonance (SPR)
and solid-state 2H-NMR experiments on theonellamide A and its interactions with sterols and
palmitoyloleoylphosphatidylcholine (POPC) liposomes containing cholesterol, ergosterol, or
epichlolesterol (Figure 1.3).14

Figure 1.3: Structures of 3β-hydroxysterols cholesterol and ergosterol, and 3α-hydroxysterol
epicholesterol
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Though they were not able to identify the exact chemistry behind these interactions,
they were able to demonstrate that theonellamide A undergoes a two-step binding process
with lipid bilayers, which involves interaction with cholesterol and other 3β-hydroxysterols
present. Because the theonellamides’ proposed mode of action is different from polyene
antibiotics which also interact with sterols, the Yoshida group postulated that theonellamides
“could be a new tool for exploring the function and localization of sterols in cells”.14
Theonellamides A-F all share a τ-HAL bridging residue. In theonellamides A, D, and E a
sugar moiety is attached to the π-nitrogen of the imidazole of the bridge (Figure 1.2) yet seems
to play no signiﬁcant role in the biological activity studied to-date. The τ-regioisomer of HAL
was found to be the only regioisomer in degradation studies of the theonellamides performed
by Matsunaga et al (Scheme 1.2).9a

Scheme 1.2: Degradation studies of histidinoalanine
Histidinoalanine was treated with KMnO4/NaIO4, resulting in the cleavage of the
imidazole ring to yield a 1:1 mixture of 2,3-diaminopropionic acid (Dpa) (11) and L-aspartic acid
(Asp) (12). Subsequent esterification of the amino acid residues, and treatment with
trifluoroacetic anhydride gave derivatives 13 and 14. The isolation of L-Asp designated L-His as
the naturally occurring stereoisomer, while an isolated 1:1 (D:L) mixture of Dpa , and later a 3:1
mixture strongly suggests D as the major isomer. These stereochemical assignments were
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further confirmed by derivatization of compounds 11 and 12 using both enantiomers of
Marfey’s reagent.8b
1.3 Retrosynthetic Analysis: Need for Flexible Protecting Group Strategy
Our goal is to synthesize theonellamide C via conjugation of the eastern hemisphere and
western hemisphere to the τ-HAL bridging residue. Synthetically, theonellamide C is the easiest
congener to make, requiring the synthesis of the least number of amino acids, prior to fragment
condensations and cyclizations. The theonellamides are the only example of a HAL residue in a
well-defined molecule. The three fragments include τ-HAL, and two pentapeptides, one which
includes Ahad and eHyAsn and makes up the western hemisphere and the other which includes
Aboa and encompasses the eastern hemisphere (Scheme 1.3). τ-Histidinoalanine has four
reactive sites, two carboxylic acids, and two amino groups. To direct coupling at the desired
sites, the reactivity of each site needs to be selectively activated and deactivated using
protecting groups. Therefore, it’s crucial to develop an orthogonally protected building block
that will be flexible enough to facilitate assembly of the eastern and western hemispheres
without competition of free functional groups present.
We chose four different protecting groups, each with different deprotection
mechanisms: trichloroethyl (TCE) and benzyl (Bn) esters along with fluorenylmethyloxycarbonyl
(Fmoc), and tert-butoxycarbonyl (Boc) carbamates (Scheme 1.3). In principle, each could be
selectively removed in the presence of one another.
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Scheme 1.3: Retrosynthetic analysis of τ-histidinoalanine
1.4 The Concept of Orthogonality vis-à-vis Protecting Groups
In 1977, Merrifield introduced the term ‘orthogonal’ to designate “[orthogonal
protecting groups are] classes of protecting groups which are removed by differing chemical
mechanisms. Therefore they can be removed in any order and in the presence of the other
classes".15 This distinction was made from the Boc and benzyl peptide protecting group
chemistry16 that utilized what is now called the modulated lability approach, which is the
process of chemoselectively removing two structurally similar functionalities under one
mechanism with graduated reactivity. Since then, with the discovery of more robust, tunable
protecting groups the application of the term ‘orthogonality’ has expanded in organic chemistry
to include orthogonal coupling reactions, chromatic orthogonality (a differentiation based on
the wavelength of light) and orthogonal chemical ligation of peptides (which we will not review)
just to name a few.
In a recent communication,17 Wong and Zimmerman outlined three main categories of
chemoselective transformations involving two orthogonal protecting groups. The three
categories: modulated lability, sequential orthogonal, and simultaneous transformations. As
mentioned earlier, Merrifield made use of the modulated lability approach during his original
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solid phase peptide synthesis. He was able to exploit the reactivity difference between Boc
carbamates and benzyl esters towards TFA which is 1000:1. By increasing the acidity, Merrifield
was able to remove the Boc group followed by the benzyl ester, while using a stronger acid (i.e.,
HF) removed both groups simultaneously and cleaved the peptide from the resin (Scheme
1.4).15

Scheme 1.4: Example of a modulated Lability Transformation – a ribonuclease A (RNase A)
fragment with a Boc N-terminus, and benzyl-based resin C-terminus
Sequential orthogonal transformation is the ability to arrive at the same substrate
regardless of the order of reagents used to effect deprotections. The Zhang group
demonstrated sequential orthogonal transformations during their deprotection of a tetraorthogonally protected galactose building block (Scheme 1.5).18 Building block 19 was treated
with HF-pyridine to remove the TBDPS group, leaving the chloroacetyl (ClAc) ester intact.
Subsequent treatment with TFA gave the diol 22 (Scheme 1.5, Route 1). If Route 2 was carried
out first, the PMB ether would be cleaved first. Subsequent TBDPS cleavage by HF-pyridine
would also give diol 22.

Scheme 1.5: Sequential Orthogonal Transformation
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1.4.1 Two Dimensional Orthogonal Protection: Solid Phase Peptide Synthesis
The most widely-utilized orthogonal protecting group pair in modern solid phase
peptide synthesis is the Fmoc carbamate and tert-butyl ester, ether, and carbamate.
Development of the Fmoc group by Carpino19 has made the Fmoc-tert-butyl strategy a mainstay
in modern solid phase peptide synthesis,20 due to the differing chemical mechanisms of
deprotection. Fmoc is cleaved with mild base via β-elimination, and tert-butyl based functional
groups by acid hydrolysis. This qualifies as a sequential orthogonal transformation. Sequential
orthogonal transformation fits within the traditional definition that Merrifield put forth, in that
using different reagents one can selectively deprotect a protecting group without affecting the
other.
The importance of orthogonal protecting group chemistry is readily illustrated in solid
phase peptide synthesis (SPPS). SPPS follows a series of steps, outlined generically in Scheme
1.6. In the Fmoc/tert-butyl strategy representation below, the α-nitrogen of the amino acid is
protected with the Fmoc group and the side chain functional groups can be protected as tertbutyl ethers, esters, or carbamates. This is an orthogonal protection system, since the side
chain protecting groups can be removed without displacing the N-terminal protection and vice
versa. For the sake of brevity we have highlighted the Fmoc/tert-butyl strategy, but understand
that there are a myriad of protecting groups used in solid phase peptide synthesis. This strategy
has allowed large libraries of very large peptides to be synthesized using automation, with large
pharmaceutical companies relying on this classical protection method to synthesize important
compounds in a short amount of time.20
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Scheme 1.6: A general representation of an Fmoc tert-butyl strategy (orthogonality based) for
peptide synthesis
1.5 Examples of the Use of Orthogonal Protecting Group Strategies
So far we have only discussed two dimensional orthogonal protection systems. There
are inherent challenges in developing higher dimensional systems, mainly mechanistic
compatibility and reagent sensitivity. There are a few examples in the literature where different
groups have attempted to tackle this challenge with varying degrees of success.
1.5.1 Tunable Protecting Groups
One technique is to create custom protecting groups which has the advantage of
tunability and tailoring the group with specific properties. This strategy is particularly useful for
oligosaccharides and monosaccharides which bear multiple hydroxyl groups with similar
reactivity. The Seeberger group adopted this strategy when developing halogenated benzyl
ether protecting groups for the synthesis of differentiated monosaccharides.21 These
specialized protecting groups allowed the assembly of a branched trisaccharide through facile
conversion of the blocking groups into labile arylamines by Pd-catalyzed amination (Scheme
1.7).22 They started with a penta-orthogonally protected monosaccharide 23, with three of the
hydroxyl groups bearing the para-halogenated benzyl protecting groups. They found that
different combinations of arylamines, acids, and phosphine ligands could selectively deprotect
each para-halogenated benzyl ether protecting group in the presence of each other.
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Scheme 1.7: Protocol for Pd-catalyzed amination and subsequent acid-catalyzed cascade
deprotection
They attributed the differences in reactivity to the relative reactivities of the halogens.
To convert the PIB group into its aryl group, they used N-methyl aniline, L1, and a protic acid to
give free alcohol 24, which was then glycosylated. These steps were repeated twice more, using
L2, N-methylaniline, and SnCl4 to remove the PBB group (Scheme 1.8, 25), and morpholine, L2,
and SnCl4 to remove the PCB group (Scheme 1.8, 26). Glycosylation gave compound 27 in 85%
yield.

Scheme 1.8: PCB: p-chlorobenzyl, PBB: p-bromobenzyl, PIB: p-iodobenzyl, L1: 1-(N,Ndimethylamino)-1′ (dicyclohexylphosphino)biphenyl, L2: (o-biphenyl)P(tBu)2 as defined in
Scheme 1.7
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Even though these specialized protecting groups are highly applicable for the synthesis of
saccharides, they are limited to one type of functional group (hydroxyl) and would have limited
utility on a more diverse molecule, bearing more diverse functional groups.
1.5.2 Protecting Group Free Synthesis
Another popular strategy is to avoid protecting groups and instead rely on the inherent
chemoselectivity of different functional groups. It is generally understood that each protecting
group adds two overall steps to a synthetic route for introduction and removal. Eliminating
protecting/leaving group manipulations could streamline the assembly of many complex
natural products and biomolecules. Through the use of carefully screened reagents and
reaction conditions Baran and coworkers were able to demonstrate the protecting-group free
synthesis of hapalindole Q (Scheme 1.9).23 To achieve this they had to develop new reaction
chemistry. It was found that treating a solution of indole (28) and carvone (29) with lithium
hexamethyldisilazide (LiHMDS) gave anions 30 and 31. Subsequent oxidation in the same pot
with copper (II) 2-ethylhexanoate led to a direct coupling of the indole C3 position and the αposition of carvone to produce compound 34. Previous synthesis of this molecule employed a
tosyl protecting group on the nitrogen in the indole ring. However, this led to more steps in the
synthesis.24

Scheme 1.9: LiHMDS-mediated coupling of carvone and indole
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Adhering to this strategy has allowed Baran to synthesize many natural products
without the use of protecting groups. However, Baran admitted that the use of protecting
groups has led to the successful synthesis of many targeted compounds of varying complexity.
He states that the masking of competitive reaction sites offers an increased level of security and
predictability, which are important factors in total synthesis. With the large library of protecting
groups that have been developed, numerous creative retrosynthetic disconnections can be
proposed for a molecule that would most likely be impossible without the assistance of
protecting groups.25
1.5.3 Higher Dimensional Orthogonal System: Utilizing Resins as a Temporary Masking Group
In 1996, Hirschmann and Smith published the synthesis of a tricyclic homodetic peptide, an
analog of somatostatin.26 They employed a 5-dimensional orthogonal amino protection
strategy,26,27 a sequential selective deprotection of carboxyl groups alongside their amino
partner. They chose three different amine/carboxyl protecting group partners; Boc/tert-Butyl,
AIIoc/Allyl, and trityl/2-chlorotrityl solid support (Scheme 1.10).

Scheme 1.10: Deprotection scheme for precursor to Somatostatin analog 37 with protecting
groups
They treated peptide 36 with dilute TFA (0.75%) which resulted in the cleavage of the
trityl amine/2-chlorotrityl resin pair. This generated the unprotected Asp side chain and the β12

amino group of 2,3-diaminopropionic acid (Dpr). Following macrolactamization, the Alloc/Allyl
pair of protecting groups was cleaved using palladium, followed by ring formation to generate
ring A. Next, a stronger solution of TFA was used to remove the Boc/tert-butyl protecting
groups, and subsequent coupling led to formation of the final two rings B and C. Lastly, mild
base, followed by hydrogenolysis gave the analog of somatostatin.
The complexity of this peptide required a multi-stage protecting group strategy that
combined modulated lability and solid phase support. This method of using resins in tandem
with traditional solution phase protecting groups allows for the development of higher
dimensional orthogonal systems that wouldn’t be accessible by traditional protecting groups
alone. It should be noted that each group was taken off in a pre-determined sequence. The
order could not be rearranged without affecting multiple protecting groups, which in practice
prevents this method from being a true orthogonal protection scheme.
1.6 bis-Amino Acid Protecting Group Strategies
Lanthionines are closely related to histidinoalanine in biological assembly and role as a
bridging crosslink. Because the literature for syntheses of τ-HAL is very scarce, we looked to
syntheses of lanthionines as our most relevant building blocks for four-dimensional protecting
group strategies for bis-amino acids.
Lanthionines consist of two alanine residues that are linked at their β-carbons by a
thioether bridge (Figure 1.4). In lantibiotics,28,29 these lanthionines are embedded within cyclic
peptides. In addition, lantibiotics typically (but not always) contain the unsaturated amino acids
2,3-dehydroalanine (Dha) and (Z)-2,3-dehydrobutyrine (Dhb).
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Figure 1.4: Lanthione stereoisomers 38a, 38b, 38c
Lantibiotics are a class of post-translationally modiﬁed peptides that belong to the
family of bacteriocins. They possess high antimicrobial activity against a broad spectrum of
Gram-positive bacteria, including food pathogens (e.g. Listeria monocytogenes) and organisms
that exhibit resistance to conventional antibiotics (i.e. methicillin-resistant Staphylococcus
aureus or MRSA and vancomycin-resistant Enterococcus or VRE). They have been used in a
variety of applications including food preservation.
Lanthionines are a great test case for orthogonal protection methods because they
contain two carboxyl and two amino groups. There have been numerous publications on the
synthesis of orthogonally protected lanthionines,30 with the most commonly used protecting
group schemes including Boc/Fmoc/Alloc carbamates and trityl (Trt) amine for N-protection in
combination with tert-Bu/allyl esters. Each approach has used one or more strategies discussed
previously. While two-dimensional systems using traditional orthogonal protecting groups are
common (i.e., Boc/Fmoc carbamates), achieving quadruple orthogonal protection has proven to
be more challenging.
In 2011, Tadd and co-workers reported the synthesis of an “orthogonally” protected
disulfide bridge mimetic (Scheme 1.11), to be used in the synthesis of bicyclic peptides with
non-terminal disulfide bridges.31 To assemble the mimetic with the alkyne bridge, the Tadd
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group coupled a β-iodoalanine 40 with bromoacetylene 41 using copper-mediated
organozinc/haloalkyne chemistry.

Scheme 1.11: Disulfide bridge mimetic with protecting groups and deprotection conditions
To demonstrate the orthogonality of this building block, deprotections were conducted
(Scheme 1.12). They cleaved the Fmoc carbamate using standard diethylamine conditions,
giving the free amine 43 in high yield. They cleaved the methyl ester under hydrolysis
conditions in good yield using trimethyltin hydroxide, conditions pioneered by the Nicolaou
group with impressive selectivity for methyl esters.32 Because the Boc and tert-butyl groups are
removed via the same chemical mechanism, they had to use a modulated lability approach to
ensure chemoselectivity. They were able to cleave the Boc carbamate selectively using a 1 M
HCl solution. Due to Boc carbamates being more acid-sensitive than tert-butyl esters, selectivity
cannot be achieved, resulting in cleavage of both acid-labile groups when alkyne 39 was treated
with TFA. To mediate this, they reprotected the free amine as a phthalimide group to leave only
the free acid. This work-around does provide them with four substrates with different points of
attachment, but due to the double cleavage, adds another two steps and does not classify this
collection of protecting groups as completely orthogonal.
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Scheme 1.12: Deprotection scheme of disulfide bridge mimetic
The Tabor group claimed a “quadruply”-orthogonal protecting group strategy for the
on-resin synthesis of overlapping lanthionine rings.33 They synthesized two lanthionine
fragments, one with Pd(0) labile protecting groups: Alloc carbamate and allyl ester. The other
bore fluoride labile groups: 2-trimethylsilyslethoxycarbonyloxy (Teoc) carbamate, and
trimethylsilylethyl (TMSE) ester (Figure 1.5). Both substrates had orthogonal transient Fmoc
groups.

Figure 1.5: "Orthogonal" lanthionine Fragments
The carboxylic acid functional group in compound 46 was coupled to a N-im-trityl protected
histidine residue to give tripeptide 49. After the cleavage of the Fmoc group, lanthionine 47 was
introduced to afford 50, which contains two orthogonally protected LAN residues (Scheme
1.13).
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Scheme 1.13: Precursor to orthogonally protected linear peptide 50
Compound 50 was used to acylate a resin-bound serine, affording compound 51
(Scheme 1.14). In this approach, the Tabor group used an acid-labile Wang resin as one of their
protecting groups, as well as the modulated lability concept.

Scheme 1.14: Quadruply 'orthogonally' protected peptide fragment 51
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The allyl ester and Alloc carbamate were cleaved simultaneously using Pd(0), followed
by cleavage of the Fmoc moiety with a piperidine solution. (7-Azabenzotriazol-1yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyAOP) facilitated ring closure to form
ring E of the Nisin fragment, viz. compound 52. An alanine residue was added at the N-terminus
and then one hundred equivalents of TBAF was employed to cleave the Teoc and TMSE groups.
This allowed for the second ring closure facilitated by PyAOP to form ring D. The remaining free
amine was coupled to Fmoc-Lys(Boc)-OH, followed by global deprotection of the remaining
acid-labile protecting groups to give ring fragments D and E of nisin.
If these protecting groups are removed in a pre-determined order they could be
considered orthogonal to each other, however that does not fit the stringent definition put
forth by Merrifield. Notably, the TMSE group is susceptible to acidic reagents, and would not
remain intact under the global deprotection conditions.
1.7 Toward an Orthogonally Protected τ-HAL
To our knowledge, there is no synthesis of a tetra-orthogonally protected τhistidinoalanine in the literature. While routes to differentially protected bis-amino acids have
been explored, these routes either require a lengthy synthesis, solid-phase methods in
conjugation with solution-phase protecting groups, or do not possess the appropriate
protecting groups for our study. In Chapter 2, we will discuss the concise synthesis of an
orthogonally protected τ-HAL. Nucleophilic opening of a 5-membered ring sulfamidate by an
orthogonally protected histidine nucleophile allows for facile preparation of a regiochemically
and stereochemically pure τ-HAL derivative (Scheme 1.15).
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A

new

set

of

orthogonal

protecting

groups

have

been

proposed:

fluorenylmethyloxycarbonyl (Fmoc), 2,2,2-trichloroethylester (TCE), tert-butyl carbamate (Boc),
and benzyl (Bn) ester. These protecting groups are ideally suited for the preparation of diamino
dicarboxylic acids. Selective deprotection of each amine and acid of this orthogonally protected
building block is also demonstrated in Chapter 2.

Scheme 1.15: Retrosynthetic analysis of the synthesis of orthogonally protected τ-HAL
1.8 References
1. Fujimoto, D., Hirama, M., Iwashita, T. “Histidinoalanine, a new crosslinking amino acid, in
calcified tissue collagen” Biochem. Biophys. Res. Commun. 1982, 104, 1102-1106.
2. Taylor, C. M., Wang. W. “Histidinoalanine: a crosslinking amino acid” Tetrahedron 2007, 63,
9033-9047.
3. Henle, T., Walter, A. W., Klostermeyer, H. Z. “Detection and identification of the cross-linking
amino acids Nτ and Nπ-(2'-amino-2'-carboxy-ethyl)-L-histidine ("histidinoalanine", HAL) in
heated milk products” Lebensm.-Unters. Forsch. 1993, 197, 114-117.
4. Cloos, P. A. C., Jensen, A. L. “Age-related de-phosphorylation of proteins in dentin: a
biological tool for assessment of protein age,” Biogerontology 2000, 1, 341-356.
5. Kanayama, T., Miyanaga, Y., Horiuchi, K., Fujimoto, D. “Detection of the crosslinking amino
acid, histidinoalanine, in human brown cataractous lens protein,” Exp. Eye. Res. 1987, 44, 165169.
6. Sass, R. L., Marsh, M. E. “Histidinoalanine: a naturally occurring crosslinking amino acid,”
Methods Enzymol. 1984, 106, 351-355.
7. a) Zhu, Y., Gieselman, M. D., Zhou, H., Averin, O., van der Donk, W. A. “Biomimetic studies on
the mechanism of stereoselective lanthionine formation” Org. Biomol. Chem. 2003, 1, 33043315 b) Goto, Y., Li, B., Claesen, J., Shi, Y., Bibb, M. J., van der Donk, W. A. “Discovery of unique
lanthionine synthetases reveals new mechanistic and evolutionary insights” PLoS 2010, 8,
e1000339

19

8. a) Tohdo, K., Hamada, Y., Shioiri, T. “Synthesis of the northern hemisphere of theonellamide
F: A bicyclic dodecapeptide of marine origin” Synlett 1994, 4, 250 b) Tohdo, K., Hamada, Y.,
Shioiri, T. “Synthesis of the southern hemisphere of theonellamide F, a bicyclic dodecapeptide
of marine origin” Synlett 1994, 4, 247-249.
9. a) Matsunaga, S., Fusetani, N., Hashimoto, K., Walchli, M. “Theonellamide F. A novel
antifungal bicyclic peptide from a marine sponge Theonella sp” J. Am. Chem. Soc. 1989, 111,
2582-2588. b) Matsunaga, S., Fusetani, N. “Theonellamides A-E, cytotoxic bicyclic peptides,
from a marine sponge Theonella sp.” J. Org. Chem. 1995, 60, 1177-1181.
10. Wright, A. E. “The Lithistida: Important sources of compounds useful in biomedical
research” Curr. Opin. Biotechnol. 2010, 21, 801−807.
11. Schmidt, E. W., Bewley, C. A., Faulkner, D. J. “Theopalauamide, a bicyclic glycopeptide from
filamentous bacterial symbionts of the lithistid sponge Theonella swinhoei from Palau and
Mozambique” J. Org. Chem. 1998, 63, 1254−1258.
12. Bewley, C. A., Faulkner, D. J. “Theonegramide, an antifungal glycopeptide from the
Philippine lithistid sponge Theonella swinhoei” J. Org. Chem. 1994, 59, 4849−4852.
13. Nishimura, S., Arita, Y., Honda, M., Iwamoto, K., Matsuyama, A., Shirai, A., Kawasaki, H.,
Kakeya, H., Kobayashi, T., Matsunaga, S., Yoshida, M. “Marine antifungal theonellamides target
3β-hydroxysterol to activate Rho1 signaling” Nat. Chem. Biol. 2010, 6, 519−526.
14. Espiritu, R. A., Matsumori, N., Murata, M., Nishimura, S., Kakeya, H., Matsunaga, S., Yoshida,
M. “Interaction between the marine sponge cyclic peptide theonellamide A and sterols in lipid
bilayers as viewed by surface plasmon resonance and solid-state 2H nuclear magnetic
resonance” Biochemistry, 2013, 52, 2410–2418.
15. Barany, G., Merrifield, R.B. “A new amino protecting group removable by reduction.
Chemistry of the dithiasuccinoyl (Dts) function,” J. Am. Chem. Soc. 1977, 99, 7363-7365.
16. Merrifield, R. B. “Solid phase synthesis" Angew. Chem. Int. Ed. Engl. 1985, 24, 799-810.
17. Wong, C-H., Zimmerman, S. C. “Orthogonality in organic, polymer, and supramolecular
chemistry: from Merrifield to click chemistry” Chem. Commun. 2013, 49, 1679-1695.
18. Wong, C.-H., Ye, X.-S., Zhang, Z. “Assembly of oligosaccharide libraries with a designed
building block and an efficient orthogonal protection-deprotection strategy” J. Am. Chem. Soc.
1998, 120, 7137-7138.
19. Carpino, L. A., Han, G. Y. “The 9-fluorenylmethoxycarbonyl amino-protecting group” J. Org.
Chem. 1972, 37, 3404-3409.
20. Amblard, M. Fehrentz, J. A., Martinez. J., Subra, G. “Methods and protocols of modern solid
phase peptide synthesis” Mol. Biotechnol. 2006, 33, 239-254.
20

21. Plante, O. J., Buchwald, S. L., Seeberger, P. H. “Halobenzyl ethers as protecting groups for
organic synthesis” J. Am. Chem. Soc. 2000, 122, 7148-7149.
22. Aranyos, A., Old, D. W., Kiyomori, A., Wolfe, J. P., Sadighi, J. P., Buchwald, S. L. “Novel
electron-rich bulky phosphine ligands facilitate the palladium-catalyzed preparation of diaryl
ethers” J. Am. Chem. Soc. 1999, 121, 4369-4378.
23. Baran, P. S., Richter, J. M. “Direct coupling of indoles with carbonyl compounds: Short,
enantioselective, gram-scale synthetic entry into the hapalindole and Fischer indole alkaloid
families” J. Am. Chem. Soc. 2004, 126, 7450-7451.
24. Kinsman, A. C., Kerr, M. A. “Total synthesis of (±)-hapalindole Q” Org. Lett. 2001, 3, 31893191.
25. Young, I. S., Baran, P. S. “Protecting-group free synthesis as an opportunity for invention”
Nature Chem. 2009, 1, 193-205.
26. Hirschmann, R., Yao, W., Arison, B., Maechler, L., Rosegay, A., Sprengeler, P. A., Smith III, A.
B. “The first synthesis of a tricyclic homodetic peptide employing coordinated orthogonal
protection” Tetrahedron Lett. 1996, 37, 5637-5640.
27. Hirschmann, R., Yao, W., Arison, B., Maechler, L., Rosegay, A., Sprengeler, P. A., Smith, A. B.
III “Synthesis of the first tricyclic homodetic peptide. Use of coordinated orthogonal
deprotection to achieve directed ring closure” Tetrahedron 1998, 54, 7179-7202.
28. a) Guder, A., Wiedemann, I., Sahl, H-G. “Posttranslationally modified bacteriocins--the
lantibiotics” Biopolymers 2000, 55, 62-73 b) Harpp, D. N., Gleason, J. G. “Preparation and mass
spectral properties of cystine and lanthionine derivatives. Novel synthesis of L-lanthionine by
selective desulfurization” J. Org. Chem. 1971, 36, 73-80 c) Dugave, C., Menez, A. “Synthesis of
natural and non-natural orthogonally protected lanthionines from N-tritylserine and allothreonine derivatives” Tetrahedron: Asymm. 1997, 8, 1453-1465.
29. Willey, J. M., van Der Donk, W. A. “Lantibiotics: Peptides of diverse structure and function”
Annu. Rev. Microbiol. 2007, 61, 477-501.
30. a) Bregant, S., Tabor, A. B. “Orthogonally protected lanthionines: synthesis and use for the
solid-phase synthesis of an analogue of nisin ring C” J. Org. Chem. 2005, 70, 2430-2438. b)
Cobb, S. L., Vederas, J. C. “A concise stereoselective synthesis of orthogonally protected
lanthionines and β-methyllanthionine” Org. Biomol. Chem. 2007, 5, 1031-1038. c) Martin, N. I.
“Concise preparation of tetra-orthogonally protected (2S-6R)-lanthionines” J. Org. Chem. 2009,
74, 946-949.
31. Tadd, A. C., Meinander, K., Luthman, K., Wallén, E. A. A. “Synthesis of orthogonally
protected disulfide bridge mimetics” J. Org. Chem. 2011, 76, 673-675.

21

32. Nicolaou, K. C., Estrada, A. A., Zak, M., Lee, S. H., Safina, B. S. “A mild and selective method
for the hydrolysis of esters with trimethyltin hydroxide” Angew. Chem. Int. Ed. 2005, 44, 13781382.
33. Mothia, B., Appleyard, A. N., Wadman, S., Tabor, A. B. “Synthesis of peptides containing
overlapping lanthionine bridges on the solid phase: An analogue of rings D and E of the
lantibiotic nisin” Org. Lett. 2011, 13, 4216-4219.

22

CHAPTER 2: SYNTHESIS OF ORTHOGONALLY PROTECTED τ-HISTIDINOALANINE
2.1 Early Syntheses of τ-HAL
In 1977, Finley and Friedman prepared what was presumed to be histidinoalanine via
conjugate addition of histidine to a dehydroalanine electrophile, however they did not report
any characterization data.1 It wasn’t until 1993 that characterization data and experimental
details were reported for HAL by Henle et al.2 They assembled HAL in a manner similar to their
predecessors through conjugate addition of the imidazole of Ac-L-His-OH (56) to 2acetylaminoacrylate (57) (Scheme 2.1), with the major isomer, τ-HAL, being formed
preferentially in a 7:1 ratio with π-HAL.

Scheme 2.1: Synthesis of HAL isomers via conjugate addition of Ac-L-His-OH (56) to 2acetylaminoacrylate (57)
Between the years 1992-1994, the Shioiri group published a series of papers
documenting their progress towards the total synthesis of theonellamide F.3 They
acknowledged the τ-HAL regioisomer as the naturally occurring bridging residue for
theonellamide F, and thus outlined a stereoselective synthesis. They moved away from
previous syntheses that utilized dehydroalanine derivatives, as that approach leads to mixtures
of regioisomers due to lack of selectivity of the τ-nitrogen of the histidine nucleophile and
stereoisomers at Cα of the alanine residue. Instead, they employed an enantiopure serine β-
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lactone as their electrophile, and Boc-L-His-OMe, which has an established stereocenter, as
their nucleophile alleviating the stereoisomers issue (Scheme 2.2).

Scheme 2.2: Shioiri’s synthesis of HAL regioisomers employing a β-lactone
Even though the Shiori group’s β-lactone yielded a single stereoisomer of each
regioisomer, it did not achieve regioselectivity in terms of the imidazole, giving a 2:1 mixture of
regioisomers in favor of τ-HAL. Their efforts highlight two main challenges one faces when
synthesizing τ-histidinoalanine, mainly histidine’s unprotected imidazole side-chain; with its
innate nucleophilicity that leads to regioisomers and controlling stereoselectivity at the αcarbon of the alanine residue.
As discussed previously, histidine contains an imidazole side-chain with two nucleophilic
nitrogens, the τ-nitrogen and π-nitrogen. Although the τ-nitrogen is less hindered and will be
the preferred nucleophilic nitrogen atom on the imidazole ring, the π-nitrogen is more basic
and will compete for alkylation which results in a mixture of regioisomers.4 To combat this lack
of differential reactivity, the π-nitrogen can be blocked with a protecting group to force
alkylation at the τ-nitrogen. The π-nitrogen reactivity can also be blocked by intramolecular ring
formation between Nα and the imidazole side-chain. These two methods will be explored later
in the chapter.
Moreover, another benefit of blocking the π-nitrogen is preventing epimerization at the
α-carbon. Histidine derivatives with an unprotected π-nitrogen are prone to epimerization
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during peptide coupling or during protection of the histidine carboxyl group (Scheme 2.3).5
Substitution at the τ-nitrogen, as in τ-HAL, alters the basicity of the π-nitrogen and may
diminish its ability to abstract the α-proton. Blocking the reactivity completely would be the
best case scenario.6

Scheme 2.3: Intramolecular base-catalyzed proton abstraction and enolization mechanism
proposed by Jones et al.5
Retention of the Cα-stereocenter of the alanine residue during the formation of τ-HAL can be
ensured via an enantiopure electrophile. One example of enantiopure electrophiles are βcation synthons with an enantiopure Cα installed, which includes β-iodoalanine electrophiles
and cyclic sulfamidates.
2.2 Synthetic Routes to τ-HAL
In pursuit of a tetra-orthogonally protected τ-histidinoalanine (Figure 2.1), different
routes were explored to reach a functional building block in a practical and efficient manner.
Each route has pros and cons and will be discussed in more detail.
2.2.1 Protected β-Iodoalanine Electrophile and Bicyclic Urea
We investigated a π-nitrogen blocking strategy (Scheme 2.4) that was explored
previously by former group members, Julia Strautmann and Weihua Wang. In 2004, Strautmann
prepared cyclic urea 657 and β-lactone 66.8
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Figure 2.1: Protecting group strategy for tetra-orthogonal τ-HAL
In 2006, Wang repeated these preparations and investigated their coupling to give τHAL. Unfortunately, while salt 67 and ring-opened product 68 were identified by mass
spectrometry, neither compound was ever isolated pure or in more than trace amounts.

Scheme 2.4: Synthesis of τ-HAL 68 via nucleophilic ring opening of fused bicyclic urea derivative
We decided to revisit this route, substituting a β-iodoalanine for the β-lactone. A halide
salt was hypothesized to be more stable than an intramolecular salt. Additionally, this approach
would eliminate the step to install a carboxylate protecting group after opening of the βlactone. Since iodide is considered the best leaving group amongst the halides, we sought
procedures that would convert the Fmoc-D-Ser-OBn into its β-iodoalanine derivative. This
reaction was achieved using a modified Appel reaction (Scheme 2.5) according to Kawai et al.9
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Scheme 2.5: Synthesis of N-fluorenylmethoxycarbonyl-β-iodoalanine
Urea 65, previously prepared by Strautmann, was coupled with iodide 70 to give the
imidazolium salt 71 (Scheme 2.6). Imidazolium salts can be stable, and are quite frequently
used as ionic liquids.10 However, some of these salts are hygroscopic, and not stable at room
temperature. Fortunately, no degradation of compound 71 was observed at room temperature
over several days. The identity of 71 was confirmed by NMR spectroscopy and mass
spectrometry. The urea ring was then opened with tert-butanol to yield the τ-HAL derivative 72.

Scheme 2.6: Synthesis of τ-HAL via bicyclic urea opening with tert-butanol
During the initial coupling between urea 65 and iodide 70, it was observed that upon
concentration of 71 from the reaction solvent, dibenzofulvene (73) (Scheme 2.7, Path 1) would
precipitate out, which was confirmed by NMR. It was postulated that the Fmoc-protecting
group was being cleaved at elevated temperatures during the course of the reaction. A report
by Höck et al. supports this observation and states that “in DMF, DMSO, and MeCN, Fmoc
groups can be cleaved at temperatures of 120 °C or higher”.11 The reaction solvent was
changed to THF because of solubility, lower boiling point, and lack of basic functionality.
Switching to THF reduced Fmoc cleavage, but did not prevent β-elimination of hydrogen iodide
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(Scheme 2.7, Path 2). Heating of N-fluorenylmethoxycarbonyl-β-iodoalanine benzyl ester (70)
increases the rate of spontaneous β-elimination and presumably competes with salt formation.

Scheme 2.7: Based mediated β-elimination of Fmoc moiety (Path 1) and iodine (Path 2)
Because of this, the temperature of the reaction was eventually decreased from 90 °C to
room temperature. It should be noted that whenever thermal conditions were used the urea
was never completely consumed, thus requiring three equivalents of iodide to compensate for
losses due to competing side-reactions. When the reaction was run at room temperature, the
number of equivalents could be reduced because side-reactions were less competitive with the
desired coupling.
With a clearer understanding of the reaction chemistry of β-iodoalanine electrophiles
and cyclic ureas, another protecting group was sought for the serine carboxylic acid. N-Fmoc-βiodoalanine benzyl ester 70 provided a suitable building block for the synthesis of τ-HAL
derivative 72, however by Merrifield’s definition of orthogonality, τ-HAL 72, with its methyl
group, is not considered to be orthogonally protected.
We employed an alternative protecting group for the serine carboxylic acid - β(trimethylsilyl)ethoxymethyl (SEM) - which should give us more flexibility in the order of
deprotection events in the assembly of theonellamide C. While SEM is most often removed by
fluoride, Joullié and co-workers have reported that this protecting group can be removed from
28

complex peptide substrates under mild conditions using MgBr2.12 We attempted to prepare the
SEM ester derivative of Fmoc-D-Ser-OH in an analogous manner to N-Fmoc β-iodoalanine
benzyl ester. Standard iodination of 76 resulted in cleavage of the SEM ester to give 78 (Scheme
2.8). Analysis by NMR showed that compound 78 was identical to N-Fmoc-β-iodoalanine
prepared by Benito and Meldal.13

Scheme 2.8: Attempted synthesis of N-Fmoc-β-iodoalanine SEM ester
It is thought that the iodine is behaving as a mild Lewis acid. To circumvent this, we
proposed changing the order of events, via synthesis of the N-Fmoc β-iodoalanine free acid and
then protection as a SEM ester (Scheme 2.9).

Scheme 2.9: Attempted synthesis of N-Fmoc-β-iodoalanine SEM ester
Unfortunately, the SEM ester protection resulted in β-elimination with stronger bases (i.e.
triethylamine), and standard coupling procedures (viz. EDC, DMAP, SEM-OH).
Since our attempts to prepare compound 77 were unsuccessful, and coupling with the
bicyclic urea required high temperatures which eliminated the iodide group, we decided to
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investigate another π-blocked nucleophile that would hopefully require far less harsh
conditions for coupling.
2.2.2 β-Iodoalanine Electrophile and (Nim), π-Blocked Histidine Nucleophiles
We explored the phenacyl (Pac) group14 in another π-nitrogen blocking strategy
(Scheme 2.10). Due to the lack of protecting groups available that selectively protect the πnitrogen of the imidazole ring, this necessitated protection of the τ-nitrogen first (82), then the
π-nitrogen (83), and finally deprotection of the τ-nitrogen to give 84. Although the route to 84 is
circuitous, this approach ought to assure regioselectivity for reaction of the τ-nitrogen during
HAL formation. We chose the Pac group because of its orthogonality to our desired protecting
groups already installed on histidine 59. It is removed via reduction by zinc in the presence of
acetic acid. Compound 84 is a known compound and was made following the procedures of
Fletcher et al.14

Scheme 2.10: Formation of Boc-His(π-Pac)-OMe
The next step was to couple compound 84 with β-iodoalanine 70 to yield an imidazolium
halide salt and then subsequent removal of the Pac group (Scheme 2.11). Because βiodoalanine is the electrophile in this reaction sequence, β-elimination under thermal
conditions has posed a problem. However, when applying the optimized conditions developed
for the bicyclic urea to this reaction sequence the desired salt was formed in trace amounts, as
confirmed by mass spectrometry, but was never characterized by NMR. The salt, when
30

subjected directly to Zn, AcOH conditions gave a mixture of products from which the desired
compound 86 could not be identified or isolated.

Scheme 2.11: Synthesis of τ-HAL via Boc-His(π-Pac)-OMe
2.2.3 Cyclic Sulfamidates
Samanthi T. De Silva, a previous group member, was tasked with reinvestigating Tohdo
and Shioiri’s approach (Scheme 2.12). The lack of details in the short communication required
De Silva to interpret and develop related procedures; fortunately she was able to obtain yields
that were comparable to previously reported results.

2:1 mixture of τ and π

Scheme 2.12: Synthesis of HAL regioisomers via coupling of Boc-L-His-OMe (59) and Cbzprotected β-lactone (60)
Poor τ-selectivity and the difficulty of separating the HAL regioisomers encouraged us to
look for a less reactive electrophile that would give better τ-regioselectivity. We surveyed other
alanine β-cation synthons and it seemed that sulfamidates, as introduced by Baldwin and coworkers,15 might provide a viable solution. These cyclic sulfamidates are similar to β-lactones in
that the β-carbon in the ring is activated toward nucleophilic attack by the two electronwithdrawing groups at the α and β-carbons. Sulfamidates, such as 90 (Scheme 2.13), retain the
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Cα-stereocenter that is derived from D-serine. Later, Lubell et al. demonstrated that an
imidazole nucleophile can be used to open cyclic sulfamidates in good yield (Scheme 2.13).16

Scheme 2.13: Conditions for synthesis of sulfamidate, and imidazole nucleophilic ring opening
Taylor and De Silva reported the regioselective synthesis of τ-HAL (93) via the coupling
of Boc-His-OMe (59) and sulfamidate 92 (Scheme 2.14).17 Boc-His-OMe was employed as a
nucleophile in order to make a meaningful comparison with the β-lactone route. Analysis by
NMR and HPLC confirmed the existence of only the τ-HAL isomer.

Scheme 2.14: Taylor and Thabrew De Silva HAL synthesis via coupling of Boc-His-OMe and
sulfamidate 92
In 2011, Avenoza and co-workers reported theoretical studies on the reactivity and
selectivity of substituted imidazoles with sulfamidates (Scheme 2.15).18 First they calculated the
minimum energy of SN2 transition states (TS) for three types of substituted imidazoles and
sulfamidate 94 using the B3LYP/6-31G+ basis set. They found the nucleophilic ring opening
process to be concerted and with full inversion of configuration at the quaternary carbon.

Scheme 2.15: Nucleophilic attack of sterically hindered sulfamidate by imidazole tautomers
yields a mixture of regioisomers
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They next investigated computationally the high site selectivity demonstrated by nonsymmetrically substituted imidazoles. Complete selectivity for nucleophilic attack by the less
hindered Nτ atom is a reflection of the great difference between the lowest energies of
activation calculated for both reaction pathways labeled as ts1 and ts2 (Figure 2.2). They
concluded that the steric interactions between the alkyl group at the C-4 position on the
imidazole and the substituents at the quaternary center at the most crowded TS are most likely
the reason for high selectivity.

Figure 2.2: Minimum energy TS for some of the proposed pathways starting from sulfamidate
94 and mono- and disubstituted imidazoles. Distances are given in Å and activation energies
(ΔG‡) in kcal/mol.
With these results in hand, they turned to the synthesis of bis-amino acid Menor-τ-HAL
(Scheme 2.16), as this substrate could potentially be obtained by ring opening of cyclic
sulfamidates with nitrogen or sulfur nucleophiles. They outlined the synthesis of Menor-τ-HAL
(96), a bis-amino acid that bears a quaternary center (Scheme 2.16). This protected analog of τHAL involves the covalent linkage of the τ-nitrogen of the imidazole of histidine with the αcarbon of the β-alanine.
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Scheme 2.16: Mechanism of sulfamidate ring opening by mono-substituted imidazole
nucleophile
Subsequent synthesis of a τ-HAL analog and these computational studies served to further
solidify our decision to continue pursuing cyclic sulfamidates as our preferred β-cation synthon.
2.3 Synthesis of Orthogonally Protected τ-HAL via a Cyclic Sulfamidate
Ultimately, cyclic sulfamidates proved to be the superior electrophile, giving
regioselectivity at the τ-nitrogen which permitted a successful synthesis of an orthogonally
protected τ-HAL. Our approach featured the coupling of reaction partners Boc-L-His-OTCE (97)
with a sulfamidate 98 derived from N-Fmoc-D-Ser-OBn (Scheme 2.17).

Scheme 2.17: Retrosynthetic analysis of orthogonally protected τ-HAL
Initial synthesis of Boc-L-His-OTCE involved a two-step process, which was modeled
after earlier group efforts on a similar substrate. First, we installed the TCE protecting group,
and then attempted to remove the imidazole Boc group (Scheme 2.18). The first step
proceeded smoothly via EDC coupling in great yield to give Boc-L-His-(Boc)-OTCE (100).
Unfortunately, attempted removal of the Boc group under NaOMe/MeOH conditions resulted
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in transesterification of the TCE group by the methoxy group to give Boc-L-His-OMe (59)
(Scheme 2.18, Route 1). This suggests that the trichloroethyl ester behaves as a good leaving
group and is susceptible to nucleophilic attack. To prevent the transesterification side-reaction
we switched to a milder, less nucleophilic base (Cs2CO3). However, using these conditions
yielded trace amounts of the desired product 97, but mostly an insoluble salt (Scheme 2.18,
Route 2). Preliminary NMR analysis of the crude product suggests the formation of the
reversible fused lactam byproduct 101 and intramolecular salt 102. Tentative peak assignments
agreed with previously reported data for the same compound by the Ogrel group,19 however no
further purification or characterization was carried out.

Scheme 2.18: Transesterification of Boc-L-His(Boc)-OTCE (96) and intramolecular ring formation
mechanisms
To avoid the use of bases and subsequent transesterification, we decided to employ a
one-step synthesis that installs the TCE group using traditional EDC/DMAP conditions (Scheme
2.19). We were able to isolate the desired product in great yield. We postulated the high yield
and absence of byproducts to the lack of strong base present to initiate the intramolecular ring
formation. The imidazole side chain of histidine has a pKa of 6.0. The imidazole is inherently
basic, but a weak base due to delocalization of the electron lone pair across the imidazole
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nitrogens. Therefore, it is not strong enough on its own to initiate intramolecular ring formation
(viz. 101).

Scheme 2.19: Direct synthesis of Boc-L-His-OTCE (97)
With the histidine reaction partner in hand, we now turned our efforts to making the
cyclic sulfamidate. We first started with commercially available Fmoc-D-Ser-OH (75) which
reacted smoothly with benzyl bromide to give Fmoc-D-Ser-OBn (69) in high yield. This was
converted to the 5-membered ring using SOCl2, and subsequent oxidation of the sulfamidite to
give cyclic sulfamidate 98 as a colorless oil in 30-40% yield (Scheme 2.20).

Scheme 2.20: Synthesis of cyclic sulfamidate 98 derived from Fmoc-D-Ser-OBn
It was found that sulfamidate 98 undergoes degradation at room temperature after 24
hours. When stored neat at 0 °C, degradation was observed after one week, which is in
agreement with the Lubell group who reported similar observations for a homologous
substrate.20 We found that the sulfamidate was most stable when stored at 0 °C in a minimal
amount of CHCl3 or CH2Cl2.
Initial attempts to recrystallize the cyclic sulfamidate failed. In previous work in our
group17 it was observed that when the methyl ester sulfamidate 92 was recrystallized, the
yields for the coupling reaction with Boc-L-His-OMe (59) increased to 55-60% (Scheme 2.14). In
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contrast, when non-crystalline Fmoc-D-Ser-OBn derived cyclic sulfamidate was coupled with
commercially available Boc-L-His-OMe, only 30-40% of τ-HAL derivative 72 was recovered
(Scheme 2.21).

Scheme 2.21: Synthesis of τ-HAL 72 via coupling of sulfamidate 98 and Boc-L-His-OMe (59)
For this coupling reaction to be viable for scale up, steps were taken to optimize the
formation of the sulfamidate reaction partner. We chose to do the optimization on a cyclic
sulfamidate derived from Fmoc-D-Ser-OtBu due to initial reproducibility issues with sulfamidate
98. Our rationale was that the tert-butyl group will lend stability to the sulfamidate because it is
bulky and will shield the α-carbon from deprotonation and the β-carbon from nucleophilic
attack. Fmoc-D-Ser-OtBu 80 was initially prepared according to Scheme 2.22.

Scheme 2.22: Synthesis of Fmoc-D-Ser-OtBu (80)
The alcohol was smoothly converted to a TBDMS ether in excellent yield, followed by
Fmoc protection of the amino group in good yield. However protection of the carboxylic acid
as the tert-butyl ester, a reaction that was not reproducibile, and tedious purification of 107,
led to a modified synthesis21,22 (Scheme 2.23) giving Fmoc-D-Ser-OtBu in good yield.
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Scheme 2.23: Synthesis of sulfamidate 110 derived from Fmoc-D-Ser-OtBu
Initial sulfamidate preparation from Fmoc-D-Ser-OtBu also gave poor yields of 30-40%
(Scheme 2.23), however the product was crystalline as predicted. Encouraged by these results,
efforts were made to optimize the cyclization/oxidation step.
In a related synthesis of cyclic sulfates, Kim and Sharpless23 found that the presence of
triethylamine or pyridine inactivated the ruthenium catalyst, greatly reducing the efficiency of
the oxidation reaction. They reported that purification of the sulfite intermediate before
oxidation increased reaction yields to greater than 90%. Table 2.1 outlines the steps taken to
increase the yields for the cyclization/oxidation sequence depicted in Scheme 2.23. Entry 2
shows an increased yield to 60% and reduced oxidation time when chromatography was
applied to the intermediate. A citric acid wash to neutralize the excess triethylamine before
chromatography slightly decreased the overall yield, perhaps due to loss of product in work-up
however it decreased the oxidation time to 1 h. A 5% citric acid wash alone proved to be the
best conditions, giving cyclic sulfamidate in 74% yield.
Table 2.1: Optimization of cyclization/oxidation sequence in conversion of 80109110
Entry

1
2
3
4
5

Citric Acid Wash
Sulfamidite 109

Chromatography
Sulfamidite 109

No
No
Yes
Yes (10%)
Yes (5%)

No
Yes
Yes
No
No
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Oxidation
Sulfamadite
109
16 h
3h
1h
1h
1h

Yield
Sulfamidate
110
30-40%
60%
50%
55%
74%

These optimized conditions were applied to the cyclization of Fmoc-D-Ser-OBn, and
improved the yields to over 70%. With reproducible yields of Fmoc-D-Ser-OBn derived cyclic
sulfamidate 97, coupling of Boc-L-His-OTCE (96) and cyclic sulfamidate 97 was carried out to
give orthogonally protected τ-HAL 15 in moderate yield (Scheme 2.24).

Scheme 2.24: Synthesis of tetra-orthogonally protected τ-HAL via coupling of Boc-L-His-OTCE
and Fmoc-D-Ser-OBn derived sulfamidate
2.4 Orthogonal Deprotection
When reasonable quantities of τ-HAL 15 had been synthesized, deprotection studies
were undertaken to demonstrate the orthogonality of the four protecting groups (Scheme
2.25). Each deprotection product was characterized by 1H NMR and
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C NMR, and mass

spectrometry.

Scheme 2.25: Orthogonal deprotection conditions for τ-HAL 15
All four derivatives were readily accessed using traditional deprotection conditions.
Cleavage of the two amine protecting groups proceeded smoothly in high yield using 1:1 TFA-
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CH2Cl2 to remove the Boc carbamate and diethylamine in acetonitrile to remove the Fmoc
residue. Amines 111 and 114 were isolated in 95% and 94% yields respectively.
To remove the benzyl ester we followed standard protocol, initially using H 2 and Pd/C in
MeOH. However we found that when MeOH was utilized as a solvent, reduction of the carbonchlorine bonds in the TCE group occurred, giving undesired side products. Changing the
reaction solvent to THF suppressed the formation of this byproduct and gave us the desired
compound in good yield. Ethyl acetate was also explored, and although it produced the desired
product, it didn’t suppress the TCE reduction as effectively as THF and gave lower yields. Finally,
the TCE ester was cleaved using zinc dust and acetic acid to give the free acid also in good yield.
Initially, purification of the free acids proved to be difficult, as derivative 113 in
particular proved to be very polar and adhered to the silica gel, lowering yields. Recovery of
derivative 112 from column chromatography also proved difficult. Passing the compounds
through a short plug of silica with 15% ethanol in dichloromethane increased the yields to 80%
and 65% respectively.
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2.5 Experimental Section
General Methods: All reactions were performed under a dry nitrogen atmosphere unless
otherwise noted. All chemicals and reagents were purchased from Sigma-Aldrich, Fisher, Acros,
and NovaBiochem and used without further purification. Triethylamine and diethylamine were
dried and distilled from CaH2 and stored over KOH pellets. Dry methanol was distilled from Mg
turnings and stored over 3Å molecular sieves. Flash chromatography was performed using 230400 mesh silica gel (40-63 mm) from Sigma-Aldrich. Reactions were followed by thin layer
chromatography (TLC) on pre-coated aluminum-backed 60 F254 silica plates from EMD
Chemicals, Inc. Compounds were visualized under UV fluorescence or by staining with KMnO 4,
or an acidic, ethanolic solution of ninhydrin.

1

H and 13C NMR spectra were recorded at room

temperature on a Bruker AV-400 and are reported in parts per million (ppm) on the δ scale
relative to residual CHCl3 or (CH3)2SO in deuterated solvents or tetramethylsilane as an internal
standard. Coupling constants (J) are reported in Hertz (Hz). High resolution mass spectrometry
(HRMS) was carried out using an Agilent 6210 electrospray ionization-time-of-flight (ESI-TOF)
mass spectrometer. Optical rotations were recorded under the specified conditions.
2.5.1 Procedures

Scheme 2.26: Synthesis of compound 69
Fmoc-D-Ser-OBn (69).24 Cesium carbonate (199 mg, 0.61 mmol, 0.50 equiv.) was added to a
solution of Fmoc-D-Ser-OH (75) (400 mg, 1.22 mmol, 1.00 equiv.) in dry MeOH (5.3 mL). The
mixture was stirred at rt for 2 h, concentrated, and the residue dissolved in dry DMF (2.7 mL)
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under N2. Benzyl bromide (175 μL, 125 mg, 1.47 mmol, 1.20 equiv.) was added dropwise and
the mixture stirred overnight. The mixture was then partitioned between EtOAc (10 mL) and
H2O (10 mL). The aqueous layer was extracted with EtOAc (10 mL), and the combined organic
extracts were washed with sat’d aq. NaHCO3 (3 x 8 mL) to remove Fmoc-D-Ser-OH completely.
The organic layer was then washed with brine (8 mL), dried over MgSO4 and concentrated. The
pale yellow oil was purified by flash chromatography on silica gel, eluting with 2:1 HexanesEtOAc, to give Fmoc-D-Ser-OBn (69) as a clear oil that gave a colorless solid upon overnight
refrigeration (332 mg, 83%). Rf 0.68 (95:5 CH2Cl2-MeOH). [α]25D -3.4 (c 1.0, MeOH); 1H NMR (400
MHz,CDCl3) δ 2.22 (br s, 1H, OH), 3.91 (d, J = 9.8 Hz, 1H), 4.01 (d, J = 9.8 Hz, 1H), 4.20 (t, J = 6.5,
1H), 4.36-4.48 (m, 3H), 5.21 (s, 2H), 5.77 (d, J = 7.5 Hz, 1H), 7.28-7.33 (m, 7H), 7.39 (t, J = 7.4 Hz,
2H), 7.58 (d, J = 7.1 Hz, 2H), 7.75 (d, J = 7.5 Hz, 2H);
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C NMR (100 MHz, CDCl3) δ 47.1, 56.2,

63.2, 67.3, 67.6, 120.0, 125.1, 127.1, 127.1, 127.8, 128.2, 128.6, 128.7, 135.1, 141.3, 141.4,
143.7, 143.8, 156.4, 170.5.

Scheme 2.27: Synthesis of compound 70
Fmoc-D-Ser(I)-OBn (70).9 A solution of triphenylphosphine (942 mg, 3.59 mmol, 3.0 equiv.) in
toluene (7.0 mL) was added dropwise over 5 min to a suspension of N-iodosuccinimide (808
mg, 3.59 mmol, 3.0 equiv.) in toluene (3.6 mL) at rt under N2. The mixture was stirred for 5 min,
followed by the dropwise addition of a solution of Fmoc-D-Ser-OBn (69) (500 mg, 1.20 mmol, 1
equiv.) in THF (7.0 mL). Finally, iodine (912 mg, 3.59 mmol, 3 equiv.) was added as a solid. The
mixture was stirred for 1 h under reflux. The reaction mixture was concentrated (35 °C), then
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diluted with EtOAc (20 mL). The organic layer was washed with H2O (2 x 10 mL). The aqueous
layers were combined and back-extracted with EtOAc (20 mL). The organic layers were
combined, and washed with sat’d aq. Na2S2O3 (12 mL). The black precipitate was removed by
filtration through a plug of Celite™. The filtrate was washed with sat’d aq. Na 2S2O3 (12 mL),
sat’d aq. NaHCO3 (8 mL), H2O (20 mL) and brine (12 mL), dried over MgSO4, filtered and
concentrated. The deep brown oil was purified by flash chromatography on silica gel, eluting
with 10:1 hexanes-EtOAc. Appropriate fractions were concentrated to give Fmoc-D-Ser(I)-OBn
(70) as a colorless powder (505 mg, 80%). Rf 0.35 (2:1 Hexanes-EtOAc). [α]26D +6.7 (c 0.6, CHCl3),
Lit.9 [α]26D +6.7 (c 0.6, CHCl3). 1H NMR (400 MHz, CDCl3) δ 3.62 (br s, 2H, Hβ), 4.25 (t, J = 7.0 Hz,
1H, Fmoc-CH), 4.36-4.46 (m, 2H, Fmoc-CH2), 4.61-4.65 (m, 1H, H), 5.24 (dd, J = 13.5, 4.0 Hz,
2H, CH2OBn), 5.72 (d, J = 7.2 Hz, 1H, NH), 7.31-7.43 (m, 9H, Ar), 7.62 (d, J =7.3 Hz , 2H, Fmoc-Ar),
7.78 (d, J = 7.4 Hz, 2H, Fmoc-Ar); 13C NMR (100 MHz, CDCl3) δ 7.4, 47.1, 54.1, 67.4, 68.2, 120.1,
125.0, 125.2, 127.2, 127.8, 128.3, 128.6, 128.7, 128.8, 134.7, 141.3, 143.6, 143.8, 155.4, 169.2.

Scheme 2.28: Synthesis of compound 76
Fmoc-D-Ser-OSEM (76). Fmoc-D-Ser-OH (75) (250 mg, 0.76 mmol, 1.0 equiv.) was dissolved in
THF (5 mL) and cooled to 0 °C. Triethylamine (213 µL, 77.3 mg, 1.53 mmol, 2.0 equiv.) was
added to the cooled solution and allowed to stir for 5 min. 2-(Trimethylsilyl)ethoxymethyl
chloride (135 µL, 127 mg, 0.76 mmol, 1.0 equiv.) was added all at once. The mixture was stirred
at 0 °C for 3 h and then diluted with sat’d aq. NH4Cl (17 mL). The aqueous layer was extracted
with CH2Cl2 (3 x 8.5 mL). The organic layers were combined, dried over MgSO4, filtered and
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concentrated. The pale yellow oil was purified by flash chromatography on silica gel, eluting
with 3:1 hexanes-EtOAc, to give Fmoc-D-Ser-OSEM (76) as a colorless oil (505 mg, 75%). Rf 0.50
(95:5 CH2Cl2-MeOH). 1H NMR (400 MHz, CDCl3) δ 0.02 (s, 9H, SiMe3), 0.97 (t, J = 16.5 Hz, 2H,
CH2), 3.73 (t, J = 16.5 Hz, 2H, CH2), 3.93 (br d, J = 8.9 Hz, 1H, Hβ), 4.04 (br d, J = 11.0 Hz, 2H, Hβ'),
4.22 (t, J = 6.9 Hz, 1H, Fmoc-CH), 4.41 (quin., J = 7.5 Hz, 2H, Fmoc-CH2), 4.48-4.50 (m, 1H, Hα),
5.38 (dd, J = 11.5, 5.7 Hz, 2H, OCH2O), 5.96 (d, J = 7.6 Hz, 1H, NH), 7.31 (t, J = 7.4 Hz, 2H, FmocAr), 7.40 (t, J = 7.4 Hz, 2H, Fmoc-Ar), 7.61 (t, J = 5.4 Hz, 2H, Fmoc-Ar), 7.76 (d, J = 7.5 Hz, 2H,
Fmoc-Ar); 13C NMR (100 MHz, CDCl3) δ -1.4, 14.2, 17.9, 47.1, 56.2, 60.5, 63.1, 67.3, 68.3, 90.1,
120.0, 125.1, 127.1, 127.8, 141.3, 141.3, 143.7, 143.9, 156.3, 170.4.

Scheme 2.29: Synthesis of compound 80
Fmoc-D-Ser-OtBu (80).21 To a solution of Fmoc-D-Ser-OH (75) (200 mg, 0.61 mmol, 1.0 equiv.) in
EtOAc (5.5 mL) was added tert-butyl 2,2,2-trichloroacetimidate (534 mg, 437 µL, 2.4 mmol, 4.0
equiv.) in cyclohexane (2.6 mL). The mixture was stirred at rt for 24 h under N2, and then
concentrated and purified by flash chromatography on silica gel, eluting with 5:1 hexanesEtOAc to yield Fmoc-D-Ser-OtBu (80) as a colorless solid upon concentration (181 mg, 70%). Rf
0.41 (95:5 CH2Cl2-MeOH). [α]20D +2.4 (c 1.0, CH2Cl2), Lit.21 [α]20D +2.0 (c 1.0, CH2Cl2); 1H NMR
(400 MHz, MeOD) δ 1.44 (s, 9H, tBu), 3.80 (dd, J = 11.2, 4.2 Hz, 1H,Hβ), 3.84 (dd, J = 11.2, 4.2 Hz,
1H,Hβ) 4.13-420 (m, 2H, Fmoc-CH, Hα), 4.26 (dd, J = 10.4, 7.1 Hz, 1H, Fmoc-CH2), 4.34 (dd, J =
10.4, 7.1 Hz, 1H, Fmoc-CH2), 7.23 (t, J = 7.4 Hz, 2H, Fmoc-Ar), 7.32 (t, J = 7.4 Hz, 2H, Fmoc-Ar),
7.61 (t, J = 6.6 Hz, 2H, Fmoc-Ar), 7.71 (d, J = 7.5 Hz, 2H, Fmoc-Ar); 13C NMR (100 MHz, MeOD) δ
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28.7, 48.6, 58.8, 63.5, 68.5, 83.5, 121.3, 126.6, 126.6, 128.5, 129.2, 142.9, 145.5, 145.6, 158.9,
171.7.

Scheme 2.30: Synthesis of compound 81
Fmoc-D-Ser(I)-OtBu (81).25 Iodine (642 mg, 2.53 mmol, 2.2 equiv.) was added to a suspension of
triphenylphosphine polymer (664 mg, 2.53 mmol, 2.2 equiv.) in anhydrous CH2Cl2 (19 mL) under
N2. The reaction was stirred at rt. After 15 min, imidazole (196 mg, 2.88 mmol, 2.5 equiv.) was
added at rt and the stirring was continued for an additional 15 min. A solution of Fmoc-D-SerOtBu (80) (445 mg, 1.16 mmol, 1.0 equiv.) in anhydrous CH2Cl2 (4.6 mL) was then added to the
suspension. The reaction was heated at reflux for 1 h. After filtration through a pad of Celite TM
and washing with CH2Cl2 (3 x 5 mL), the filtrate was washed with sat’d aq. Na2S2O3 (8 mL), H2O
(2 x 8 mL), dried over MgSO4, filtered and concentrated. The residue was purified by flash
chromatography on silica gel eluting with 5:1 hexanes:EtOAc to give Fmoc-D-Ser(I)-OtBu (81) as
a colorless oil (449 mg, 78%). Rf 0.31 (2:1 hexanes-EtOAc). Lit.26 ent-81[α]23D 16.3 (c 1.05, CHCl3);
1

H NMR (400 MHz, CDCl3) δ 1.53 (s, 9H, tBu), 3.58-3.65 (m, 2H, Hβ), 4.25 (t, J = 7.2 Hz, 1H, Fmoc-

CH), 4.35 (dd, J = 10.4, 7.2 Hz, 1H, Fmoc-CH2), 4.41-4.45 (m, 3H, Fmoc-CH2, Hα), 5.71 (d, J = 6.8
Hz, 1H, NH), 7.33 (t, J = 7.4 Hz, 2H, Fmoc-Ar), 7.41 (t, J = 7.4 Hz, 2H, Fmoc-Ar), 7.60 (d, J = 7.1 Hz,
2H, Fmoc-Ar), 7.77 (d, J = 7.5 Hz, 2H, Fmoc-Ar);

13

C NMR (100 MHz, CDCl3) δ 8.4, 28.0, 47.1,

54.1, 67.3, 83.7, 120.0, 125.2, 125.2, 127.1, 127.8, 141.3, 143.7, 143.7, 155.4, 168.2.
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Scheme 2.31: Synthesis of compound 78
Fmoc-D-Ser(I)-OH (78).13 Fmoc-D-Ser(I)-OtBu (81) (148 mg, 0.30 mmol, 1.0 equiv.) was treated
with 50% TFA in CH2Cl2 (4.2 mL) for 1 h under N2. Evaporation of the solvents and
coevaporation with toluene (4.2 mL) furnished Fmoc-D-Ser(I)-OH (78) (118 mg, 90%). Rf 0.15
(9:1 C H2Cl2-MeOH). [α]25D -4.2(c 1.0, CH3OH); 1H NMR (400 MHz, CD3OD) δ 3.51 (dd, J = 10.3
,7.5 Hz, 1H, Hβ) 3.64 (dd, J = 10.3 ,4.1 Hz, 1H, H’β), 4.24 (t, J = 7.0 Hz, 1H, Fmoc-CH), 4.30-4.42
(m, 3H, Fmoc-CH2, Hα), 6.01 (d, J = 8.0 Hz, 1H, NH), 7.31 (t, J = 7.4 Hz, 2H, Fmoc-Ar), 7.38 (t, J =
7.4 Hz, 2H, Fmoc-Ar), 7.68 (d, J = 7.2 Hz, 2H, Fmoc-Ar), 7.79 (d, J = 7.4 Hz, 2H, Fmoc-Ar);

13

C

NMR (100 MHz, CD3OD) δ 3.7, 47.0, 55.4, 66.8, 119.5, 124.9, 126.8, 127.4, 141.2, 143.7, 143.8,
156.7, 170.7.

Scheme 2.32: Synthesis of compound 82
Boc-L-His(Trt)-OMe (82). Boc-L-His-OMe (59) (1.00 g, 3.71 mmol, 1.0 equiv.) was added to a
solution of triphenylmethyl chloride (1.14 g, 4.08 mmol, 1.1 equiv.) and triethylamine (543 µL,
395 mg, 3.90 mmol, 1.05 equiv.) in dry benzene (7.5 mL) under N2. The mixture was heated at
reflux for 1 h, and the resultant triethylammonium chloride precipitate was removed by
filtration and washed with benzene. The combined filtrate and washings were washed with
H2O (20 mL), dried over MgSO4, filtered and concentrated. The pale yellow oil was purified by
flash chromatography on silica gel, eluting with 3:1 hexanes-EtOAc, to give Boc-L-His(Trt)-OMe
(82) as a colorless oil, that was redissolved in CH2Cl2 (5 mL) and concentrated to give a colorless
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solid (1.78 g, 94%). Rf 0.68 (95:5 CH2Cl2-MeOH). [α]20D +3.1 (c 1.0, MeOH), Lit.27 [α]20D +3.8 (c
1.0, MeOH). 1H NMR (400 MHz, CDCl3) δ 1.43 (s, 9H, tBu), 2.96 (dd, J = 14.5, 4.7 Hz, 1H, Hβ),
3.03 (dd, J = 14.5, 5.1 Hz, 1H, H’β), 3.57 (s, 3H, OMe), 4.54 (dt, J = 9.0, 8.3 Hz, 1H, H), 6.09 (d, J
= 8.4 Hz, 1H, NH), 6.52 (s, 1H, H5), 7.07-7.12 (m, 5H, Trt-Ar), 7.28-7.31 (m, 10 H, Trt-Ar), 7.34 (s,
1H, H2);

13

C NMR (100 MHz, CDCl3) δ 28.4, 30.3, 52.0, 53.8, 75.2, 79.5, 119.6, 128.1, 129.8,

136.5, 138.8, 142.3, 155.6, 172.4; HRMS (ESI) calcd for C31H34N3O4 (M+H)+ 512.2544, obsd
512.2567.

Scheme 2.33: Synthesis of compound 83
Boc-L-His(Nπ-Pac, Nτ-Trt)-OMe imidazolium bromide salt (83).14 Boc-L-His(Trt)-OMe (82) (500
mg, 0.98 mmol, 1.0 equiv.) and phenacyl bromide (195 mg, 0.98 mmol, 1.0 equiv.) were
dissolved in diethyl ether (0.83 mL), and stirred at rt for 2 d. The precipitate was filtered and
washed with ether to yield the Boc-L-His(π-Pac, τ-Trt)-OMe imidazolium bromide salt (83) (591
mg, 85%). Rf 0.20-.50 (95:5 CH2Cl2-MeOH). [α]20D -8.2 (c 1.0, MeOH), Lit.14 [α]20D -9.2 (c 1.0,
MeOH). 1H NMR (400 MHz, CDCl3) δ 1.36[1.28]* (s, 9H, tBu), 3.06-3.20 (m, 2H, Hβ), 3.73[3.63]
(s, 3H, OMe), 4.45-4.51 (m, 1H, Hα), 5.50[5.88] (br s, 1H, NH), 6.16[6.50] (d, J = 18.3 Hz, 1H,
CH2), 6.36[6.69] (d, J = 18.3 Hz, 1H, CH2), 6.91 (s, 1H, H5), 7.20-7.31 (m, 10 H, Trt-Ar), 7.47-7.54
(m, 2H, Pac-Ar), 7.62 (p, J = 5.8 Hz, 1H, Pac-Ar), 8.07[8.12] (d, J = 7.3 Hz, 2H, Pac-Ar), 9.47[9.21]
(s, 1H, H2);

13

C NMR (100 MHz, CDCl3) δ 26.5, 28.1, 52.4, 52.9, 55.0, 79.7, 80.5, 121.8, 128.8,

129.0, 129.1, 129.3, 129.7, 132.0, 133.4, 134.7, 139.1, 139.4, 155.4, 170.7, 191.2; HRMS (ESI)
calcd for C39H40N3O5 (M+H)+ 630.2962, obsd 630.2974
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* [] denotes minor tautomer peak

Scheme 2.34: Synthesis of compound 84
Boc-L-His(Nπ-Pac)-OMe (84).14 Silver acetate (195 mg, 0.98 mmol, 1.0 equiv.) was added to a
stirred solution of Boc-L-His(π-Pac, τ-Trt)-OMe imidazolium bromide salt (83) (500 mg, 0.98
mmol, 1.0 equiv.) in 80% acetic acid (1.32 mL). The precipitated silver bromide was then filtered
off, and the solution was left to stir at rt for 24 h. The triphenylmethanol precipitate was
removed by filtration, and the filtrate was concentrated. Sat’d aq. NaHCO3 was added to the
residue, and the mixture was extracted with ether (5 x 5 mL). The organic extracts were left to
stand at rt while the methyl ester crystallized from the solution (217 mg, 85%). Rf 0.65 (95:5
CH2Cl2-MeOH). [α]20D -8.3 (c 1.0, MeOH), Lit.14 [α]20D -9.3 (c 1.0, MeOH). 1H NMR (400 MHz,
CDCl3) δ 1.37 (s, 9H, tBu), 3.00 (br d, J = 4.8 Hz, 1H, Hβ), 3.70 (s, 3H, OMe), 4.47 (br d, J = 5.6 Hz,
1H, H), 5.33 (d, J = 6.3 Hz, 1H, NH), 5.39 (d, J = 18.3 Hz, 1H, CH2Ph), 5.48 (d, J = 18.3 Hz, 1H,
CH2Ph), 6.88 (s, 1H, H5), 7.42 (s, 1H, H2), 7.54 (t, J = 7.5 Hz, 2H, Pac-Ar), 7.67 (t, J = 7.4 Hz, 1H,
Pac-Ar), 8.01 (d, J = 7.6 Hz, 2H, Pac-Ar);

13

C NMR (100 MHz, THF-d8) δ 26.5, 27.6, 50.4, 51.1,

53.3, 78.3, 127.3, 127.7, 127.9, 128.6, 133.4, 135.1, 138.2, 155.3, 171.7, 192.4; HRMS (ESI) calcd
for C20H26N3O5 (M)+ 388.1867, obsd 388.1873.

Scheme 3.35: Synthesis of compound 100
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Boc-L-His-Boc-OTCE (100). N,N-Dimethylaminopyridine (289 mg, 2.31 mmol, 0.5 equiv.) and
trichloroethanol (530 µL, 103 mg, 5.54 mmol, 1.2 equiv.) were added sequentially to a solution
of commercially available Boc-L-His(τ-Boc)-OH (99) (2.00 g, 4.61 mmol, 1.0 equiv.) in CH2Cl2 (16
mL) at rt under N2. The mixture was cooled to 0 °C, and EDC (1.06 g, 5.54 mmol, 1.2 equiv.) was
added. The solution was stirred for 21 h at 0 °C. The mixture was diluted with EtOAc (200 mL),
washed with sat’d aq. NaHCO3 (2 x 40 mL), water (2 x 100 mL) and brine (40 mL), dried over
MgSO4, filtered and concentrated. The clear yellow oil was subjected to flash chromatography
on silica gel, eluting with 2:1 hexanes-EtOAc, to give Boc-L-His-(Boc)-OTCE (100) as a colorless
oil that was crystallized from methanol to yield a colorless solid (2.03 g, 90%). Rf 0.68 (95:5
CH2Cl2-MeOH). 1H NMR (CDCl3, 400 MHz) δ 1.44 (s, 9H,tBu), 1.61 (s, 9H, tBu), 3.10 (dd, J = 14.9,
5.0 Hz, 1H, Hβ), 3.16 (dd, J = 14.9, 5.8 Hz, 1H, H’β), 4.67 (d, J = 11.9 Hz, 1H, CH2CCl3), 4.69-4.74
(m, 1H, Hα), 4.82 (d, J = 11.9 Hz, 1H, CH2CCl3), 6.01 (d, J = 8.2 Hz, 1H, NH), 7.18 (s, 1H, H5), 8.00
(s, 1H, H2);

13

C NMR (CDCl3, 100 MHz) δ 27.9, 28.3, 29.6, 53.3, 74.6, 80.0, 85.7, 94.6, 114.9,

137.0, 138.2, 146.8, 155.5, 170.5; HRMS (-ESI) calcd for C18H2635Cl3N3O6 (MH-) 485.0887, obsd
484.9260.

Scheme 2.36: Synthesis of compound 97
Boc-L-His-OTCE (97). A solution of DMAP (0.57 g, 4.70 mmol, 1.2 equiv.) in anhydrous CH2Cl2
(1.2 mL) was added dropwise to a suspension of commercially available Boc-L-His-OH (103)
(1.00 g, 3.92 mmol, 1.0 equiv.) in 2,2,2-trichloroethanol (4.0 mL) under N2. The reaction mixture
was then cooled to 0 °C. A solution of EDC (0.901 g, 4.70 mmol, 1.2 equiv.) in anhydrous CH2Cl2
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(2.8 mL) was added dropwise. The mixture was warmed to rt and stirred overnight. The solution
was partitioned between H2O (40 mL) and CH2Cl2 (40 mL). The layers were separated and the
aqueous layer extracted further with CH2Cl2 (3 x 20 mL). The combined organic layers were
dried over MgSO4, filtered and concentrated. The pale yellow oil was purified by flash
chromatography on silica gel, eluting with 4% MeOH in CH2Cl2 to give Boc-L-His-OTCE (97) as a
colorless solid (1.21 g, 80%). Rf 0.21 (9:1 CH2Cl2-MeOH). [α]25D -16.2 (c 1.0, CHCl3). 1H-NMR (400
MHz, CDCl3) δ 1.44 (s, 9H), 3.15 (dd, J = 14.7, 4.8 Hz, 1H), 3.22 (dd, J = 14.7, 4.8 Hz, 1H), 4.63 (d,
J = 11.9 Hz, 1H), 4.66-4.70 (m, 1H), 4.81 (d, J = 11.9 Hz, 1H), 6.15 (br s, 1H), 6.84 (s, 1H), 7.57 (s,
1H); 13C-NMR (100 MHz, CDCl3) δ 28.3, 29.4, 53.7, 74.5, 80.1, 94.6, 115.4, 134.4, 135.3, 155.7,
170.8. HRMS (ESI+) calcd for C13H18Cl3N3O4Na (M+Na)+ 408.0255, obsd 408.0243.

Scheme 2.37: Synthesis of compound 98
Sulfamidate (98). Triethylamine (520 μL, 377 mg, 3.73 mmol, 3.0 equiv) was added to a stirred
solution of Fmoc-D-Ser-OBn (69) (519 mg, 1.24 mmol, 1.0 equiv) in dry CH2Cl2 (11 mL) under N2
at -78 °C. Distilled thionyl chloride (135 μL, 222 mg, 1.87 mmol, 1.5 equiv) was added dropwise
over 5 min which turned the solution yellow. After 2 h at -78 °C, H2O (7 mL) was added and the
mixture was warmed to rt. The two layers were separated and the aqueous layer was extracted
with CH2Cl2 (3 x 11 mL). The combined organic layers were washed with 5% citric acid (8 mL)
and brine (8 mL). The organic layer was dried over MgSO4, filtered and concentrated. The crude
sulfamidite (104) was taken to the next step.
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The residue was dissolved in MeCN (8 mL) and cooled to 0 °C. Sodium periodate (283
mg, 1.32 mmol, 1.1 equiv) was added followed by ruthenium (III) chloride (25 mg, 0.120 mmol,
0.1 equiv). Water (5 mL) was added dropwise to the solution and the mixture was left to stir
vigorously for 1 h at 0 °C. The mixture was allowed to warm to rt and stirred an additional 15
min. The mixture was diluted with Et2O (15 mL), and the two layers separated. The aqueous
layer was extracted with Et2O (3 x 15 mL) and the combined organic layers were washed with
sat’d aq. NaHCO3 (2 x 15 mL) and brine (15 mL), dried over MgSO4, filtered and concentrated.
The light yellow oil was purified by flash chromatography on silica gel, eluting with 5:1 hexanesEtOAc

3:1 hexanes: EtOAc, to give Fmoc-D-Ser-OBn derived sulfamidate as a colorless

solid (97) (417 mg, 70%). Rf 0.34 (2:1 Hexane-EtOAc). 1H NMR (400 MHz, CDCl3) δ 4.26 (br s, 1H),
4.44 (t, J = 8.8 Hz, 1H), 4.56 (appt. t, J = 8.8 Hz, 1H), 4.72 (d, J = 8.7 Hz, 1H), 4.83 (t, J = 8.7 Hz,
1H), 4.87 (br s, 1H), 5.24 (d, J = 3.0 Hz, 2H), 7.30 – 7.37 (m, 7H), 7.41 (t, J = 7.4 Hz, 2H), 7.67 (br
s, 2H), 7.76 (d, J = 7.5 Hz, 2H);

13

C NMR (100 MHz, CDCl3) δ 14.2, 46.5, 58.0, 60.4, 68.1, 68.7,

70.7, 120.1, 125.3, 127.4, 128.1, 128.3, 128.8, 128.9, 134.3, 141.3, 141.3, 142.8, 142.9, 149.5,
166.5; HRMS (-ESI) calcd for C25H20NO7S (M-H)- 478.0966, obsd 478.0958.

Scheme 2.38: Synthesis of compound 72
τ-HAL derivative (72). Boc-L-His-OMe (59) (51 mg, 0.19 mmol, 3.0 equiv.) was added to a
solution of sulfamidate 98 (30 mg, 0.06 mmol, 1.0 equiv.) in 1,2-DME (3 mL). This mixture was
then heated at 80 °C under N2 and allowed to stir for 5 h. 1 M potassium phosphate (6 mL) was
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added to the mixture which then stirred at RT overnight. This mixture was partitioned between
EtOAc (3 mL) and H2O (3 mL) to dissolve the precipitate. The two layers were separated, and
the aqueous layer was extracted with EtOAc (3 x 3 mL). The combined organic extracts were
dried over MgSO4, filtered and concentrated. The clear oil was subjected to flash
chromatography on silica gel, eluting with 2:1 hexanes-EtOAc, to give τ-HAL (72) as a colorless
oil (13 mg, 30%). Rf 0.34 (95:5 CH2Cl2-MeOH). 1H NMR (CDCl3, 400 MHz) δ 1.42 (s, 9H,tBu), 2.91
(dd, J = 14.0, 3.2 Hz, 1H, Hβ), 2.99 (dd, J = 14.0, 5.1 Hz, 1H, H’β), 3.69 (s, 3H, OMe), 4.21 (t, J =
6.3 Hz, 1H, Fmoc-CH), 4.29, (br s, 2H, Hβ’), 4.41-4.53 (m, 3H, Fmoc-CH2, Hα), 4.62 (m, 1H, Hα’),
5.16 (d, J = 11.9 Hz, 2H, CH2OBn), 5.26 (d, J = 11.9 Hz, 2H, CH2OBn), 5.58 (d, J = 5.2 Hz, 1H, NH),
5.89 (d, J = 7.8 Hz, 1H, NH), 5.89 (d, J = 7.8 Hz, 1H, NH), 6.32 (s, 1H, H5), 7.16 (s, 1H, H2), 7.31 –
7.42 (m, 11 H, Fmoc-Ar, Ph-Ar), 7.58 (d, J = 7.2 Hz, 2H, Fmoc-Ar), 7.78 (d, J = 7.2 Hz, 2H, FmocAr); 13C NMR (CDCl3, 100 MHz) δ 28.3 ((CH3)3), 30.1 (Cβ), 30.9, 47.1 (Fmoc-CH), 47.9 (Cβ’), 52.2
(OMe), 53.5 (Cα), 54.8 (Cα’), 67.2 (CH2Ph), 68.2 (Fmoc-CH2), 79.6 (4°Boc), 117.1, 120.1 (FmocAr), 125.0 (Fmoc-Ar), 125.0 (Fmoc-Ar), 127.1 (Fmoc-Ar), 127.2 (Fmoc Ar), 127.9 (Fmoc Ar), 128.5
(Ph-Ar), 128.9 (Ph-Ar), 129.0 (Ph-Ar), 129.1(Ph-Ar), 134.3 (C=C Ph), 137.5 (C5), 141.3 (C2), 143.5,
143.6, 155.6, 168.8, 172.5; HRMS (+ESI) calcd for C37H41N4O8 (M+H)+ 669.2919, obsd 669.2932.

Scheme 2.39: Synthesis of compound 106
H-D-Ser(OTBS)-OH (106).28 A suspension of commercially available H-D-Ser-OH (105) (1.00 g,
9.52 mmol, 1.0 equiv.) in anhydrous DMF (10 mL) was treated with imidazole (1.30 g, 19.0
mmol, 2.0 equiv.) and TBDMS-Cl (1.58 g, 10.5 mmol, 1.1 equiv.) under N2. The solution was left
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to stir at rt overnight. A biphasic solution of 1:1 H2O:hexanes (30 mL) was added and the
mixture stirred for an additional 4 h. The resulting solid was collected by filtration, rinsed with
hexanes, and air dried to give H-D-Ser(OTBDMS)-OH (106) as a colorless solid (1.89 g, 90%). Rf
0.56 (6:4:1 CHCl3-MeOH-H2O). [α]20D 1.21 (c 0.174, MeOH), Lit.29

ent-X

[α]20D -29.3 (c 0.174,

MeOH). 1H NMR (CDCl3, 400 MHz) δ 0.11 (s, 6H, CH3Si), 0.92 (s, 9H, tBuSi), 3.63 (pent., J = 3.9
Hz, 1H, Hα), 4.00 (dd, J = 10.9, 5.9 Hz, 1H, Hβ), 4.04 (dd, J = 10.8 ,3.8 Hz, 1H, Hβ’), 4.82 (br s, 2H,
NH2); 13C NMR (CD3OD, 100 MHz) δ -6.8, 17.9, 25.0, 56.6, 62.2, 170.5.

Scheme 2.40: Synthesis of compound 107
Fmoc-D-Ser(OTBS)-OH (107).30 1,4-Dioxane (5 mL) was added to a cooled solution of H-DSer(OTBDMS)-OH (106) (1.00 g, 4.56 mmol, 1.0 equiv.) in 10% aq. Na2CO3 (10 mL) at 0 °C and
stirred for 5 min. A solution of Fmoc-Cl (2.03 g, 9.80 mmol, 1.03 equiv.) in 1,4-dioxane (7.5 mL)
was added dropwise. The mixture was stirred for 1 h at 0 °C and then allowed to warm to rt to
stir overnight. The reaction mixture was concentrated to remove the dioxane, and the residual
aqueous solution was acidified to pH 4 by the dropwise addition of 1 M HCl. The aqueous layer
was extracted with EtOAc (3 x 50 mL). The combined extracts were washed with brine (30 mL),
dried over MgSO4, filtered and concentrated. The pale oil was purified by flash chromatography
on silica gel, using a gradient system eluting first with 95:5 Hexanes-EtOAc
EtOAc

5:1 Hexanes-EtOAc

10:1 Hexanes-

2:1 Hexanes-EtOAc to give Fmoc-D-Ser(OTBDMS)-OH (107)

as a colorless oil (1.75 g, 87%). Rf 0.40 (9:1 CH2Cl2-MeOH). 1H NMR (CDCl3, 400 MHz) δ 0.07 (s,
6H, CH3Si), 0.90 (s, 9H, tBuSi), 3.87 (d, J = 6.6 Hz, 1H, Hβ), 4.13 (t, J = 7.3 Hz, 1H, Fmoc-CH2), 4.04
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(t, J = 6.2 Hz, 1H, Hβ’), 4.40 (t, J =7.9 Hz, 1H, Fmoc-CH), 4.46 (m, 1H, Hα), 5.61 (d, J = 6.8 Hz, 1H,
NH), 7.31 (t, J = 7.1 Hz, 2H, Fmoc-Ar), 7.40 (t, J = 7.1 Hz, 2H, Fmoc-Ar), 7.60 (t, J = 7.1 Hz, 2H,
Fmoc-Ar), 7.76 (d, J = 7.1 Hz, 2H, Fmoc-Ar); 13C NMR (CDCl3, 100 MHz) δ -5.5, 18.2, 25.7, 47.2,
55.6, 63.3, 67.3, 120.0, 125.2, 127.1, 127.7, 141.3, 143.8, 156.1, 174.4; HRMS (ESI+) calcd for
C24H32NO5Si (M+H)+ 442.2044, obsd 442.2051.

Scheme 2.41: Synthesis of compound 108
Fmoc-D-Ser(OTBDMS)-OtBu (108).31 Fmoc-D-Ser(OTBDMS)-OH (107) (700 mg, 1.59 mmol, 1.0
equiv.) was dissolved in tert-butanol (16 mL) and heated gently (~27 °C) under N2 to keep the
tert-butanol liquid. Di-tert-butyl dicarbonate (1.38 g, 6.34 mmol, 4.0 equiv.) and DMAP (58 mg,
0.48 mmol, 0.3 equiv.) were added sequentially, and the solution was allowed to stir at 27 °C
for 16 h. The solution was concentrated and the residue purified by flash chromatography on
silica gel, eluting with 10:1 hexanes-EtOAc to give Fmoc-D-Ser(OTBDMS)-OtBu (107) as a pale
yellow oil (670 mg, 85%). Rf 0.45 (5:1 Hexanes-EtOAc). 1H NMR (CDCl3, 400 MHz) δ 0.05 (s, 3H,
CH3Si), 0.06 (s, 3H, CH3Si), 0.89 (s, 9H, tBuSi), 1.48 (s, 9H, OtBu), 3.85 (dd, J = 9.8, 2.5 Hz, 1H, Hβ),
4.04 (dd, J = 9.8, 1.7 Hz, 1H, H’β), 4.24 (t, J = 7.0 Hz, 1H, Fmoc-CH), 4.28-4.32 (m, 1H, Hα), 4.36
(d, J = 7.2 Hz, 2H, Fmoc-CH2), 5.62 (d, J = 7.8 Hz, 1H, NH), 7.30 (t, J = 7.3 Hz, 2H, Fmoc-Ar), 7.39
(t, J = 7.4 Hz, 2H, Fmoc-Ar), 7.61 (t, J = 7.0 Hz, 2H, Fmoc-Ar), 7.76 (d, J = 7.5 Hz, 2H, Fmoc-Ar); 13C
NMR (CDCl3, 100 MHz) δ -5.5, 18.2, 25.7, 28.1, 30.9, 47.2, 56.4, 63.8, 67.1, 82.1, 120.0, 125.2,
127.1, 127.7, 141.3, 143.8, 144.0, 155.9, 169.5; HRMS (ESI+) calcd for C28H39NO5SiNa (M+Na)+
520.2490, obsd 520.2496.
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Scheme 2.42: Synthesis of compound 80
Fmoc-D-Ser-OtBu (80).32 A solution of Fmoc-D-Ser(OTBDMS)-OtBu (108) (700 mg, 1.41 mmol,
1.0 equiv.) in 6:3:1 THF-HCOOH-H2O (125 mL) was stirred at rt for 4 h. The mixture was cooled
to 0 °C and neutralized with sat’d. aqueous NaHCO3 (125 mL). The mixture was partitioned
between EtOAc (300 mL) and brine (300 mL). The aqueous layer was further extracted with
EtOAc (300 mL). The combined organic layers were dried over anhydrous MgSO4, filtered, and
concentrated. The residue was purified by flash chromatography on silica gel, eluting with 5:1
hexanes-EtOAc to give Fmoc-D-Ser-OtBu as a colorless solid (448 mg, 83%). 1H NMR and

13

C

NMR data were in good agreement with compound 80 prepared via reaction of Fmoc-D-Ser-OH
and tert-butyl-2,2,2-trichloroacetimidate.

Scheme 2.43: Synthesis of compound 110
Sulfamidate (110). Triethylamine (382 μL, 277 mg, 2.7 mmol, 3.0 equiv) was added to a stirred
solution of Fmoc-D-Ser-OtBu (350 mg, 0.91 mmol, 1.0 equiv) in dry dichloromethane (8 mL)
under N2 at -78 °C. Distilled thionyl chloride (99 μL, 163 mg, 1.4 mmol, 1.5 equiv) was added
dropwise over 5 min. After 1 h at -78 °C, H2O (5 mL) was added and the mixture was warmed to
rt. The two layers were separated and the aqueous layer was extracted with dichloromethane
(3 x 8 mL). The combined organic layers were washed with 5% citric acid (6 mL) and brine (6
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mL). The organic layer was dried over MgSO4, filtered and concentrated. The crude sulfamidite
(109) was taken to the next step.
The residue was dissolved in acetonitrile (5.3 mL) and cooled to 0 °C. Sodium periodate
(187 mg, 0.88 mmol, 1.1 equiv) was added followed by ruthenium (III) chloride (17 mg, 0.08
mmol, 0.1 equiv). Water (3.3 mL) was added dropwise to the solution and the mixture was left
to stir for 1 h at 0 °C. The mixture was diluted with diethyl ether (10 mL), and the two layers
separated. The aqueous layer was extracted with diethyl ether (3 x 10 mL) and the combined
organic layers were washed with sat’d aq. NaHCO3 (2 x 10 mL) and brine (10 mL), dried over
MgSO4, filtered and concentrated. The light yellow oil was purified by flash chromatography on
silica gel, eluting with 10:1 hexanes-EtOAc, to give Fmoc-D-Ser-OtBu derived sulfamidate 110 as
a colorless solid (284 mg, 70%). Rf 0.39 (2:1 Hexanes-EtOAc). [α]25D +15.9 (c. 1.0, CHCl3). 1H NMR
(400 MHz, CDCl3) δ 1.51 (s, 9H, tBu), 4.35 (app. t, J = 7.4 Hz, 1H, Hβ), 4.48 (dd, J = 10.2,7.6 Hz,
1H, H’β), 4.61 (dd, J = 10.2, 7.6 Hz, 1H, H), 4.72-4.77 (m, 2H, Fmoc-CH2), 4.82-4.87 (m, 1H,
Fmoc-CH), 7.34 (t, J = 7.4 Hz, 2H, Fmoc-Ar), 7.43 (t, J = 7.4 Hz, 2H, Fmoc-Ar), 7.72 (br s, 2H,
Fmoc-Ar), 7.78 (d, J = 7.5 Hz, 2H, Fmoc-Ar); 13C NMR (100 MHz, CDCl3) δ 27.8, 46.6, 53.5, 58.5,
68.5, 70.6, 85.0, 120.1, 125.4, 127.4, 128.1, 141.3, 142.9, 143.0, 149.6, 165.6. HRMS (ESI+) calcd
for C22H23NNaO7S (M+Na)+ 468.1087, obsd 468.1069.

Scheme 2.44: Synthesis of compound 15
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τ-HAL (15). Boc-L-His-OTCE (96) (302 mg, 0.781 mmol, 3.0 equiv.) was added as a solid to a
solution of sulfamidate (97) (127 mg, 0.265 mmol, 1.0 equiv.) in 1,2-DME (7.0 mL). The mixture
was heated at 80 °C under N2 and allowed to stir for 5 h. An aqueous solution of 1 M potassium
dihydrogen phosphate (7.0 mL) was immediately added to the mixture and allowed to cool and
stir at rt overnight. The mixture was partitioned between EtOAc (22 mL) and H 2O (7.0 mL). The
two layers were separated, and the aqueous layer was extracted with EtOAc (3 x 11 mL). The
combined organic extracts were dried over MgSO4, filtered and concentrated. The clear oil was
subjected to flash chromatography on silica gel, eluting with 2:1 EtOAc-Hexanes, to give τ-HAL
(15) as a light yellow foam (105 mg, 50%). Rf 0.33 (95:5 CH2Cl2-MeOH). [α]25D -3.17 (c. 1.0,
CHCl3). 1H NMR (CDCl3, 400 MHz) δ 1.43 (s, 9H, Boc), 2.98 (dd, J = 14.4, 3.7 Hz, 1H, Hβ), 3.07 (dd,
J = 14.4, 5.2 Hz, 1H, H’β), 4.21 (t, J = 6.4 Hz, 1H, Fmoc-CH), 4.28 (br s, 2H, Hβ’), 4.40 (appt. t, J =
8.6 Hz, 1H, Fmoc-CH2), 4.52 (appt. t, J = 8.6 Hz, 1H, Fmoc-CH2), 4.60–4.61 (m, 2H, Hα, Hα’), 4.66
(d, J = 11.9 Hz, 1H, CH2TCE), 4.82 (d, J = 11.9 Hz, 1H, CH2TCE), 5.16 (d, J = 11.8 Hz, 1H, CH2OBn),
5.27 (d, J = 11.8 Hz, 1H, CH2OBn), 5.57 (d, J = 5.4 Hz, 1H, NH) 6.18 (d, J = 7.8 Hz, 1H, NH), 6.30 (s,
1H, H5), 7.08 (s, 1H, H2), 7.30-7.43 (m, 9H, Fmoc-Ar, Ph-Ar), 7.58 (d, J = 7.3 Hz, 2H, Fmoc-Ar),
7.78 (d, J = 7.2 Hz, 2H, Fmoc-Ar); 13C NMR (CDCl3, 100 MHz) δ 28.4, 29.6, 47.1, 47.8, 53.6, 54.7,
67.2, 68.3, 74.6, 79.8, 94.8, 117.1, 120.1, 125.0, 125.1, 127.1, 127.2, 127.9, 128.9, 129.1, 129.2,
134.3, 137.7, 141.4, 143.6, 155.5, 155.6, 168.8, 170.7; HRMS (ESI+) calcd for C38H40Cl3N4O8
(M+H)+ 785.1912, obsd 785.1906.

57

Scheme 2.45: Synthesis of compound 111
τ-HAL [His-NH2] (111). A solution of τ-HAL (15) (30 mg, 0.04 mmol, 1.0 equiv.) in CH2Cl2 (0.50
mL) was treated with TFA (0.50 mL) at 0 °C. The mixture was stirred at rt for 1 h, then quenched
with a 10% triethylamine in CH2Cl2 solution (0.50 mL). The solution was partitioned between
EtOAc (10 mL) and H2O (10 mL). The layers were separated, and the organic layer was washed
with brine (3 mL), dried over MgSO4, and concentrated. Diethyl ether was added to the residue
which was then concentrated. This was done two additional times. The residue was purified on
silica gel eluting with 9:1 CH2Cl2 -MeOH to give the free amine as a cloudy yellow oil (20 mg,
77%). Rf 0.21 (9:1 CH2Cl2-MeOH). [α]25D -3.0 (c. 1.0, CHCl3). 1H NMR (DMSO-d6, 400 MHz) δ 2.68
(dd, J = 13.9, 7.5 Hz, 1H, Hβ), 2.83 (dd, J = 14.3, 4.7 Hz, 1H, H’β), 3.72 (t, J = 5.8 Hz, 1H, Hα),
4.13-4.38 (m, 5H, Hβ’, Fmoc-CH2, Fmoc-CH), 4.46-4.49 (m, 1H, Hα’), 4.85 (s, 2H, CH2TCE), 5.13
(d, J = 12.6 Hz, 1H, CH2OBn), 5.17 (d, J = 12.6 Hz, 1H, CH2OBn), 6.93 (s, 1H, H5), 7.30 – 7.34 (m,
10H, Fmoc-Ar, Ph-Ar), 7.42 (t, J = 7.4 Hz, 2H, Fmoc-Ar), 7.48 (s, 1H, H2), 7.65 (t, J = 7.0 Hz, 2H,
Fmoc-Ar), 7.90 (d, J = 7.4 Hz, 2H, Fmoc-Ar), 8.02 (d, J = 8.4 Hz, 2H, NH); 13C NMR (d6-DMSO, 100
MHz) δ 33.6, 46.4, 47.0, 54.7, 55.4, 66.3, 66.9, 73.7, 95.7, 117.8, 120.6, 125.6, 127.6, 128.1,
128.3, 128.6, 128.9, 136.0, 137.6, 138.0, 141.2, 144.1, 144.2, 156.4, 170.1, 173.9. HRMS (ESI+)
calcd for C33H31Cl3N4O6 (M+H)+ 685.1382, obsd 685.1387.

58

Scheme 2.46: Synthesis of compound 112
τ-HAL [Ala-OH] (112). τ-histidinoalanine (15) (30 mg, 0.04 mmol , 1.0 equiv.) was dissolved in
anhydrous THF (1 mL) and 10% Pd-C (9 mg, 30% w/w) was added under N2. The suspension was
stirred at rt under an atmosphere of H2 for 4 h. The reaction mixture was filtered through a
syringe filter, and the filtrate was concentrated. The residue was purified on silica gel eluting
with 20% EtOH in CH2Cl2 to give the free acid 112 as a colorless oil (20 mg, 77%). Rf 0.20 (9:1
CH2Cl2-MeOH). [α]25D -2.98 (c. 1.0, CHCl3). 1H NMR (DMSO-d6, 400 MHz) δ 1.35 (s, 9H), 2.822.90 (m, 2H, Hβ), 4.11-4.24 (m, 4H, Hβ’, Fmoc-CH, Hα’), 4.29 (t, J = 10.9 Hz, 2H, Fmoc-CH2), 4.354.40 (m, 1H, Hα), 4.82 (d, J = 12.3 Hz, 1H, CH2TCE), 4.91 (d, J = 12.3 Hz, 1H, CH2TCE), 6.87 (s, 1H,
H5), 7.28 (d, J = 7.8 Hz, 1H, NH), 7.33 (t, J = 7.4 Hz, 2H, Fmoc-Ar), 7.41 (t, J = 7.4 Hz, 2H, FmocAr), 7.45 (s, 1H, H2), 7.65 (t, J = 12.0 Hz, 2H, Fmoc-Ar), 7.89 (d, J = 7.5 Hz, 3H, NH, Fmoc-Ar); 13C
NMR (DMSO-d6, 100 MHz) 28.6, 29.8, 47.1, 47.3, 54.1, 55.4, 66.1, 74.0, 79.0, 95.5, 118.0, 120.6,
125.6, 125.7, 127.6, 128.1, 136.9, 138.1, 141.2, 144.3, 144.4, 155.7, 156.2, 171.3, 171.6; HRMS
(ESI+) calcd for C31H34Cl3N4O8 (M+H)+ 695.1437, obsd 695.1426.

Scheme 2.47: Synthesis of compound 113
τ-HAL [His-OH] (113). Zinc dust (125 mg, 2.00 mmol , 50.0 equiv.) was added to a solution of τhistidinoalanine (15) (30 mg, 0.04 mmol , 1.0 equiv.) in glacial acetic acid (1.5 mL). The mixture
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was stirred at rt for 16 h. The zinc dust and colorless precipitate that formed was filtered off.
The residue was dissolved in EtOAc (5 mL) and washed with H2O (5 mL), brine (2 x 5 mL), dried
over MgSO4, filtered, and concentrated. The residue was purified on silica gel eluting with 9:1
CH2Cl2:MeOH to give the free acid 113 as a cloudy pale yellow solid (15 mg, 80%). Rf 0.34 (9:1
CH2Cl2-MeOH). [α]25D -8.12 (c. 1.0, CHCl3). 1H NMR (DMSO-d6, 400 MHz) δ 1.34 (s, 9H, Boc),
2.89 (dd, J = 14.9, 9.5 Hz, 1H, Hβ), 3.02 (dd, J = 14.9, 4.3 Hz, 1H, H’β), 4.18-4.42 (m, 5H, Hα, Hβ’,
Fmoc-CH2), 4.57-4.65 (m, 2H, Hα’, Fmoc-CH), 5.17 (s, 2H, CH2OBn), 7.20 (d, J = 8.0 Hz, 1H, NH),
7.30-7.34 (m, 10H, Fmoc-Ar, Ph-Ar, H5, H2), 7.42 (t, J = 7.5 Hz, 2H, Fmoc-Ar), 7.64 (d, J = 7.5 Hz,
2H, Fmoc-Ar), 7.90 (d, J = 7.5 Hz, 2H, Fmoc-Ar), 8.10 (d, J = 8.2 Hz, 2H, NH), 8.73 (br s, 1H,
COOH); 13C NMR (d6-DMSO, 100 MHz) δ 28.5, 29.5, 30.4, 46.4, 47.0, 54.4, 55.3, 66.3, 66.9, 78.3,
117.4, 120.6, 125.6, 127.6, 127.8, 128.1, 128.3, 128.5, 128.9, 129.4, 136.0, 137.9, 138.2, 141.2,
144.1, 144.2, 155.7, 156.4, 170.1, 174.6; HRMS (ESI+) calcd for C36H39N4O8 (M+H)+ 655.2762,
obsd 655.2763.

Scheme 2.48: Synthesis of compound 114
τ-HAL [Ala-NH2] (114). τ-Histidinoalanine (15) (45 mg, 0.06 mmol) was dissolved in a mixture of
Et2NH (0.6 mL) and MeCN (0.6 mL). The mixture was allowed to stir for 45 min, until the starting
material was completely consumed. The solution was concentrated and then concentrated
twice more from CH3CN (2 x 3 mL). The residue was purified by flash chromatography on silica
gel eluting with 4% MeOH in CH2Cl2 to give the free amine as a colorless oil (35 mg, 94%). Rf
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0.62 (9:1 CH2Cl2-MeOH). [α]25D -2.1 (c. 1.0, CHCl3). 1H NMR (CDCl3, 400 MHz) δ 1.44 (s, 9H, Boc),
2.63 (br s, 2H, NH2), 3.04 (dd, J = 14.7, 4.3 Hz, 1H, Hβ), 3.13 (dd, J = 14.7, 5.7 Hz, 1H, H’β), 3.82
(app. t, J = 4.9 Hz, 1H, Hα), 4.15 (dd, J = 14.1, 5.7 Hz, 1H, Hβ’) 4.22 (dd, J = 14.1, 4.4 Hz, 1H, H’β’),
4.64 (d, J = 11.8 Hz, 1H, CH2TCE), 4.83 (d, J = 11.8 Hz, 1H, CH2TCE), 5.16 (d, J = 11.9 Hz, 1H,
CH2OBn), 5.21 (d, J = 11.9 Hz, 1H, CH2OBn), 6.20 (d, J = 8.0 Hz, 1H, NH), 6.62 (s, 1H, H5), 7.357.41 (m, 5H, Ph-Ar), 7.46 (s, 1H, H2);

13

C NMR (CDCl3, 100 MHz) 28.4, 29.4, 50.3, 53.6, 55.0,

67.7, 74.5, 79.8, 94.7, 117.4, 128.8, 128.9, 134.8, 137.0, 137.6, 155.7, 170.6, 172.1; HRMS (ESI+)
calcd for C23H30Cl3N4O6 (M+H)+ 563.1225, obsd 563.1204.
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2.5.2 1H and 13C NMR Spectra
Fmoc-D-Ser-OBn in CDCl3 at 400 MHz

Compound 69 (Scheme 2.20) – 1H NMR spectrum
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Compound 69 (Scheme 2.20) – 13C NMR spectrum
Fmoc-D-Ser-OBn in CDCl3 at 400 MHz
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Compound 70 (Scheme 2.5) – 1H NMR spectrum
Fmoc-D-Ser(I)-OBn in CDCl3 at 400 MHz

Acetone
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Compound 70 (Scheme 2.5) – 13C NMR spectrum
Fmoc-D-Ser(I)-OBn in CDCl3 at 400 MHz
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Compound 76 (Scheme 2.8) – 1H NMR spectrum
Fmoc-D-Ser-OSEM in CDCl3 at 400 MHz
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Compound 76 (Scheme 2.8) – 13C NMR spectrum
Fmoc-D-Ser-OSEM in CDCl3 at 400 MHz
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Compound 80 (Scheme 2.9) – 1H NMR spectrum
Fmoc-D-Ser-OtBu in MeOD at 400 MHz

H2O
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Compound 80 (Scheme 2.9) – 13C NMR spectrum
Fmoc-D-Ser-OtBu in MeOD at 100 MHz

69

Compound 81 (Scheme 2.9) – 1H NMR spectrum
Fmoc-D-Ser(I)-OtBu in CDCl3 at 400 MHz

Acetone
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Compound 81 (Scheme 2.9) – 13C NMR spectrum
Fmoc-D-Ser(I)-OtBu in CDCl3 at 400 MHz

71

Compound 78 (Scheme 2.9) – 1H NMR spectrum
Fmoc-D-Ser(I)-OH in CD3OD at 400 MHz

H2O
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Compound 78 (Scheme 2.9) – 13C NMR spectrum
Fmoc-D-Ser(I)-OH in CD3OD at 400 MHz
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Compound 82 (Scheme 2.10) – 1H NMR spectrum
Boc-L-His(Trt)-OMe in CDCl3 at 400 MHz
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Compound 82 (Scheme 2.10) – 13C NMR spectrum
Boc-L-His(Trt)-OMe in CDCl3 at 400 MHz
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Compound 83 (Scheme 2.10) – 1H NMR spectrum
Boc-L-His(π-Pac, τ-Trt)-OMe imidazolium bromine salt in CDCl3 at 400 MHz
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Compound 83 (Scheme 2.10) – 13C NMR spectrum
Boc-L-His(π-Pac, τ-Trt)-OMe imidazolium bromine salt in CDCl3 at 400 MHz
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Compound 84 (Scheme 2.10) – 1H NMR spectrum
Boc-L-His(π-Pac)-OMe in CDCl3 at 400 MHz
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Compound 84 (Scheme 2.10) – 13C NMR spectrum
Boc-L-His(π-Pac)-OMe in THF-d8 at 400 MHz
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Compound 100 (Scheme 2.18) – 1H NMR spectrum
Boc-L-His(Boc)-OTCE in CDCl3 at 400 MHz
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Compound 100 (Scheme 2.18) – 13C NMR spectrum
Boc-L-His(Boc)-OTCE in CDCl3 at 400 MHz
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Compound 97 (Scheme 2.19) – 1H NMR spectrum
Boc-L-His-OTCE in CDCl3 at 400 MHz
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Compound 97 (Scheme 2.19) – 13C NMR spectrum
Boc-L-His-OTCE in CDCl3 at 400 MHz
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Compound 98 (Scheme 2.20) – 1H NMR spectrum
Sulfamidate in CDCl3 at 400 MHz

EtOAc
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EtOAc

H2O EtOAc

Compound 98 (Scheme 2.20) – 13C NMR spectrum
Sulfamidate in CDCl3 at 400 MHz
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Compound 72 (Scheme 2.21) – 1H NMR spectrum
τ-HAL in CDCl3 at 400 MHz

Acetone
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Compound 72 (Scheme 2.21) – 13C NMR spectrum
τ-HAL in CDCl3 at 400 MHz
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Compound 106 (Scheme 2.22) – 1H NMR spectrum
H-D-Ser(OTBS)-OH in CDCl3 at 400 MHz
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Compound 106 (Scheme 2.22) – 13C NMR spectrum

H-D-Ser(OTBS)-OH in CDCl3 at 400 MHz
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Compound 107 (Scheme 2.22) – 1H NMR spectrum
Fmoc-D-Ser(OTBS)-OH in CDCl3 at 400 MHz
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Compound 107 (Scheme 2.22) – 13C NMR spectrum
Fmoc-D-Ser(OTBS)-OH in CDCl3 at 400 MHz
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Compound 108 (Scheme 2.22) – 1H NMR spectrum
Fmoc-D-Ser(OTBS)-OtBu in CDCl3 at 400 MHz
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Compound 108 (Scheme 2.22) – 13C NMR spectrum
Fmoc-D-Ser(OTBS)-OtBu in CDCl3 at 400 MHz
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Compound 110 (Scheme 2.23) – 1H NMR spectrum
Sulfamidate in CDCl3 at 400 MHz

H2O

Hexane
s

CH2Cl2
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Compound 110 (Scheme 2.23) – 13C NMR spectrum
Sulfamidate in CDCl3 at 400 MHz
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Compound 15 (Scheme 2.24) – 1H NMR spectrum
τ-HAL in CDCl3 at 400 MHz
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Compound 15 (Scheme 2.24) – 13C NMR spectrum
τ-HAL in CDCl3 at 400 MHz
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Compound 111 (Scheme 2.25) – 1H NMR spectrum
τ-HAL [His-NH2] in DMSO at 400 MHz

H2O

CH2Cl2
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Compound 111 (Scheme 2.25) – 13C NMR spectrum
τ-HAL [His-NH2] in DMSO at 400 MHz
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Compound (Scheme 2.25)– 1H NMR spectrum
τ-HAL [Ala-OH] in DMSO at 400 MHz

H2O

CH2Cl2

EtOH

100

Compound 112 (Scheme 2.25) – 13C NMR spectrum
τ-HAL [Ala-OH] in DMSO at 400 MHz
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Compound 113 (Scheme 2.25) – 1H NMR spectrum
τ-HAL [His-OH] in DMSO at 400 MHz

H2O
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Compound 113 (Scheme 2.25) – 13C NMR spectrum
τ-HAL [His-OH] in DMSO at 400 MHz
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Compound 114 (Scheme 2.25) – 1H NMR spectrum

τ-HAL [Ala-NH2] in CDCl3 at 400 MHz
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Compound 114 (Scheme 2.25) – 13C NMR spectrum

τ-HAL [Ala-NH2] in CDCl3 at 400 MHz
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CHAPTER 3: NEAR-INFRARED NANOGUMBOS PRODRUG DELIVERY SYSTEM
3.1 Cancer: An Overview
Cancer is the unregulated growth of genetically-mutated cells that form masses called
tumors over time. These tumors eventually become malignant, or mobile, in advanced stages of
cancer through metastasis and migrate to other parts of the body and form new tumors. The
rapidly growing cells eventually displace normal cells and disrupt function of the infected
tissues and organs.
There are over 100 different forms of cancer, with 14 types making up over 80% of all
cases diagnosed. Cancer cells can develop in any of our tissues, but are most commonly found
in epithelial (carcinomas), connective (sarcomas), and blood-forming (leukemias) tissues. It is
noteworthy that more than 90% of all human cancers are carcinomas.1
It is estimated that over 1.6 million people in the United States will be diagnosed with
some form of cancer in 2014, with prostate cancer being the leader for men at 27% of cases
and breast cancer for women at 29% (Table 3.1).2
Table 3.1: Ten leading cancer types for estimated new cancer cases in 2014 by sex in the United
States, adapted with permission.2

109

If these numbers are extrapolated globally, the estimated number grows to over 14
million.3,4 Developed countries have traditionally had the highest incidences of cancer; more
recently, developing countries in Africa, South America, and Asia make up over 70% of all new
reported cases. The cancer epidemic is a worldwide problem and adversely affects everyone.
3.1.1 Chemotherapy
The complexity of cancer, with the ability of cancer cells to adapt, has resulted in a
myriad of cancer therapies including: surgery, chemotherapy, radiation therapy, hyperthermia,
and photodynamic therapy. Most therapies can be divided into two major groups: preventative
therapies aimed at identifying and eradicating cancer cells before they become malignant, and
therapies that contain the spread of cancer cells before metastasis. All cancer therapies try to
target characteristics that are unique to cancer cells so as not to damage normal cells, however
the amount of success in that endeavor is dependent on the treatment.
Surgery and radiation therapy are most effective during the early stages of cancer
before metastasis. They operate at the point of origin, removing and killing tumors with the
hope that all cancer cells are eradicated and have not spread. In a lot of cases, this has proven
adequate treatment for the cancer to not return. However, if even one errant cell escapes, the
process starts over again. This is where chemotherapy is most effective, as it acts systematically
with the chemotherapeutic drugs distributed throughout the entire body.
3.2 Paclitaxel
Paclitaxel (Figure 3.1) was isolated from the bark of the Pacific yew tree, Taxus brevifolia
by Monroe Wall and Mansukh Wani in 1967.5 Commercially known as TaxolTM, this potent
chemotherapeutic agent, by way of inhibition of mitosis, is used clinically to treat non-small cell
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lung, ovarian, and breast tumors. Systematic toxicity, poor aqueous solubility, and drug
resistance have marred drug development and to some extent delayed widespread clinical
usage.

Figure 3.1: Structure of Paclitaxel
3.2.1 Paclitaxel Mode of Action
TaxolTM belongs to a class of cancer compounds called taxanes. Taxanes inhibit mitosis
by acting on tubulin, specifically interfering with polymerization of microtubulins. Microtubules
are derived from polymerized heterodimers of α and β-tubulin proteins. These proteins are
found in eukaryotic cells where they facilitate intracellular trafficking of macromolecules and
organelles, along with regulating maintenance of cell shape, motility, and cell division
(mitosis).6 TaxolTM binds stoichiometrically to the β-tubulin subunit in malignant cells, stabilizing
the microtubule and suppressing disassembly. This over-stabilization prevents cell proliferation
and ultimately results in apoptotic cell death.7 Unfortunately, this mechanism proves to be nondiscriminating, also affecting normal cells, manifesting in bone marrow suppression
(myelosuppression), reducing the overall efficacy of the drug.8
3.2.2 Taxol Solubility in Aqueous Media
TaxolTM suffers from poor solubility in water (less than 0.03 mg/mL), and by proxy, in
biological systems.9 Clinically, TaxolTM is administered intravenously in a 1:1 solution of ethanol
and Cremophor EL (polyethoxylated castor oil, CrEL).10 Small doses are administered over a long
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period of time to suppress acute toxicity due to overdose and poor permeability. This
formulation has proven to have many side effects including hypersensitivity, nephrotoxicity and
neurotoxicity. Most of these effects stem from the CrEL vehicle.11 Precipitation of the
formulation upon aqueous dilution has also been reported.12
Alternative formulations of TaxolTM have been developed to eliminate usage of the CrEL
drug delivery vehicle by increasing aqueous solubility, which will also increase bioavailability.
The use of co-solvents and emulsions have markedly increased TaxolTM solubility in aqueous
media13 but do not address systematic toxicity associated with prolonged local drug delivery.
Drug delivery vehicles such as liposomes, prodrugs, and nanoparticle encapsulation have been
used to increase Taxol solubility through varying mechanisms, and could be effective systems in
preventing multidrug resistance.
3.2.3 Multidrug Resistance
Multidrug resistance (MDR) arises when cancer cells exhibit reduced sensitivity to
structurally and functionally different chemotherapeutic agents, and is a major factor in the
reduced effectiveness of many forms of chemotherapy.14 Tumor environments consist of mixed
populations of drug-sensitive and drug-resistant malignant cells. Inadequate drug exposure and
treatment-free periods due to intermittent chemotherapy select for drug-resistant cancer cells,
resulting in new tumors that are resistant to traditional chemotherapy.15
Various mechanisms by which cancer cells can acquire MDR have been identified;
however the most common is over-expression of the plasma membrane drug efflux
transporter, P-glycoprotein (P-gp). P-Glycoprotein belongs to the ATP-binding cassette family of
ABC transporters that facilitate intra- and extra-cellular trafficking of molecules across
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membranes.16 This protein behaves like a “pump” in drug-resistant cells, actively expelling
chemotherapeutic agents from the cell (Figure 3.2). Long-term drug exposure induces
overexpression of P-gp, effectively converting cancer cells into the drug-resistant type.17

Figure 3.2: Drug-resistant cell expelling chemotherapeutic agents via P-gp efflux pump. Adapted
with permission.
A series of studies conducted by the Piquette-Miller group have demonstrated
increased tumor responsiveness to chemotherapeutic agents administered at a low-dosage on
a more frequent, prolonged or sustained schedule.18 These studies were corroborated by Ho et
al. who reported that ovarian cancer tumors exposed to sustained delivery of TaxolTM did not
induce P-gp overexpression compared to traditional intermittent chemotherapy, which saw
significant downregulation.
A recent report by Pierre et al. reported significant cellular uptake of olivacine derivative
S16020-2 in cells in vitro and in vivo that exhibit resistance mediated by the MDR-1 phenotype
(Figure 3.3).19 This may be a result of the rapid uptake of the compound which bypasses the Pgp, leading to its high intracellular accumulation and effectiveness.
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Figure 3.3: S16020-2
With the ability of cancer cells to develop resistance to drugs that once proved effective,
it becomes imperative that we focus our efforts on how to administer these drugs more
effectively, specifically targeting drug delivery systems that can administer a drug’s dosage
rapidly and efficiently at the site of interest over a sustained period of time. This system would
ideally eradicate cancer cells faster than they could develop resistance. Carrier-linked vehicles,
or prodrugs, seem to meet these criteria.20
3.3 Prodrugs
“Drugs need to be designed with delivery in mind.” - Takeru Higuchi21
The last couple of decades have seen exponential growth in the research and
development of prodrugs (Chart 3.1).

Chart 3.1: Plot of published journal articles, reviews, patents, conference proceedings, and
clinical trials using the search term prodrugs according to Sci-Finder Scholar Database
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Prodrugs currently account for 10% of globally marketed drugs, with 2008 being a
highlight year where one-third of all approved small molecular weight drugs were prodrugs.22
Prodrugs are biologically inactive precursors to therapeutic agents that undergo
enzymatic or chemical transformation in vivo to release a bioactive drug. They are designed to
increase the efficacy of a parent drug through optimization of a drug’s ADMET (absorption,
distribution, metabolism, excretion, and unwanted toxicity) properties. Although designdependent, prodrugs can be very effective in addressing many of the stability, solubility,
permeability and targeting problems that plague drug discovery and development, and is often
a more practical solution than searching for new therapeutic agents that meet ADMET
criteria.23
Mechanistically, prodrugs work through modification of a functional group that is
responsible for biological activity, temporarily masking the chemical reactivity of the active
compound. Functional groups that are amenable to prodrug design include carboxylate,
hydroxyl, amine, thiol, phosphate/phosphonate and carbonyl groups.
There are two main classes of prodrugs: carrier-linked prodrugs, and bioprecursor
prodrugs. Carrier-linked prodrugs bond the parent drug to a promoiety (carrier) either directly
or through a linker via a bioreversible covalent linkage in the form of esters, carbonates,
carbamates, amides, phosphates and oximes.
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Biotransformation of the prodrug through

hydrolysis, oxidation, or reduction releases the parent drug and the carrier (Figure 3.4).
Macromolecular prodrugs (macromolecular promoiety), and drug-antibody conjugates
(antibody promoiety) can be classified as carrier-linked prodrugs.25 Bioprecursor prodrugs do
not contain a promoiety but result from a molecular modification of the active compound itself.
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Biotransformation of the bioprecursor prodrug occurs metabolically or chemically by hydration,
oxidation, or reduction. Examples of these prodrug classes are given throughout the chapter.

Figure 3.4: Biotransformation of prodrug into parent molecule
3.3.1 Trimethyl Lock – Kinetics and Application
Many groups have successfully incorporated TaxolTM into prodrug systems, reporting
improvements such as increased water solubility, reduced cytotoxicity, and enhanced
permeability. The trimethyl lock carrier-linked prodrug is a great example of this system used to
solvate TaxolTM.
The coumarin-based promoiety, i.e. o-hydroxydihydrocinnamic lactone derivatives, have
found use as a versatile prodrug carrier due to their tunable “trimethyl lock” motif. The name is
derived from unfavorable steric interactions between three pendant methyl groups which
encourage rapid lactonization to form a dihydrocoumarin derivative (Scheme 3.1).

Scheme 3.1: Rapid lactonization to hydrocoumarin facilitated by the trimethyl lock
phenomenon.
The trimethyl lock (TML) system was first investigated by Louis A. Cohen who found that
substituted phenol acid derivatives undergo spontaneous lactonization in mild biological
116

systems.26 The rate constant for lactonization of 117 was found experimentally to exceed that
of the non-methylated version by a factor of 3 x 1015 M3. Cohen postulated this was due to a
“relief-of-strain”. This was further corroborated by a study that replaced all the methyl
hydrogens with deuterium, decreasing the lactonization rate by 10%, presumably because
deuterium-carbon bonds are shorter.
The trimethyl lock system is a viable prodrug strategy for alcohols, but also makes
amines accessible as well. Usually amines aren’t utilized in prodrug systems because they
hydrolyze too slowly to be useful, however, when installed in a trimethyl lock system, lactams
form at similar rates to the analogous lactones.27
This system is highly tunable and can be modified to address different phyisochemical
properties of cancer therapeutic drugs. If the aromatic ring is phosphorylated it can enhance
water solubility of historically insoluble drugs such as TaxolTM. The Borchardt group employed
this technique, incorporating TaxolTM into a trimethyl lock prodrug moiety that had been
phosphorylated. They observed markedly increased solubility in water [>10 mg/mL at 37 °C]
compared to free Taxol [~2 μg/mL] (Figure 3.5, 121-122). They also reported that derivative 122
was as potent as TaxolTM in an M109 mouse xenograft model, requiring no solubilizing agents
for in vivo studies.28 In contrast, attempts to increase solubility by phosphorylation of the
hydroxyl groups positioned at C7 or C2’ of free TaxolTM by the Doyle group were unsuccessful.
They found that although water solubility did increase for the phosphorylated derivatives, the
phosphoryl groups could not be hydrolyzed in plasma or by alkaline phosphatase (Figure 3.5).29
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Figure 3.5: Structures of TaxolTM (115), phosphorylated TaxolTM derivatives (119-120), and
trimethyl lock-based TaxolTM prodrugs (121-122)
If the TML motif is embedded in a quinone precursor, reduction triggers aromatization
and lactonization. This increases the system’s site-selectivity as tumors have high levels of
reductase enzymes and low oxygen tension. Cho et al. demonstrated this in their preparation of
polymeric nanoparticles composed of the shell: a biodegradable polymer, which was
conjugated to the trimethyl lock-based benzoquinone via an amide linkage, and a TaxolTM core
(Scheme 3.2).30 Upon reduction of the quinone moiety to a free phenol by sodium dithionite,
the encapsulated Taxol was released after spontaneous lactonization, producing a water
soluble polymer and a biocompatible dihydrocoumarin derivative as byproducts. About 52% of
the TaxolTM was released in vitro within three hours of sodium dithionite treatment.

Scheme 3.2: Reduction of benzquinone-based trimethyl lock prodrug by sodium dithionate to
release TaxolTM, and dihydrocoumarin-derivative and a water soluble polymer chain as
byproduct
The findings of Cho et al. highlight a shift towards using nanoparticles as prodrug
delivery vehicles “to enhance storage stability, modulate prodrug release, enhance tumor-
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targeting, and protect against enzymatic attack”.31 Efficiency of the drug carrier is crucial for
optimal employment of prodrug’s ADMET enhancing properties.
3.4 Nanomaterials
A diverse range of nanomaterials has been developed to address rapid deactivation,
poor solubility, and biodistribution challenges. These include inorganic materials (quantum
dots, metal oxides, gold nanoparticles, carbon nanotubes), and organic materials (liposomes,
natural and synthetic polymers, dendrimers) (Figure 3.6).32 Drugs can be attached,
encapsulated, absorbed, entrapped, or dissolved in these materials rendering them as drug
delivery vehicles.

Figure 3.6: Selected examples of organic and inorganic nanoparticles. Reprinted with
permission.31
Many of these materials are biocompatible, and biodegradable, breaking down to form
benign species. They range from 10-100nm in scale, small enough to penetrate capillaries and
be taken up by malignant tissues, but large enough to target and deliver at specified sites via
the enhanced permeation and retention (EPR) effect. The EPR effect is due to the anatomic and
pathophysiological differences between tumors and normal tissues (Figure 3.7). Angiogenesis,
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which is the ability for tumors to develop nerve systems, leads to high vascular density which
causes large gaps in the endothelial cells in tumor blood vessels. This allows for enhanced drug
uptake in tumor tissue instead of normal tissues.

Figure 3.7: Tumor uptake of nanoscale drug carriers via the EPR effect. Reprinted with
permission.32
A polymeric nanoparticle, with prostate-specific membrane antigen (PSMA) targeting
properties is currently in clinical trials.33 This nanoparticle, which contains Docetaxal, another
member of the taxane family, attributed its enhanced tumor accumulation and prolonged
tumor growth suppression in part due to the EPR effect. This accumulation was not seen with
solvent-based Docetaxal formulations.
3.4.1 Targeted Drug Delivery
Although traditional prodrug strategies have helped to improve physiochemical
properties of chemotherapeutic agents, allowing for enhanced permeability, targeting, and
overall increased effectiveness, they didn’t address dosage. They only allowed for a slower
release of the drug at a predetermined rate. There has been increasing interest in developing
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methods where drug release can be controlled directly. These remote control systems could
dictate the timing, duration, dosage, and location of drug release.
There have been many recent reports of new materials that have been designed with
specific sensitivity to visible light, near-infrared (NIR) light, ultrasound, and magnetic fields
making these viable triggers for on-demand drug delivery. To be an effective trigger, the system
must allow for precise control of the timing, duration, and magnitude of drug release. 34
Ultraviolet and visible light are strongly absorbed by the skin and tissue and cannot be
utilized in applications that require activation deep into skin tissue. However, one of the
advantages of using light in the NIR region, ca. 650-900 nm is its minimal absorbance by skin
and tissue. At the low end of this region, hemoglobin absorbs light (650 nm) while at the high
end the absorbance of water (900 nm) (Figure 3.8).
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Figure 3.8: NIR Therapeutic Optical Window.35
The ANSI (American National Standards Institute) has given maximum exposure values
for human tissue using a 700 nm light from a continuous wave source to be between 200 mW
cm-2 for long exposure and as high as 10 W cm-2 for no longer than a second. NIR triggers more
specifically also have the added benefit of photothermal application, where absorption in the
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NIR region of specific materials often leads to a thermally induced change. Remotely triggered
drug delivery systems are most ideally suited for nanoscale applications as they can take
advantage of the EPR effect.32
3.4.2 NanoGUMBOS: NIR-based Targeted Drug Delivery Application
Not all nanomaterials are biocompatible, and frequently some materials are thought to
be non-toxic only to be revealed to be cytotoxic upon further studies. Carbon nanotubes, silver
nanoparticles, and quantum dots are examples of nanomaterials that have been proposed as
drug delivery vehicles that can assist with permeation,36 but are known for their acute toxicity
in biological systems.37 Ionic liquid-based nanoparticles are a promising alternative to these
existing inorganic nanomaterials.
Ionic liquids are organic salts with melting points below 100 °C. They can be divided into
two categories, room temperature ionic liquids (RTIL), which are ionic liquids that are in the
liquid state at room temperature, and frozen ionic liquids, which are solid above room
temperature. Their low melting point stems from the asymmetry of the ion pairs, preventing
stable crystal lattice stacking.38 Ionic liquids usually contain a 1:1 ratio of an organic cation and
an inorganic or organic anion. Some common anion and cation combinations are outlined in
Figure 3.9.
Ionic liquids have powerful solvent capabilities due to their diverse ion pairings.
Although the concept of ionic liquids is not new, suspending them as nanoparticles is fairly
recent. The Warner group has pioneered these ionic liquid-based nanoparticles giving them the
portmanteau GUMBOS or (groups of uniform materials based on organic salts).39
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Figure 3.9: Common cations and anions used in ionic liquids.
What distinguishes these materials from traditional nanoparticles, is that nanoGUMBOS
can be designed for specific uses, rather than simply adapted for a particular use after being
synthesized. The myriad of different ion combinations available make these nanomaterials
extremely tunable. They can be prepared from biologically safe compounds and depending on
the application and ion pairs used, can increase permeability through biological membranes,
add optimal site-selectivity, and minimize non-specific cytotoxicity. Their high melting points
versus traditional ionic liquids lend them thermal stability.
Dumke et al. recently demonstrated the high photothermal stability of near-infraredbased GUMBOS (NIR-nanoGUMBOS).40 They paired an organic NIR-absorbing laser dye (IR1048, IR-1061 not shown) with either deoxycholate or ascorbate (Scheme 3.3). They prepared
the bulk GUMBOS using the ion exhange method, which is the process of mixing two charged
species, each introduced with a inorganic ion, in a biphasic system (i.e. water and
dichloromethane) resulting in migration of the formed inorganic salt to the aqueous layer, and
the organic salt to the organic layer.

123

Scheme 3.3: Ion exchange of NIR laser dye IR-1048 and deoxycholate or ascorbate.
Initial photothermal response of the solid bulk GUMBOS under continuous irradiation at
1000 mW led to heat generation within seconds upon excitation, reaching temperatures as high
as 500 °C (Figure 3.10, A). In contrast, when the bulk GUMBOS were suspended in aqueous
media as nanoGUMBOS, excitation led to more reasonable temperatures between 40-50 °C
(Figure 3.10, B).
A

B

Figure 3.10: Photothermal profile of 4 mg bulk GUMBOS and nanoGUMBOS samples under
continuous NIR irradiation for five minutes at a 1000 mW. Reprinted with permission.40
The purpose of this study was to introduce nanoGUMBOS as novel materials for NIRlaser-triggered hypothermia cancer therapy. These nanoGUMBOS can be prepared using
biocompatible compounds (e.g. vitamins, amino acids, organic acids) which would assist in
tumor targeting. Their “nano” size (10-100 nm) enables the rapid uptake in cellular membranes
and increased permeability. Preliminary results with these NIR-based nanoGUMBOS in
experiments with malignant MDA-MB-231 and non-malignant HS-578-BST epithelial human
breast cells demonstrate the ability of the particles to reach the temperature threshold
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necessary for cancer cell apoptosis.41 These results make nanoGUMBOS a promising candidate
for use as a drug delivery system. Ideally, a chemotherapeutic agent could be incorporated into
NIR-based nanoGUMBOS and, due to their powerful solvent properties and high temperature
threshold, would lend stability at high temperatures and increased solubility.
3.5 Drug Delivery System Overview
We demonstrate in the next chapter our proposed nano-mediated prodrug system that
attempts to address the aforementioned limitations of drug delivery by focusing on
transporter-mediated delivery of cancer agents to help permeate membranes, and exploring an
alternative prodrug “trigger”. Because of GUMBOS’ inherent stability at high temperatures,
they should also exhibit better control of photothermal destruction of cancerous tissues.
Prodrugs that could take advantage of the high temperature threshold of the GUMBOS by using
indirect heat generated from light absorption of organic NIR absorbing dyes as a trigger,
combined with ease of permeability via nanoparticles would make an innovative drug delivery
system.
We ultimately want to attach a full TaxolTM moiety to a trimethyl lock-based prodrug
conjugate, and subsequently convert the system into NIR-based GUMBOS (Figure 3.11). This
will be achieved by giving the prodrug an anionic functionality. Synthesis of the drug delivery
system will focus on four main goals: 1) Synthesis of a model prodrug system with Taxol
sidechain, 2) rearrangement studies in different solvent systems, 3) synthesis of NIRGUMBOS/nanoGUMBOS derivatives of model produg, and 4) rearrangment studies of NIRGUMBOS in the presence of laser irradiation.
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Figure 3.11: Trimethyl lock-based TaxolTM prodrug incorporated into NIR-absorbing
nanoGUMBOS
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CHAPTER 4: SYNTHESIS OF ALLYL AND PRENYL ETHERS AND INVESTIGATION OF THE TANDEM
CLAISEN REARRANGEMENT-LACTONIZATION REACTIONS
4.1 Drug Delivery System: Mechanism of Action
Our thermally-induced prodrug drug delivery system involves two reactions (Scheme 4.1):
1) Upon heating, a [3,3]-sigmatropic rearrangement (aromatic Claisen rearrangement)
will occur, followed by tautomerism, revealing the free phenol.
2) Spontaneous lactonization based on the well-established “trimethyl lock” (TML) motif
previously discussed in Chapter 3 would then release the drug molecule.

Scheme 4.1: Ionic liquid-based prodrug drug delivery system. NIR+= cationic near-infrared laser
dye
4.2 Claisen Rearrangement: A [3,3’]-Sigmatropic Rearrangement
Since its discovery in 1912 by Ludwig Claisen, the Claisen rearrangement and its many
variations has become a significant stereoselective carbon-carbon-bond forming reaction.1
Originally, the Claisen rearrangement was described as “the thermal isomerization of an allyl
aryl ether” and was eventually expanded to include rearrangements of allyl vinyl ethers into
unsaturated carbonyl compounds, which were then classified as [3,3’]-sigmatropic
rearrangements (Scheme 4.2).2

Scheme 4.2: [3,3]-Sigmatropic rearrangement of allyl vinyl ether
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It is generally accepted that the aromatic Claisen rearrangement proceeds through a
concerted pericyclic reaction (Scheme 4.3, ts1).3 Upon heating, the allyl ether moiety undergoes
a [3,3’] shift resulting in bond formation between the -carbon of the allyl group and the carbon
on the aromatic ring at the ortho-position to the ether, generating the trienone intermediate
(133, Scheme 4.3). If there are no substituents present at the ortho position, the dienone
intermediate undergoes rapid enolization to re-establish aromaticity to generate the ortho allyl
phenol product (134, Scheme 4.3).

Scheme 4.3: Aromatic Claisen rearrangement mechanism with alternative transition state
Theoretical and experimental studies have been ongoing to elucidate the mechanism for
the Claisen rearrangement.4 A number of reports attempted to clarify the geometry of the
transition state. Most groups agree that the Claisen rearrangement proceeds via a favorable sixmembered ring chair-like transition state (Scheme 4.3, ts1), however there have been
alternative transition states proposed. One proposal suggests the formation of “ion
pairs”(Scheme 4.3, ts2) as an intermediate step between the allyl aryl ether and the dienone.
The allyl group will ionize as an anion and the aromatic moiety as a cation.5 The true nature of
the transition state probably lies between these two scenarios, and is likely substrate
dependent.
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4.2.1 Aromatic Claisen Rearrangement: Solvent Effects
Under standard conditions, the aromatic Claisen rearrangement proceeds at high
temperatures, between 180°C-225 °C, in a hydrocarbon solvent. It has been established
experimentally that the reaction rate increases marginally in protic solvents; the more polar the
solvent, the faster the reaction rates.6 This marginal increase in rate has resulted in the
exploration of catalysts for milder conditions. Water has been shown to accelerate Claisen
rearrangements, lowering the temperature required.7 Rearrangements that can occur at
temperatures below 70 °C are important in order for this reaction to be feasible in physiological
systems.
4.2.2 Water Promoted Claisen Rearrangement: Mechanistic Studies
Deducing the mechanism behind the water-induced acceleration of the Claisen
rearrangement has proven difficult. Early on, this was mostly due to the false assumption that
all variations of the Claisen rearrangement were generally resistant to solvent effects.8 As more
studies appeared, detailing the accelerating effects of hydrogen-bonding solvents on the
pericyclic rearrangement, interest grew in understanding the mechanism. Early theories hinted
at the importance of hydrogen bonding,9 at first contested,10 but eventually corroborated by an
enlightening study done by two groups out of Cornell and Indiana universities in the late 80’s.11
They were studying solvent effects on the non-enzymatic Claisen rearrangement of chorismate.
Chorismate (135) is the anionic form of chorismic acid, which is an important biological
precursor to aromatic amino acids such as tryptophan, phenylalanine, and tyrosine, as well as
the precursor to the biosynthesis of folate and Vitamin K in plants, and ubiquinone. 12
Chorismate mutase catalyzes the rearrangement of chorismate to prephenate in biological
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media (Scheme 4.4). Rearrangement of chorismate represents one of few examples of
pericyclic reactions in nature.

Scheme 4.4: Chorismate rearrangement to prephenate ion catalyzed by chorismate mutase
Surprisingly, the rearrangement of dimethyl chorismate in an aqueous methanolic
solution was only 18 times faster than that of allyl vinyl ether in the same solution. 11 They
concluded that the ability of chorismate to rapidly rearrange in biological media at room
temperature was largely due to the presence of an aqueous environment, and not by the
unusual structural motif as previously thought.
A Monte Carlo simulation done by Severance and Jorgenson further explored this
hydration theme in an effort to understand the role of enhanced solvent hydrogen bonding in
accelerating the rate of Claisen rearrangements.13 They concluded that “with hydrogen bonding
increasing as the reactant moves towards the transition state, n->π* conjugation in the vinyl
ether ground state is disrupted,” stabilizing the transition state and lowering the activation
barrier for rearrangement (Figure 4.1).4

Figure 4.1: Solvent hydrogen bonding in vinyl ether transition state
High-resolution X-ray structures of the N-terminal domain of the E. Coli enzyme
chorismate mutase prephenate dehydratase (EcCM)14 and the monofunctional B. subtilis
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chorismate mutase (BsCM)15 provided real mechanistic insight into the role water plays in this
biologically relevant Claisen rearrangement.
Both BsCM and EcCM structures were solved as complexes with a chorismate-type
intermediate 137 (Figure 4.2). The Ganem group, who reported the X-ray structure of EcCM,
postulated that adjacent, positively charged active site residues exert conformational control by
locking the reoriented chorismate ion in the requisite chair conformer for rearrangement. This
stabilizes the transition state in a network of hydrogen bonds which reduces the activation
enthalpy for rearrangement. Of particular importance are the Lys39 and Gln88 residues in the
EcCM enzyme and arginine residue 90 in the BsCM enzyme which forms two hydrogen bonds
with the enol ether group of the chorismate ion that further promotes the pericyclic
rearrangement.

Figure 4.2: Amino acid residues of active site in EcCM and BsCM complexed with dianionic
competitive inhibitor 137
4.3 Synthesis of Prodrug Conjugate Model System
On the basis of this background information on Claisen rearrangements, specifically
acceleration in aqueous solutions, we sought to apply this reaction to our prodrug project. As
TaxolTM has precedent for successful incorporation into prodrugs, it will serve as our target drug
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for drug release.16 TaxolTM’s amino alcohol sidechain provides the opportunity to conjugate via
an ester linkage, and cleavage of that bond will be the focus of our prodrug model system.
Because there is a proven, established linkage site, we can focus our efforts on the thermal
release of the drug.
4.3.1 Retrosynthetic Analysis
Scheme 4.5 outlines our approach to the assembly of the prodrug model system. To test
the feasibility of the system, we opted to synthesize a model system that will mimic Taxol TM
drug release (Scheme 4.5, 141). Structure-activity relationship studies determined that the bulk
of TaxolTM’s biological activity is centered on the amido alcohol sidechain, particularly the
hydroxyl group.17 If this group is masked, in our case as an ester, the biological activity will be
severely reduced. Because of this, we have opted to synthesize the Taxol sidechain 142 as a
simplified representative for the drug molecule. This will then be conjugated to the allyl ether
trimethylock linker 143.

Scheme 4.5: Retrosynthetic analysis of prodrug model system 140
4.3.2 Previous Synthesis of Taxol Sidechain Amino Alcohol
In 1999, the Choi group published the highly enantioselective one-step synthesis of the
paclitaxel side chain precursor, (2R,3S)-isopropyl 3-benzamido-2-hydroxy-3-phenylpropionate
(142).18 This was achieved through Sharpless asymmetric aminohydroxylation of isopropyl
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trans-cinnamate. Through careful optimization of the chiral ligands, solvent choice, and mole
ratio of ligand to oxidant they were able to synthesize the amino alcohol in 40% yield with 97%
e.e. Although there are other reported syntheses of amido alcohol 142,19 the convenience of a
one-step asymmetric synthesis with high enantioselectivity offsets the poor yield.

Scheme 4.6: Asymmetric aminohydroxylation of isopropyl trans-cinnamate
Preparation of TaxolTM sidechain 142 is outlined in Scheme 4.7. Bromobenzamide (145)
was prepared via bromination of benzamide in moderate yield. Synthesis of bromobenzamide
was not trivial and required interpretation of dated literature procedures 20 and optimization of
the purification step. Bromobenzamide cannot be stored at room temperature, or exposed to
light for long periods of time as it degrades back to its parent compound benzamide. It also
reacts rapidly when in solution, preventing purification by column chromatography.
Fortunately, recrystallization from chloroform-hexanes, provided colorless crystals that could
be stored indefinitely at 0 °C.
Trans-cinnamic acid 147 was protected as the isopropyl ester using standard EDC
coupling conditions in good yield. The trans-cinnamate ester was subjected to Sharpless
conditions for amino hydroxylation giving a mixture of products. While the two regioisomers
142 and 146 could be separated by flash column chromatography, 142 was contaminated with
diol 149. Removal of the diol was achieved using HPLC.
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Scheme 4.7: Synthesis of Taxol amido alcohol sidechain
With the purified TaxolTM side-chain fragment in hand, we turned our attention to the
allyl ether trimethyl lock reaction partner (Scheme 4.8). 3,5-Dimethylphenol was converted to
lactone 151 via acid catalyzed aromatic alkylation in good yield.21 The lactone was then opened
with one equivalent of potassium hydroxide. The phenol is deprotonated with sodium hydride,
and the resulting salt is reacted with allyl bromide to give intermediate 152. The allyl ester is
then removed by hydrolysis to furnish compound 143 in moderate yield. Monoallylation is not
possible due to the trimethylock effect. If the phenol is left unprotected, spontaneous
lactonization will occur, cleaving the allyl ester.

Scheme 4.8: Synthesis of allyl ether trimethylock linker 143
Next, amido alcohol 142 was coupled to the acid 143 using procedures based on those
of Tsuchiya and coworkers, EDC/DMAP, to give the prodrug model system 141 in good yield
(Scheme 4.9).22 Surprisingly the bulkiness of the gem-dimethyl group did not seem to impede
the coupling of the two reaction partners.

137

Scheme 4.9: Coupling of amido alcohol 142 and acid 143 to give prodrug model system 141
4.4 Rearrangement Studies
With the model system prepared, we turned our efforts towards studying solvent
effects on the rearrangement of model system 141 (Scheme 4.10). We were specifically
searching for a solvent system that would give us efficient rearrangement at the lowest possible
temperature (Table 4.1), as this system will eventually be used under physiological conditions.

Scheme 4.10: Thermal rearrangement of prodrug model system 141
We first explored the time required for rearrangement in a traditional hydrocarbon
solvent to establish a “baseline”. Our findings are summarized in Table 4.1. Although TLC
confirmed the disappearance of compound 141 and the emergence of lactone 153 and amido
alcohol 142, continued heating for complete disappearance of starting material led to
degradation of both products. We next tested ethylene glycol, a moderately polar compound
that should decrease the time required for maximum rearrangement. To reduce the risk of
product degradation, the reaction was stopped after 24 hours. Product isolated was not
positively identified from the mixture. It was apparent that the high temperatures were having
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undesired consequences on the rearrangement products. We next moved to aqueous solutions,
first attempting water as the sole solvent. All attempts to promote rearrangement were
unsuccessful; it seems that the presence of a co-solvent (MeOH) was needed to realize the rate
accelerating effects of water. We can only conclude that to promote rearrangement in pure
water, vigorous stirring that promotes universal contact between both hydrophobic and
hydrophilic layers is crucial.
Table 4.1: Various solvents, temperatures, and reaction times for thermal Claisen
rearrangement trials of model system 141. Yields are given.
Trial
1
2
3
4

Solvent
Xylenes
Ethylene Glycol
H2O
3:1 EtOH:H2O

Temp. (°C) Reaction Time (h)
100-140
16 h – 72
110
24
rt – 100
24 h – 48
100
24

Disappearance 141 (%)
100 (loss of 141)
30
0 – trace
67

4.5 “On-Water” Claisen Rearrangement
A report by the Sharpless group detailed the enhanced reactivity of pericyclic reactions
in aqueous suspensions,23 in particular, they demonstrated an aromatic Claisen rearrangement
in various solvents at room temperature, noting 100% conversion using solely water after 120
hours (Scheme 4.11, Table 4.2). This was of interest to us, as previously stated, we were not
able to lower the temperature required for rearrangement under 100 °C. Upon closer
inspection, the only distinguishing feature was the presence of a gem-dimethyl group on the
allyl moiety. There was no discussion on why this particular substrate was chosen for
rearrangement studies. This 1,1-dimethylallyl group (DMA), is also known as a “reverse” prenyl
group.
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Scheme 4.11: Aromatic Claisen rearrangement of 1-(4-chloronaphthyl)-1,1-dimethylallyl ether
at room temperature
Table 4.2: Comparison of solvents for aromatic Claisen rearrangement of 1-(4-chloronaphthyl)1,1-dimethylallyl ether and associated yields.23
Solvent
Toluene
DMF
CH3CN
MeOH
Neat
“On H2O”

Yield [%]
16
21
27
56
73
100

4.6 Prenyl Moiety and its Derivatives
The prenyl group (3-methyl-but-2-en-1-yl) and its derivatives 1,1-dimethylallyl, geranyl
(E-3,7-dimethyl-2,6-octadienyl), and lavandulyl (5-methyl-2-isoprophenyl-hex-4-enyl) are
hydrophobic moieties derived from isoprene (Figure 4.3).

Figure 4.3: Prenyl group and its derivatives
Prenyl groups in the form of prenylated proteins were first identified by the Harker
group during a study of the effects of plasma lipoproteins on smooth muscle cells.24 During
preparation of the lipoproteins, the centrifuge process to extract and separate the lipoproteins
from blood cells inadvertently separated the lipoproteins from platelets and a then-unknown
growth factor. This growth factor, which was later identified as platelet-derived growth factor
(PDGF), was purified and used to stimulate Swiss 3T3 cells which were used in mevalonic acid140

based DNA synthesis studies. The Harker group observed cellular uptake of the acid into cell
proteins which was regulated by prenyl containing proteins.24 Since then over 100 prenyl
transferases have been identified as a result of posttranslational modification of proteins in
eukaryotic cells.
The prenyl structural motif can be found in many natural products including flavonoids,
xanthones, and cyanobactins. Each of these families represents a diverse group of compounds
that are known to have anti-malarial, anti-cancer, anti-oxidant, anti-bacterial, and antiinflammatory properties. These properties are often attributed to the lipophilic nature of the
prenyl moiety, which facilitates transmembrane transport, and may increase biological activity.
4.6.1 Claisen Rearrangement: Is There An Enzyme In Nature?
The aforementioned natural products all undergo electrophilic alkylation via a prenyl
transferase enzyme. These enzymes install the prenyl group as a fixed moiety, where it is not
altered after installation. In general, it has been established that aromatic prenyl transferases
attach prenyl groups at the ortho-position via electrophilic aromatic substitution (Scheme 4.12,
Pathway II).25

Scheme 4.12: 1) Mechanism of action for LynF demonstrated on tyrosine (Pathway I) 2) LynF
enzyme sequence 159 3) Traditional prenyl transferase mechanism of installation of prenyl
group ortho to the phenol
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However, with the recent characterization of the enzyme LynF (159, Scheme 4.12),
isolated from the marine cyanobacterium Lyngbya aestuarii, may challenge that assumption.26
LynF, from the TruF family, represents the first prenyl transferase enzyme characterized
that leads to the synthesis of ribosomal peptide natural products. Most dimethylallyl
pyrophosphate (DMAPP) based transferases functionalize single amino acids or small
dipeptides. LynF acts by a novel mechanism in that it O-prenylates (reverse and forward)
tyrosine, serine, and threonine residues in polypeptides, specifically cyanobactins, after the
leader sequence and recognition elements have been removed. This is a deviation from the
traditional ribosomal peptide natural product synthesis model which requires a leader
sequence to direct post-translational modifications. The proposed mechanism of action of LynF
is O-prenylation, and then a Claisen rearrangement, that happens at physiological temperature
to give C-prenylation (Scheme 4.12, Pathway I).
Scientists have been unclear as to how prenylation occurs on peptides made by
ribosomes. It was suggested as early as the 1970’s that some natural products could arise by a
Claisen rearrangement, but experimental evidence for the proposal was lacking until now. The
LynF enzyme’s amino acid sequence is completely different from that of other prenyltransferring enzymes.
4.6.2 Computational Studies of Water-Accelerated gem-Dimethyl Allyl Ether Rearrangement
Cramer and Truhlar proposed that acceleration of Claisen rearrangements in aqueous
systems is caused by electrostatic polarization and first-hydration-shell hydrophilic effects. As
stated earlier Jorgenson and Severance used QM calculations to show that two water
molecules hydrogen-bond with the ether oxygen atom in the transition state and accelerate the
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reaction. Calculations by the Hillier group with two explicit solvent water molecules have been
used to explain the decrease in the activation energy due to solvation.
The Houk group developed a computation design of a biocatalyst for the Claisen
rearrangement of prenyl coumaryl ethers. They first conducted benchmark test on traditional
Claisen rearrangement substrates (i.e. aryl allyl ethers) where the activation enthalpy is known,
and then applied these calculations to the rearrangement of O-prenylated tyrosine.27
They calculated the aromatic Claisen rearrangement to be slower than its alkyl
counterpart, which agrees with experimental data. The activation energy was computed to be
5.6-7.1 kcal/mol higher in energy than the prototypical alkyl Claisen rearrangement. The larger
enthalpy of activation is due to the loss of aromaticity in the aromatic-Claisen TS. When these
same calculations were applied to the O-prenylated tyrosine, they found that explicit solvation
was necessary for acceleration of the Claisen rearrangement, and for lowering the activation
barrier. Hydrogen bonding plays a significant role, especially between protic solvents and the
TS, resulting in a lower barrier to activation.
4.6.3 Experimental Evidence of gem-Dimethyl Allyl Ether Rearrangement
Literature evidence for rate-acceleration of Claisen rearrangements by gem-dimethyl
substituents is scarce. Harfenist and Thom demonstrated the rate-acceleration of propargyl aryl
ethers in o-dichlorobenzene in 1972 (Scheme 4.13).28 They found, during rearrangement
studies, that the addition of one methyl substituent at the α-position increases the Claisen-like
cyclization by a factor of 10. A second methyl group increases the rate by a factor of 1000
(Table 4.3).
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Scheme 4.13: Relative rates of cyclization and chemical yields of propargyl aryl ether derivatives
in o-dichlorobenzene
Table 4.3: Relative rates of cyclization and chemical yields of propargyl aryl ether derivatives in
o-dichlorobenzene
Propargyl ether R1 R2 R3
krela
160a
H
H
NO2 1
160b
H
Me NO2 9.1
160c
Me Me NO2 1400
160d
H
H
CN 1
160e
H
Me CN 10
160f
Me Me CN 1000
a
Data were extrapolated to 161.6 °C.

Yield (%)
46
84
75
99
100

This experimental data suggests that the gem-dimethyl group is the sole determining
factor in the rate acceleration of the Claisen rearrangement. To our knowledge, there haven’t
been any studies concerning the rate acceleration properties of the 1,1-dimethylallyl group on
regular Claisen rearrangements nor rate acceleration kinetics.
4.7 Synthesis of O-Prenylated Derivatives
With the realization that the “reverse” prenyl group has rate accelerating properties, we
set out to synthesize a library of aryl DMA ethers with different substituents on the aromatic
ring (i.e. electron donating, electron withdrawing) to first demonstrate the rate-accelerating
effect of the gem-dimethyl group on the aromatic Claisen rearrangement and then to study
substituent effects on the rate acceleration of gem-dimethyl aryl allyl ethers compared to
traditional aryl allyl ethers.
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Naturally, we revisited the reported procedures for dimethylallylation of 4-chloro-1naphthol by the Sharpless group.23 They prepared compound 164 by installing a
dimethylpropargyl group on the hydroxyl group, followed by reduction of the triple bond in the
presence of barium sulfate to give the 1,1-dimethylallyl napthyl ether 154 (Scheme 4.14).

Scheme 4.14: Sharpless and coworkers synthesis of 4-chloro-1,1-dimethylallyl napthyl ether 154
We attempted to prepare 168 by analogy to Scheme 4.14. Transformation to ether 166, which
is mediated by copper chloride, proceeded smoothly, but is accompanied by formation of an
expected side product, allene 167 (Scheme 4.15). Compounds 166 and 167 could not be
separated by flash chromatography or HPLC. Reduction of the mixture of 166 and 167 led to a
mixture of 168 and 169, from which 168 could now be partially purified by HPLC. Due to the
tedious purification for both steps, a more efficient route to dimethylallyl ethers was sought.

Scheme 4.15: Attempted synthesis of aryl prenyl ether 168
An alternative approach to prenylate heteroatoms is the use of allylic carbonates and
Pd(PPh3)4. The DMA carbonate was prepared using n-butyllithium, 1,1-dimethylallyl alcohol,
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and isobutyl chloroformate in quantitative yield.

Using isobutyl prenyl carbonate (171)

compounds 168, and 173a-e were prepared in very high yields (85-90%) (Scheme 4.16).

Scheme 4.16: Synthesis of 1,1-dimethylallyl ether derivatives
After preparation of the library of DMA aryl ether derivatives, we turned to
rearrangement studies (Scheme 4.17). Substrate 168 was chosen as the prototype for a survey
of potential solvents for the reaction. Table 4.3 summarizes our findings. It was observed that
the DMA group does accelerate the Claisen rearrangement relative to prodrug model system
141 (Scheme 4.9) enough to facilitate rearrangement at 70 °C. Rearrangement at lower
temperatures was observed, but required longer time for complete conversion. It seems that
with the gem-dimethyl group present, the rearrangement is stunted in hydrocarbon solvents
but greatly accelerated in polar solvents. This was an interesting finding as traditional Claisen
rearrangements require high boiling hydrocarbon solvents for rearrangement. Another point of
interest was the rapid rearrangement of the prenylated ether (168) on pure water. The nonpolar nature of the DMA group rendered the compounds volatile liquids at room temperature.
On the positive side, this low viscosity enabled effective mixing of the hydrophobic and
hydrophilic layers.
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Scheme 4.17: Thermal rearrangement of aryl prenyl ether 168
Table 4.4: Comparison of solvents and reaction times for the aromatic claisen rearrangement of
aryl prenyl ether 168 and associated yields.
Trial
1
2
3
4
5

Solvent
Temperature (°C) Reaction Time (h)
Yield (%)
Neat
70
15
70
Xylenes
100-140
16 – 72
Trace-10
Ethylene Glycol
70
24
56
H2O
70
3 quantitative
3:1 EtOH:H2O
70
9
95

Since this project is focusing on rearrangement in aqueous solutions, the rest of the
derivatives underwent rearrangement in the EtOH:H2O solvent system and were compared to
the p-OMe derivative to see any trends. In essence, the electron donating groups at the para
position on the ring led to rearrangement at a faster rate than electron withdrawing groups,
which is a trend that has been observed in other systems.29 Although “on-water” conditions led
to the fastest reaction time and highest yield, subsequent trials were not reproducible due to
difficulty in achieving a consistent uniform dispersion of a heterogeneous mixture.
4.8 Synthesis of Second Generation Prodrug Model System: Preliminary Results
Now that rearrangement at acceptable temperatures has been achieved, the synthesis
of the second generation of the prodrug model system (175, Figure 4.5) was the next step. Due
to the nature of the installation of the DMA group via the allylic carbonate, it wasn’t feasible to
use this same method in conjugation with the prodrug model system (Scheme 4.16). Excess
base is present when lactone 151 is opened, and the resultant nucleophiles could compete with
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the Pd(0) to give isobutyl alkylation instead of prenyl alkylation. Our goal was to synthesize this
second generation model system in an efficient manner.

Figure 4.4: 1st and 2nd generation prodrug model systems
Our first approach was a direct alkylation of DMA derivative 173b with dimethyl
acrylate, analogous to the preparation of the lactone precursor 151 (vide supra, Scheme 4.8).
Unfortunately, many byproducts were formed including the rearranged product, and
subsequent lactonization of the free phenol. Methanesulfonic acid appears to be too acidic for
the DMA group.

Scheme 4.18: Attempted aromatic alkylation of aryl prenyl ether 173b
A less direct approach involved converting the acid in compound 142 to a tert-butyl
ester (Scheme 4.19). We postulated that the bulky ester would prevent the lactonization upon
liberation of the phenol. Steric hindrance around the acid is known to disfavor bulky
alkylation.30 Deallylation of the allyl ether proceeded smoothly by TLC, but subsequent NMR of
the recovered product revealed the lactone 151 as the major product.
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Scheme 4.19: Attempted synthesis of compound 178
It appeared that a straightforward, short synthesis of the DMA prodrug model system was not
going to be possible. There were a few relevant reports that reduced the acid to a primary
alcohol, effectively eliminating the problematic spontaneous lactonization. This gives us the
opportunity to install the DMA group on the phenol without interference.
Thus, synthesis of model system 175 begins with LAH reduction of lactone 151 to give
diol 179 in modest yield (Scheme 4.20). The primary alcohol was then protected as a TBDMS
group in excellent yield. Initially, we attempted to install the DMA ether using the established
procedures. However, the bulkiness of the TBS group, and the gem-dimethyl groups of the
substituent ortho to the phenol were hindering alkylation. Longer reaction times and heat (50
°C) were needed to get some conversion to the DMA ether. Oxidation with Jones Reagent,
cleaving the TBDMS group in situ, will furnish free acid 182. Standard coupling using EDC/DMAP
gives DMA prodrug model system 175.

Scheme 4.20: Proposed synthesis of second generation prodrug model system 175
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4.9 Experimental Section
General Methods: All reactions were performed under a dry nitrogen atmosphere unless
otherwise noted. All chemicals and reagents were purchased from Sigma-Aldrich, Fisher, and
Acros and used without further purification. Triethylamine and diethylamine were dried and
distilled from CaH2 and stored over KOH pellets. Dry methanol was distilled from Mg turnings
and stored over 3Å molecular sieves. Flash chromatography was performed using 230-400
mesh silica gel (40-63 µm) from Sigma-Aldrich.

Reactions were followed by thin layer

chromatography (TLC) on pre-coated aluminum-backed 60 F254 silica plates from EMD
Chemicals, Inc. Compounds were visualized under UV fluorescence or by staining with KMnO 4,
or an acidic, ethanolic solution of ninhydrin.

1

H and 13C NMR spectra were recorded at room

temperature on a Bruker AV-400 or Bruker Nanobay-400 and are reported in parts per million
(ppm) on the δ scale relative to residual CHCl3 or CH3OH in deuterated solvents or
tetramethylsilane as an internal standard. Coupling constants (J) are reported in Hertz (Hz).
High resolution mass spectrometry (HRMS) was carried out using an Agilent 6210 electrospray
ionization-time-of-flight (ESI-TOF) mass spectrometer. Optical rotations were recorded under
the specified conditions.
4.9.1 Procedures

Scheme 4.21: Synthesis of compound 144
Isopropyl trans-cinnamate (144).31 A solution of DMAP (495 mg, 4.05 mmol, 1.2 equiv.) in
anhydrous CH2Cl2 (0.9 mL) was added dropwise to a suspension of trans-cinnamic acid (147)
(500 mg, 3.37 mmol, 1.0 equiv.) in isopropyl alcohol (3.4 mL) under N 2. The reaction mixture
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was cooled to 0 °C. A solution of EDC (776 mg, 4.05 mmol, 1.2 equiv.) in anhydrous CH 2Cl2 (2.4
mL) was added dropwise. The mixture was warmed to rt and stirred overnight. The solution was
partitioned between H2O (34 mL) and CH2Cl2 (34 mL). The layers were separated and the
aqueous layer extracted further with CH2Cl2 (3 x 17 mL). The combined organic layers were
dried over MgSO4, filtered and concentrated. The pale yellow oil was purified by flash
chromatography on silica gel, eluting with 2:1 hexanes:EtOAc to give isopropyl trans-cinnamate
as a light yellow viscous oil (490 mg, 76%). Rf 0.21 (9:1 CH2Cl2-MeOH). 1H-NMR (400 MHz,
CDCl3) δ 1.31 (d, J = 6.2 Hz, 6H, CHMe2), 5.14 (septet, J = 6.2 Hz, 1H, iPr-CH), 6.42 (d, J = 16.0 Hz,
1H, CH=CH-Ph), 7.36-7.38 (m, 3H, Ar-H), 7.52 (d, J = 3.3 Hz, 2H, Ar-H), 7.67 (d, J = 16.0 Hz, 1H,
CH=CH-Ph);
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C-NMR (100 MHz, CDCl3) δ22.0, 67.8, 118.8, 128.0, 128.9, 130.1, 134.6, 144.3,

166.5.

Scheme 4.22: Synthesis of compound 145
N-Bromobenzamide (145).20 Benzamide (148) (1.0 g, 8.3 mmol, 1.0 equiv.) was added to a
vigorously stirred solution of freshly prepared sodium hypobromite* (15 mL) at 0 °C. After 10
min, the solution was rapidly filtered, and the filtrate was collected in a flask containing an
aqueous solution of acetic acid (30%, 4 mL). The filtrate was discarded. The orange-yellow
precipitate that formed was then filtered, and washed with water that had been cooled to 0 °C.
The precipitate was dried under N2 and then vacuum to remove all water. The crude precipitate
(1.5 g) was dissolved in chloroform (25 mL) and heated at reflux. Immediately after the solid
had dissolved, the solution was transferred to an Erlenmeyer flask. This solution was treated
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with hexanes (~35 mL), and as the solution cooled, a colorless precipitate formed. The solid was
collected by filtration and washed with hexanes to give N-bromobenzamide as a colorless solid
(952 mg, 58%). Rf 0.50 (9:1 CH2Cl2-MeOH). The compound was stored in an amber vial at 0 °C to
avoid degradation back to benzamide.
*Sodium hypobromite was prepared by dissolving NaOH pellets (920 mg, 23.0 mmol, 2.80
equiv.) in H2O (14.4 mL) for a total volume of 15 mL. The solution was cooled to 0 °C. Bromine
(462 µL, 1.44 g, 9.01 mmol, 1.09 equiv.) was added dropwise and the solution was stirred for 10
min during which time it turned a bright yellow.

Scheme 4.23: Synthesis of compound 142, 149, and 146
Amido alcohol (142).18 K2OsO2(OH)4 (12 mg, 0.032 mmol, 0.04 equiv.) was added to an aqueous
solution of LiOH-H2O (7.1 mg, 0.30 mmol, 2.4 mL). After addition of MeCN (9.5 mL),
(DHQ)2PHAL (123 mg, 0.158 mmol, 0.20 equiv.) was added, and the mixture stirred for 10 min
giving a transparent solution. Water (2.4 mL) was added, and the mixture cooled to 0 °C. After
addition of isopropyl trans-cinnamate (144) (150 mg, 0.788 mmol, 1.00 equiv.), Nbromobenzamide (145) (315 mg, 1.580 mmol, 2.00 equiv.) was added in one portion, and the
mixture stirred vigorously at 0 °C for 10 h. The reaction color changed from deep green to
yellow. The reaction was quenched by the addition of sat’d aq. Na 2SO3 (~2-3 mL) and stirred for
an additional hour at 0 °C. The phases were separated, and the aqueous layer extracted with
ethyl acetate (3 x 5 mL). The combined organic layers were washed with 3 M HCl (5 mL) to
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recover the ligand, H2O (5 mL), brine (5 mL), dried over MgSO4, filtered and concentrated. The
residue was purified by flash chromatography on silica gel eluting with 3:1 hexanes:EtOAc to
yield a mixture of amido alcohol 142 and diol 149 as a colorless solid (155 mg, 60%). Followed
by the regioisomeric amido alcohol 146 (20%). Compounds 142 and 149 were separated by
HPLC using a Alltima 10µ 10mm x 20mm silica column eluting with 20% EtOAc in hexanes at 5
mL/min. Absorbance was detected at 254 and 218 nm.
(2R,3S)-Isopropyl 3-benzamido-2-hydroxy-3-phenylpropionate (142): Rf 0.34 (9:1 CH2Cl2-MeOH).
Lit.18 [α]16D -24.7 (c 0.618, CHCl3). 1H-NMR (400 MHz, CDCl3) δ 1.26 (d, J = 6.3 Hz, 3H, iPrCH3),
1.31 (d, J = 6.3 Hz, 3H, iPrCH3), 3.32 (br s, 1H, OH), 4.60 (app. s, 1H, CH-OH), 5.12 (sept., J = 6.3
Hz, 1H, iPrCH), 5.77 (dd, J = 9.2, 1.7 Hz, 1H, CH-NH), 7.01 (d, J = 9.1 Hz, 1H, NH), 7.28-7.53 (m,
8H, Ar-H), 7.76 (d, J = 7.9 Hz, 2H, Ar-H); 13C-NMR (100 MHz, CDCl3) δ 21.6, 21.7, 54.6, 71.1, 73.4,
126.9, 127.0, 127.9, 128.7, 131.7, 134.3, 138.8, 166.7, 172.5.
Diol 149: Rf 035 (9:1 CH2Cl2-MeOH). 1H-NMR (400 MHz, CDCl3) δ 1.21 (d, J = 6.2 Hz, 3H, iPrCH3),
1.26 (d, J = 6.2 Hz, 3H, iPrCH3), 2.86 (br s, 1H, OH), 3.20 (br s, 1H, OH), 4.31 (app. s, 1H, CH-OH),
4.95 (app. s, 1H, CH-OH), 5.12 (sept., J = 6.2 Hz, 1H, iPrCH), 7.30-7.39 (m, 5H, Ar-H); 13C-NMR
(100 MHz, CDCl3) δ 21.6, 21.7, 70.2, 74.7, 74.7, 126.3, 128.0, 128.4, 140.0, 172.3.
(2R,3S)-Isopropyl 3-hydroxy-2-benzamido-3-phenylpropionate (146): Rf 0.30 (9:1 CH2Cl2-MeOH).
Lit.18 [α]16D 28.02 (c 0.760, CHCl3). 1H-NMR (400 MHz, CDCl3) δ 1.18 (d, J = 6.3 Hz, 3H, iPrCH3),
1.27 (d, J = 6.3 Hz, 3H, iPrCH3), 2.97 (d, J = 3.8 Hz, 1H, OH), 5.02 (dd, J = 8.5, 3.7 Hz, 1H, CH-NH),
5.06 (sept., J = 6.3 Hz, 1H, iPrCH), 5.32 (t, J = 3.7 Hz, 1H, CH-OH), 6.87 (d, J = 8.1 Hz, 1H, NH),
7.29 (d, J = 7.1 Hz, 1H, Ar-H), 7.34 (t, J = 7.3 Hz, 2H, Ar-H), 7.40-7.44 (m, 2H, Ar-H), 7.49-7.52 (m,

153

2H, Ar-H), 7.71 (d, J = 8.4 Hz, 2H, Ar-H); 13C-NMR (100 MHz, CDCl3) δ 21.6, 21.8, 58.7, 69.8, 74.4,
126.0, 127.1, 128.3, 128.5, 128.6, 131.8, 133.8, 139.6, 167.7, 169.9.

Scheme 4.24: Synthesis of compound 151
4,4,5,7-Tetramethylchroman-2-one (151).21 Methyl-3,3-dimethylacrylate (289 mg, 313 µL, 2.25
mmol, 1.1 equiv.) was added to a solution of 3,5-dimethylphenol (150) (250 mg, 2.05 mmol, 1.0
equiv.) in methanesulfonic acid (0.25 mL). The reaction was heated to 70 °C and stirred for 14 h.
The mixture was diluted with water (35 mL) and extracted with CH 2Cl2 (3 x 10 mL). The
combined organic layers were washed with sat’d. aq. NaHCO3 (2 x 5 mL), brine (2.5 mL), then
dried over MgSO4, filtered and concentrated. The dark orange oil was purified by flash
chromatography on silica gel, eluting with 30% CH2Cl2 in hexanes to give 4,4,5,7tetramethylchroman-2-one (151) as a light brown solid (380 mg, 91%). Rf 0.21 (5:1 hexanesEtOAc). 1H-NMR (400 MHz, CDCl3) δ 1.43 (s, 6H, CMe2), 2.27 (s, 3H, Ar-CH3), 2.46 (s, 3H, Ar-CH3),
2.58 (s, 2H, CH2), 6.73 (s, 1H, Ar-H), 6.74 (s, 1H, Ar-H); 13C-NMR (100 MHz, CDCl3) δ20.6, 23.1,
27.8, 35.0, 45.7, 116.1, 126.6, 129.5, 136.1, 137.6, 151.1, 168.5.

Scheme 4.25: Synthesis of compound 143
Allyl aryl ether 143.32 4,4,5,7-Tetramethylchroman-2-one (151) (500 mg, 2.45 mmol, 1.00
equiv.) was added to a solution of KOH (143 mg, 2.55 mmol, 1.04 equiv.) in MeOH (4 mL), and
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left to stir at rt for 3 h under N2. The mixture was concentrated and redissolved in anhydrous
CH3CN (15 mL) and cooled to 0 °C. Sodium hydride (141 mg, 5.87 mmol, 60% dispersion in
mineral oil, 2.4 equiv.) was added in one portion, and the mixture stirred for 10 min at 0 °C
before allyl bromide (508 µL, 711 mg, 5.87 mmol, 2.4 equiv.) was added dropwise. The reaction
was warmed to rt and stirred overnight. The solution was cooled to 0 °C, and H 2O (2.5 mL) was
added dropwise. The solution was warmed to rt and allowed to stir for 5 h, and then acidified
with 2 M HCl to pH 3. Acetonitrile was removed under reduced pressure, and the aqueous layer
extracted with CH2Cl2 (3 x 3 mL). The combined organic extracts were washed with H2O (3 mL),
dried over MgSO4, filtered, and concentrated. The residue was purified by flash
chromatography on silica gel eluting with 7:1 hexanes:EtOAc to yield the allyl aryl ether 143 as
a colorless oil (591 mg, 85%). Rf 0.21 (5:1 hexanes-EtOAc). 1H-NMR (400 MHz, CDCl3) δ 1.61 (s,
6H, CMe2), 2.22 (s, 3H, Ar-CH3), 2.50 (s, 3H, Ar-CH3), 3.03 (s, 2H,CH2COOH), 4.52 (d, J = 5.2 Hz,
2H, CH2OPh), 5.26 (d, J = 10.5 Hz, 1H, allyl-Hc), 5.39 (d, J = 17.3 Hz, 1H, allyl-Hb), 6.10 (ddt, J =
17.3, 10.5, 5.2 Hz, 1H, allyl-Ha), 6.53 (s, 1H, Ar-H), 6.56 (s, 1H, Ar-H); 13C-NMR (100 MHz, CDCl3)
δ 20.8, 25.6, 31.6, 39.6, 46.8, 69.6, 85.9, 112.4, 117.4, 127.5, 130.0, 133.6, 136.1, 137.6, 157.9,
176.7; HRMS (ESI+) calcd for C16H22O3Na (M+Na)+ 285.1461, obsd 285.1458.

Scheme 4.26: Synthesis of compound 141
Compound 141. Acid 143 (19.2 mg, 0.07 mmol, 1.20 equiv.) was added to a solution of amido
alcohol 142 (20.0 mg, 0.06 mmol, 1.00 equiv.) in anhydrous CH2Cl2 (1 mL) under N2. 4-
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Dimethylaminopyridine (10.4 mg, 0.09 mmol, 1.40 equiv.) and EDC (16.4 mg, 0.09 mmol, 1.40
equiv.) were added sequentially, and the reaction was allowed to stir at rt overnight. The
solution was concentrated and the product isolated by flash chromatography on silica gel,
eluting with 3:1 hexanes:EtOAc to give the ester 141 as a colorless oil (25 mg, 86%). Rf 0.34 (3:1
Hexanes-EtOAc). 1H-NMR (400 MHz, CDCl3) δ 1.16 (d, J = 6.2 Hz, 3H, iPrCH3), 1.23 (d, J = 6.2 Hz,
3H, iPrCH3), 1.49 (s, 3H, CH3), 1.60 (d, 3H, CH3), 2.03 (s, 3H, CH3-Ar), 2.46 (s, 3H, CH3-Ar), 2.82 (d,
J = 15.1 Hz, 1H,CH2COOR), 3.43 (d, J = 15.1 Hz, 1H,CH2COOR), 4.30 (dd, J = 12.2, 4.1 Hz, 1H,
CH2OPh), 4.36 (dd, J = 12.2, 4.1 Hz, 1H, CH2OPh), 5.04 (sept., J = 6.0 Hz, 1H, iPrCH), 5.20 (d, J =
10.5 Hz, 1H, allyl-Hc), 5.30-5.33 (m, 2H, CHCOOiPr, allyl-Hb), 5.71 (d, J = 9.2 Hz, 1H, CH-NH), 5.98
(ddt, J = 17.3, 12.2, 4.1 Hz, 1H, allyl-Ha), 6.26 (s, 1H, Ar-H), 6.43 (d, J = 9.2 Hz, 1H, NH), 6.46 (s,
1H, Ar-H), 7.08 (d, J = 6.4 Hz, 2H, Ar-H), 7.26-7.30 (m, 3H, Ar-H), 7.49 (t, J = 7.2 Hz, 2H, Ar-H),
7.57 (t, J = 7.2 Hz, 1H, Ar-H), 7.71 (d, J = 7.2 Hz, 2H, Ar-H); 13C-NMR (100 MHz, CDCl3) δ 20.6,
21.5, 21.7, 25.6, 31.3, 39.7, 47.4, 53.3, 69.3, 70.0, 74.2, 112.4, 117.4, 126.5, 127.3, 127.55,
127.62, 128.4, 128.6, 130.3, 131.7, 133.5, 134.6, 135.9, 137.2, 137.5, 157.8, 167.5, 167.6, 172.1.

Scheme 4.27: Synthesis of compound 171
Isobutyl prenyl carbonate (171).33 A solution of 1.6 M nBuLi in hexanes (8.0 mL, 5.42 g, 84.6
mmol, 7.3 equiv.) was added dropwise to a clear solution of 1,1-dimethyl prop-2-en-1-ol (170)
(1.2 mL, 1.00 g, 11.6 mmol, 1.0 equiv.) in dry THF (20 mL) under N 2 at 0 °C. After 30 min at 0 °C,
isobutyl chloroformate (2.3 mL, 2.38 g, 17.4 mmol, 1.5 equiv.) was added dropwise to the clear
yellow mixture. The reaction was allowed to gradually warm to rt and stirred for an additional 4
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h. The cloudy solution was partitioned between brine (20 mL) and ether (20 mL). The layers
were separated and the aqueous layer extracted further with ether (3 x 10 mL). The combined
organic layers were dried over MgSO4, filtered and concentrated. Traces of ether were removed
under a stream of nitrogen to give the isobutyl prenyl carbonate (171) as a volatile colorless
liquid (2.16 g, 100%). No further purification was needed. Rf 0.21 (15:1 hexanes-EtOAc). 1HNMR (400 MHz, CDCl3) δ 0.93 (d, J = 1.0 Hz, 3H, iBuCH3), 0.95 (d, J = 1.0 Hz, 3H, iBuCH3), 1.56 (s,
6H, CMe2), 1.96 (septet, J = 6.7 Hz, 1H, iBuCH), 3.85 (dd, J = 6.7, 1.0 Hz, 2H, iBuCH2), 5.13 (d, J =
10.9 Hz, 1H, HC=CH2-cis), 5.22 (d, J = 17.5 Hz, 1H, HC=CH2-trans), 6.11 (ddd, J = 17.5, 10.9, 0.9
Hz, 1H, HC=CH2); 13C-NMR (100 MHz, CDCl3) δ19.0, 26.2, 27.8, 73.3, 82.0, 113.5, 141.8, 153.6;
MS (EI, 70 eV) calcd for C10H18O3 (M)+ 187.1, obsd 187.2.

Scheme 4.28: Synthesis of aryl prenyl ether derivatives
Aryl Prenyl Ether 173b: Pd(PPh3)4 (18.4 mg, 0.02 mmol, 0.01 equiv.) was added to a solution of
phenol 172b (150 mg, 1.59 mmol, 1.0 equiv.) and isobutyl prenyl carbonate (534 mg, 2.87
mmol, 1.8 equiv.) in THF (10 mL) under N2 at rt. The mixture was stirred at rt for 1.5 h and then
partitioned between CH2Cl2 (10 mL) and brine (10 mL). The aqueous layer was further extracted
with EtOAc (5 mL). The organic layers were combined, dried over MgSO4, filtered, and
concentrated. The yellow liquid was purified on silica gel eluting with 50:1 hexanes:EtOAc, to
give 173b as a colorless liquid (210 mg, 90%). Rf 0.61 (5:1 hexanes-EtOAc). 1H-NMR (400 MHz,
CDCl3) δ 1.43 (s, 6H, CMe2), 2.24 (s, 6H, Ar-CH3), 5.11 (d, J = 10.9 Hz, 1H, =CH2-cis), 5.16 (d, J =
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17.6 Hz, 1H, =CH2-trans) 6.13 (dd, J = 17.6, 10.9 Hz, 1H, HC=), 6.61 (s, 2H, Ar-H), 6.63 (s, 1H, ArH); 13C-NMR (100 MHz, CDCl3) δ19.0, 21.4, 27.1, 79.1, 113.1, 119.4, 124.0, 138.4, 144.7, 156.0;
MS (EI, 70 eV) calcd for C13H18O (M)+ 190.1, obsd 190.0.
173a: prepared by analogy to 173b on a scale of 1.59 mmol to give an extremely volatile
colorless liquid (195 mg, 95%). Rf 0.59 (5:1 Hexanes-EtOAc). 1H-NMR (400 MHz, CDCl3) δ 1.43 (s,
6H, iPrCH3), 5.09-5.17 (m, 2H, =CH2), 6.13 (dd, J = 17.6, 10.8 Hz, 1H, HC=), 6.95-6.99 (m, 3H, ArH), 7.19 (d, J = 7.1 Hz, 1H, Ar-H), 7.21 (d, J = 7.1 Hz, 1H, Ar-H); 13C-NMR (100 MHz, CDCl3) δ27.1,
79.4, 113.4, 121.8, 122.3, 128.8, 144.5, 156.0.
168: prepared by analogy to 173b on a scale of 1.21 mmol to give a colorless liquid (223 mg,
96%). Rf 0.51 (5:1 Hexanes-EtOAc). 1H-NMR (400 MHz, CDCl3) δ 1.39 (s, 6H, iPrCH3), 3.75 (s, 3H,
OMe), 5.09 (d, J = 10.8 Hz, 1H, =CH2), 5.12 (d, J = 17.6 Hz, 1H, =CH2) 6.10 (dd, J = 17.6, 10.8 Hz,
1H, HC=), 6.75 (d, J = 9.1 Hz, 2H, Ar-H), 6.91 (d, J = 9.1 Hz, 2H, Ar-H); 13C-NMR (100 MHz, CDCl3)
δ26.7, 55.5, 79.3, 113.7, 123.9, 144.3, 149.1, 155.3; HRMS (ESI+) calcd for C12H17O2 (M+H)+
193.1223, obsd 193.1213.
173c: prepared by analogy to 173b on a scale of 1.05 mmol to give colorless oil (195 mg, 84%).
Rf 0.42 (10:1 Hexanes-EtOAc). 1H-NMR (400 MHz, CDCl3) δ 1.50 (s, 6H, CH3x2), 3.87 (s, 3H,
OMe), 5.18 (d, J = 10.9 Hz, 1H, HC=CH2), 5.22 (d, J = 17.6 Hz, 1H, HC=CH2), 6.13 (dd, J = 17.6,
10.9 Hz, 1H, CH=CH2), 7.00 (d, J = 8.9 Hz, 2H, Ar-H), 7.90 (d, J = 8.9 Hz, 2H, Ar-H); 13C-NMR (100
MHz, CDCl3) δ 27.2, 51.8, 80.2, 114.0, 119.5, 123.0, 130.9, 143.8, 160.6, 166.9; HRMS (ESI+)
calcd for C13H17O3 (M+H)+ 221.1172, obsd 221.117.
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173d: prepared by analogy to 173b on a scale of 1.45 mmol to colorless liquid (314 mg, 90%). Rf
0.36 (10:1 Hexanes-CH2Cl2). 1H-NMR (400 MHz, CDCl3) δ 1.43 (s, 6H, CH3x2), 5.12-5.17 (m, 2H,
=CH2), 6.09 (dd, J = 17.6, 10.9 Hz, 1H, CH=CH2), 6.86 (d, J = 8.9 Hz, 2H, Ar-H), 7.31 (d, J = 8.9 Hz,
2H, Ar-H); 13C-NMR (100 MHz, CDCl3) δ 26.9, 79.9, 113.9, 114.8, 123.4, 131.7, 143.9, 155.1.

Scheme 4.29: Synthesis of compound 179
Diol 179. Lithium aluminum hydride (52.0 mg, 1.36 mmol, 1.5 equiv.) was added in a single
portion to a solution of 4,4,5,7-tetramethylchroman-2-one (151) (185 mg, 0.91 mmol, 1.0
equiv.) in anhydrous THF (4 mL) under N2 at 0 °C. The solution was allowed to warm to rt and
stirred for 8 h. Saturated aq. NH4Cl (1-2 mL) was added dropwise to quench excess LAH. The
mixture was filtered, and the solid was washed with THF (3 x 5mL) . The filtrate and combined
washings was concentrated, and the oily yellow residue was purified by flash chromatography
on silica gel eluting with 5:1 hexanes:EtOAc

1:1 hexanes:EtOAc to give the diol 179 as a

colorless solid (100 mg, 56%). Rf 0.21 (3:1 hexane-EtOAc). 1H-NMR (400 MHz, CDCl3) δ 1.53 (s,
6H, CMe2), 1.89 (br s, 1H, OH), 2.15 (s, 3H, Ar-CH3), 2.23 (t, J = 7.2 Hz, 2H, CH2OH), 2.46 (s, 3H,
Ar-CH3), 3.61 (t, J = 7.6 Hz, 2H, CH2CMe2), 6.31 (s, 1H, Ar-H), 6.34 (s, 1H, Ar-OH), 6.46 (s, 1H, ArH); 13C-NMR (100 MHz, CDCl3) δ20.3, 25.6, 31.9, 39.5, 44.9, 61.5, 116.3, 126.9, 128.6, 136.2,
137.8, 155.5.
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Scheme 4.30: Synthesis of compound 180
2-((4-tert-Butyldimethylsilyloxy)-2-methylbutan-2-yl)-3,5-dimethylphenol (181).
4-Dimethylaminopyridine (80.1 mg, 0.66 mmol, 1.57 equiv.) was added in one portion to a
solution of diol 179 (87.0 mg, 0.42 mmol, 1.00 equiv.) in anhydrous THF (1 mL). tertButyldimethylsilyl chloride (71.0 mg, 0.47 mmol, 1.13 equiv) was added and the reaction was
cooled to 0 °C and left to stir at this temp. overnight. Ethyl acetate (10 mL) was added and the
mixture was washed with water (5 mL), brine (3 x 5 mL), dried over MgSO4, filtered, and
concentrated. The residue was purified by flash chromatography on silica gel, eluting with 5:1
hexanes:EtOAc to give the TBS ether 180 as a colorless solid (111 mg, 82%). Rf 0.31 (10:1
Hexanes-EtOAc). 1H-NMR (400 MHz, CDCl3) δ 0.04 (s, 6H, Si(CH3)2), 0.89 (s, 9H, tBuSi), 1.56 (s,
6H, CMe2), 2.15 (t, J = 7.1 Hz, 2H, CH2CMe2), 2.19 (s, 3H, Ar-CH3), 2.47 (s, 3H, Ar-CH3), 3.61 (t, J =
7.1 Hz, 2H, CH2OTBS), 5.83 (s, 1H, Ar-OH), 6.41 (s, 1H, Ar-H), 6.49 (s, 1H, Ar-H); 13C-NMR (100
MHz, CDCl3) δ-5.3, 18.3, 20.2, 25.5, 26.0, 32.1, 39.3, 45.0, 61.8, 116.8, 126.8, 129.2, 135.9,
137.7, 155.5.
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4.9.2 1H and 13C-NMR Spectra
Compound 144 (Scheme 4.7) – 1H NMR spectrum
Isopropyl trans-cinnamate in CDCl3 at 400 MHz
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Compound 144 (Scheme 4.7) – 13C NMR spectrum
Isopropyl trans-cinnamate in CDCl3 at 100 MHz
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Compound 142 (Scheme 4.7) – 1H NMR spectrum
Taxol amido alcohol sidechain (major) in CDCl3 at 400 MHz
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Compound 142 (Scheme 4.7) – 13C NMR spectrum
Taxol amido alcohol sidechain (major) in CDCl3 at 100 MHz
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Compound 149 (Scheme 4.7) – 1H NMR spectrum
Diol in CDCl3 at 400 MHz

165

Compound 149 (Scheme 4.7) – 13C NMR spectrum
Diol in CDCl3 at 100 MHz
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Compound 146 (Scheme 4.7) – 1H NMR spectrum
Taxol amido alcohol sidechain (minor) in CDCl3 at 400 MHz

H2O
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Compound 146 (Scheme 4.7) – 13C NMR spectrum
Taxol amido alcohol sidechain (minor) in CDCl3 at 100 MHz
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Compound 151 (Scheme 4.8) – 1H NMR spectrum
4,4,5,7-tetramethylchroman-2-one in CDCl3 at 400 MHz
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Compound 151 (Scheme 4.8) – 13C NMR spectrum
4,4,5,7-tetramethylchroman-2-one in CDCl3 at 100 MHz
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Compound 143 (Scheme 4.8) – 1H NMR spectrum
Allyl phenyl ether in CDCl3 at 400 MHz
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Compound 143 (Scheme 4.8) – 13C NMR spectrum
Allyl phenyl ether in CDCl3 at 100 MHz
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Compound 141 (Scheme 4.9) – 1H NMR spectrum
Allyl Model System in CDCl3 at 400 MHz
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Compound 141 (Scheme 4.9) – 13C NMR spectrum
Allyl Model System in CDCl3 at 100 MHz
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Compound 171 (Scheme 4.16) – 1H NMR spectrum
Isobuytyl prenyl carbonate in CDCl3 at 400 MHz
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Compound 171 (Scheme 4.16) – 13C NMR spectrum
Isobuytyl prenyl carbonate in CDCl3 at 100 MHz
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Compound 173a (Scheme 4.16) – 1H NMR spectrum
Aryl prenyl ether in CDCl3 at 400 MHz
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Compound 173a (Scheme 4.16) – 13C NMR spectrum
Aryl prenyl ether in CDCl3 at 100 MHz
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Compound 173b (Scheme 4.16) – 1H NMR spectrum
Aryl prenyl (m-3,5-dimethyl) ether in CDCl3 at 400 MHz
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Compound 173b (Scheme 4.16) – 13C NMR spectrum
Aryl prenyl (m-3,5-dimethyl) ether in CDCl3 at 100 MHz
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Compound 168 (Scheme 4.16) – 1H NMR spectrum
Aryl prenyl (p-OMe) ether in CDCl3 at 400 MHz
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Compound 168 (Scheme 4.16) – 13C NMR spectrum
Aryl prenyl (p-OMe) ether in CDCl3 at 100 MHz
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Compound 173c (Scheme 4.16) – 1H NMR spectrum
Aryl prenyl (p-COOMe) ether in CDCl3 at 400 MHz
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Compound 173c (Scheme 4.16) – 13C NMR spectrum
Aryl prenyl (p-COOMe) ether in CDCl3 at 100 MHz
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Compound 173d (Scheme 4.16) – 1H NMR spectrum
Aryl prenyl (p-Br) ether in CDCl3 at 400 MHz
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Compound 173d (Scheme 4.16) – 13C NMR spectrum
Aryl prenyl (p-Br) ether in CDCl3 at 100 MHz
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Compound 179 (Scheme 4.20) – 1H NMR spectrum
3,5-dimethyldiol in CDCl3 at 400 MHz
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Compound 179 (Scheme 4.20) – 13C NMR spectrum
3,5-dimethyldiol in CDCl3 at 100 MHz
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Compound 180 (Scheme 4.20) – 1H NMR spectrum
3,5-dimethyl TBS ether in CDCl3 at 400 MHz
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Compound 180 (Scheme 4.20) – 13C NMR spectrum
3,5-dimethyl TBS ether in CDCl3 at 400 MHz
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CHAPTER 5: INCORPORATION OF AN ANIONIC SUBSTRATE FOR A CLAISEN REARRANGEMENT
INTO NANOGUMBOS
5.1 1,1-Dimethylallyl Aryl Ether Building Block: A Model System for Photothermal
Rearrangement
To emulate TaxolTM release from the prodrug delivery system in vivo, the prodrug model
system needs to be combined with a NIR-absorbing laser dye. Incorporation of the prodrug into
an ionic liquid requires the introduction of an anionic functional group. As this will not be trivial,
and the prodrug model system is valuable, a DMA aryl ether building block was synthesized for
optimization of photothermal rearrangement studies.
5.2 Synthesis of an Anionic Substrate for a Claisen Rearrangement
Commercially available 4-hydroxybenzoic acid (183) was protected as the methyl ester
to give phenol 184. The DMA group was installed via isobutyl prenyl carbonate, and the methyl
ester was removed to give 4-(1,1-dimethylallyloxy)benzoic acid (185) as an colorless solid in
good yield.

Scheme 5.1: Synthesis of 4-(1,1-dimethylallyloxy)benzoic acid 185
Previously prepared aryl prenyl ethers (Chapter 4), were volatile liquids where 185 is
solid. Presumably, the carboxylic acid’s ability to hydrogen bond leads to stronger
intermolecular forces and a more ordered structure. Recrystallization of 185 from ethyl acetate
and hexanes yielded thin, needle like crystals. Analysis by X-Ray crystallography revealed a
monomer with a refractory index of 12% illustrated in Figure 5.1, A. The steric influence of the
gem-dimethyl group on the conformation of the allyl moiety is apparent. When compared to
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the unsubstituted counterpart, 4-(allyoxy)benzoic acid (187, Figure 5.1, B), the methyl groups in
185 orient the allyl group toward the aromatic ring. This facilitates the [3,3’]-rearrangement, as
evidenced in Chapter 4.
B

A

≡

≡

Figure 5.1: Crystal structures of 4-(1,1-dimethylallyloxy)benzoic acid (185) and 4(allyloxy)benzoic acid (186) reported by Zugenmaier 1
5.3 Kinetic Studies of Claisen Rearrangement of Aryl Prenyl Ethers
As discussed in Chapter 4, Harfenist and Thom reported that the thermal rearrangement
of propargyl ethers to chromenes followed first-order kinetics.2 They postulated that this
acceleration was due to the gem-dimethyl effect, specifically the rotamer that orients the
methyl groups away from the ring and the alkyne towards the ring lowering the barrier for
activation. With experimental evidence for the alkene being oriented towards the aromatic
ring, it seemed further investigation of the rate-accelerating effects of the gem-dimethyl on aryl
Claisen rearrangements was of interest. One can assume that prenyl ethers would follow the
same kinetic behavior as propargyl ethers. To our knowledge, rate constants for the
rearrangement of aryl prenyl ethers in aqueous solutions have not been reported. Compounds
185, 173c, 173b, 168 were chosen for the kinetic studies, as they presented an opportunity to
explore substituent effects on the rate-acceleration.
To monitor the rate of disappearance of starting material, 1H-NMR spectroscopy was
used. A typical sample was prepared using a known quantity of prenyl ether, which was
dissolved in a 1:1 solution (300 µL total) of deuterated methanol and deionized water. The
195

solution, in an NMR tube, was then heated to 60 °C in the magnet of the spectrometer, with the
sample spinning. Spectra were recorded at fifteen minute intervals. For each spectrum, the
integrals of the gem-dimethyl protons of the reactant and aromatic protons of the product
(Figure 5.2, Ha’) can be measured, because the aromatic and gem-dimethyl signals are well
resolved and do not overlap each other. In Figure 5.2 you can clearly see the Hc singlet forming
as the prenyl group rearranges from the oxygen to the ortho position on the ring, reducing the
intensity of Ha.

Scheme 5.2: Aryl Claisen rearrangement of prenyl ether 185
Hb’

Hb

Hc

Ha

Ha’

t5h

t0

Figure 5.2: Time profile of 1H-NMR spectra of reaction mixture
Integration of the area under the gem-dimethyl signal (δ1.53, s, 6H, 100%) was
compared with the area under the growing Ha’ aromatic signal (δ6.9, d) with the progress of the
reaction expressed as a percentage conversion. These calculated percentages were plotted
against reaction time (Figure 5.3). The resulting polynomial curves suggest that the thermal
rearrangement of prenyl aryl ethers follow first-order rate kinetics. Therefore, the rate constant
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can be obtained from Equation (1), dividing 0.693 by the half-time it takes for the reaction to
reach 50% completion. Another advantage of first-order reactions is that they are independent
of the concentration of the starting reactant, eliminating the need to control concentration of
starting material for each substrate.

(1)

% of Production of Formation

Rearrangement of Aryl Prenyl Ethers at 60 °C
100%
80%
60%
40%
20%
0%
0

1
p-COOH

185

2

3
Time (h)

m-3,5-dimethyl

173b

4
p-COOMe

173c

5

6
p-OMe

168

Figure 5.3: Plot of percentage of product formed versus reaction time of prenyl phenyl ethers.
Initial results closely mimic studies done by White et al. on the substituent effects of the
ortho-Claisen rearrangement3 in that electron withdrawing groups at the para position slow
down the reaction whereas electron donating groups speed up the reaction. A comparison of
the rate constants follows a similar pattern, with derivative 185 being significantly faster than
derivatives 173c, and 173b despite the electron withdrawing group at the para position (Table
5.1). This can be explained by the carboxylic acids ability to hydrogen bond. It has already been
established that hydrogen bonding decreases the activation energy due to solvation.4 If you
combine that with the increasing polarity of the solvent due to the increased concentration of
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phenolic protons over time, you get an accelerated reaction rate. Compound 173c does not
have hydrogen-bonding capability, and therefore the methyl ester’s electron withdrawing
characteristics takes precedence, destabilizing the charged transition state which slows the
reaction down considerably.
Table 5.1: Rate constants and relative rates for rearrangement of aryl prenyl ethers (185, 173c,
173b, 168) at 60 °C in 1:1 CD3OD:H2O compared with the rate constant of 1-(allyloxy)-4methoxybenzene in carbitol at 181 °C prepared by White et al.
Prenyl ether R1 R2 R3
k x 105(sec-1) krel Yielda,b (%)
185
H
H
COOH
8.6 2.5
97
173c
H
H COOMe
3.5
1
50
173b
Me Me
H
5.5 1.5
66
168
H
H
OMe
9.6 3.7
100
188c
H
H
OMe
9.2c 2.6
60c
a
b
c
After 5.5 hours. Percent conversion See reference 3
Comparison of the rate constant of 1-(allyloxy)-4-methoxybenzene (188, Table 5.1),
calculated by White et al.3 to the similar compound 168, indicates a similar reaction rate.
However, the rate constant of 188 was calculated for temperatures above 180 °C in carbitol.
The presence of the prenyl group allows for comparable rates, at much lower temperatures.
5.4 Assembly of NIR-GUMBOS Model System
With substantial experimental evidence of accelerated rearrangement via the prenyl
group at reasonable temperatures, we now focused our efforts on ionic pairing of our aryl
prenyl ether anion to a cationic NIR laser dye. Our heat source in vivo would come from laser
irradiation of organic near-infrared absorbing dyes, specifically polymethine cyanine-based
dyes, as they are highly touted for their molar absorptivity, photostability, and tunability.5 We
expect that upon irradiation with the appropriate wavelength NIR laser, heat will be generated.
This indirect heat is expected to induce rearrangement of the prodrug moiety, releasing the
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TaxolTM side chain. These dyes have been reported to reach temperatures of over 400 °C, even
when complexed with organic anions.5
Previous work by John Dumke (Warner Group, LSU) on NIR-absorbing nanoGUMBOS
utilized heptamethine cyanine laser dyes 1061 and 1048 as the preferred counter-ion (Scheme
5.3). Naturally, these dyes were our starting point.
To prepare the NIR-GUMBOS we used the ion exchange method. Prenyl ether 185 was
reacted with 1.05 equivalents of sodium hydroxide in ethanol for thirty minutes. The resulting
salt was concentrated, and redissolved in a biphasic 4:1 dichloromethane-water solution. IR1061 or IR-1048 laser dye was added as a tetrafluoroborate salt solution in dichloromethane,
and the reaction stirred for two days (Scheme 5.3).

Scheme 5.3: Ion exchange of aryl prenyl ether 186 and IR-1061 and IR-1048 laser dye
Unfortunately, exposure to water, even at room temperature for an extended period of
time led to partial rearrangement of compound 186. This gave a mixture of products by TLC,
seemingly the target compound 189a if IR-1061 was used, along with the salt containing the
rearranged carboxylate anion 189b. This was observed with both dyes. The aqueous layer
contained nominal amounts of the expected NaBF4 salt. Tetrafluoroborate ions are used to
render salts more soluble in organic solvents. It seems from the lack of sodium
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tetrafluoroborate recovered from the aqueous layer, that there are significant sodium and
tetrafluroborate impurities present in the GUMBOS. It was apparent that traditional ion
exchange procedures, as well as the BF4- ion, were not suitable for this water-sensitive
substrate. Alternative procedures and dyes were sought.
5.4.1 IR-780: An Antitumorgenic Cationic Dye
We selected NIR-absorbing laser dyes IR-655 and IR-780 (Figure 5.4) based on their
iodine cation which would give more water soluble salts, and their absorbance in the NIR
therapeutic optical window. They also had reduced costs compared to IR-1048 and IR-1061.
Significant work by the Shi group has revealed new insight into IR-780 as a potential theranostic
agent.

Figure 5.4: Phthalocyanine-based dyes that absorb at 655 and 780 nm
In 2010, Shi and coworkers reported the unexpected accumulation of IR-780
preferentially in tumor cells over normal cells.6 When cancer cells were exposed to
sulfobromophthalein (BSP), an organic anion transporter peptide (OATP) inhibitor, reduced
uptake of IR-780 suggested that cellular uptake was facilitated by OATPs.
Two follow-up studies were reported by Shi and coworkers in 2014. The first focused on
the mechanism of IR-780’s tumor selective activity and how the dye transcends the tumor cell
mitochondria membrane.7 Through a series of cell motility inhibitor assays on cancer cell lines,
it was determined that preferential accumulation in the mitochondria by IR-780 was dictated by
energy metabolism, OATPs, and plasma membrane potential. Inhibition of common modes of
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cellular transport like ATP binding-cassette (ABC) transporters and endocytosis did not affect
the uptake of IR-780.
An energy dependent pathway was established, due to a cellular response of the dye
uptake at low temperature (0 °C). Various cancer cell lines were treated with endocytosis
inhibitors Cyto-D and PAO. These inhibitors did not affect the uptake of IR-780 (Scheme 5.5, A),
ruling out endocytosis as the mechanism of internalization. However when they treated these
same cell lines with different OATP inhibitors (Scheme 5.5, B) they saw suppression of cellular
uptake, suggesting that OATPs play a large role in facilitating transport of IR-780 into cancer
cells.
A

B

Figure 5.5: Cancer cell lines incubated with IR-780 A) Treated with endocytosis inhibitors:
control (blue), with Cyto-D (maroon), PAO (yellow) B) Treated with OATP inhibitors: control
(blue), Bromsulphthalein (BSP) (maroon), Pravastatin (yellow), Doxorubicin (light blue), Hoechst
33342 (purple). Reprinted with permission.7
The second paper heralded the emergence of IR-780 as anti-tumorgenic.8 The Shi group
first tested IC50 values of IR-780 in different cancer cell lines, noting that longer incubation
periods led to smaller IC50 values. Lung cancer cell line A549 was most affected by IR-780, so the
remaining assays concentrated on this cell line. When drug-resistant A549 cells were treated
with IR-780, they established that IR-780 preferentially accumulated in drug resistant (DR) cells
(Figure 5.6, A). Once accumulated, the dye was able to prevent further cell proliferation of the
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tumor cells, and even prevented tumor recurrence (Figure 5.6, B), with better results than
existing anticancer drugs.
A

B

Figure 5.6: A) The uptake of IR-780 and the influence on the mitochondrial activities of A549/DR
cells. A549/DR cells exhibit increased staining of IR-780 B) The tumor volume and weight of
mice received cyclophosphamide (CTX), doxorubicin hydrochloride (ADM) and IR-780 treatment
at dosage of 20, 2.0 and 5.0 mg/kg respectively. Reprinted with permission.8
Preliminary tests suggest that IR-780 is biocompatible with no acute toxicity at high
dosage (10-fold), and can be safely eliminated from the body in a few days. 9 With this new
information establishing IR-780 as tumorigenic and tumor targeting, IR-780 was chosen as our
NIR laser dye for model studies.
5.4.2 Single Solvent Ion Exchange
The ion exchange method was repeated with the new laser dye as described above, with
a few changes (Scheme 5.4). Only one solvent was used, thus relying on potassium iodide’s low
solubility in isopropanol to precipitate out. The solution of potassium salt of the aryl prenyl
ether 186 was not concentrated; instead the laser dye was added directly to the solution after
thirty minutes.
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Scheme 5.4: Single solvent ion exchange of aryl prenyl ether 186 and IR-780 laser dye
Some precipitate was observed after two days, however NMR analysis (Figure 5.7) of
the product after aqueous work-up suggests that complete ion exchange did not take place.
The ratio of aryl prenyl ether carboxylate 195 to NIR cation 194 was 5:1 (Figure 5.7, C). This
incomplete ion exchange was attributed to relative solubility of starting materials. Once the aryl
prenyl ether was converted to its potassium salt it became slightly insoluble in isopropanol. IR780 was also slightly insoluble in isopropanol.
A

B

C

Figure 5.7: 1H-NMR of aryl prenyl ether 186, IR-780, and IR-780 based GUMBOS
5.4.3 Ion Exchange Resin Chromatography
On the upside, the lack of rearrangement of the aryl prenyl ether under the conditions
described in Scheme 5.4 encouraged optimization of single solvent ion exchange conditions for
GUMBO formation. Partial insolubility of the starting material prompted a change to ethanol.
Potassium iodide is fairly soluble in ethanol; potassium chloride is not. It was impractical to do a
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halide ion exchange using the biphasic method as this would not guarantee complete exchange.
Ion exchange resins presented a clear way to exchange the halide counter-ion of IR-780.
Ion exchange resins consist of polymeric beads or resin that are covalently bound to
tethers, usually quaternary ammonium cations for anion exchange and sulfate anions for cation
exchange. When salts are passed through the charged resin, the affinity for certain ions over
others will induce an ion exchange. Amberlyst A-26 is a strongly basic, quaternary ammonium
based resin designed for non-aqueous applications.
IR-780+Cl- was prepared by passing a solution of IR-780+I- in methanol through a column
that contained A-26, which had been previously treated with an aqueous solution of HCl. The
ammonium cation’s higher affinity for chlorine ions combined with the hydroxyl anion’s basicity
ensured complete ion exchange for Cl- ions (Scheme 5.5). Proton NMR of the resulting
compound looked identical to the starting material. Mass spectrometry in negative-ion mode
confirmed the disappearance of the iodine anion, which was presumably replaced by chlorine.
Due to the low molecular weight of chlorine atoms, and lack of instrument sensitivity in that
range, chlorine anions cannot be detected by mass spectrometry.

Scheme 5.5: Halide exchange of IR-780 from iodide to chloride anion via ion exchange resin
The single solvent ion exchange method was used with the IR-780+Cl- 196. After addition
of chlorinated IR-780 196, immediate precipitation was observed. Because of this, the reaction
time was reduced to four hours instead of the traditional two days. Proton NMR analysis

204

revealed a 1:1 ratio of the GUMBOS salt 197 (Scheme 5.6). The prenyl ether carboxylate anion
was detected by HRMS.

Scheme 5.6: Single solvent ion exchange of chlorinated IR-780 and DMA aryl ether
Solubility of the IR-780 based GUMBOS in deuterated solvents was limited to methanol,
precluding the ability to monitor the disappearance of the carboxylic acid proton as an indicator
of deprotonation. Infrared spectroscopic analysis revealed absorption bands at 1602, 1593,
1397, and 1703 cm-1 which are consistent with the presence of a carboxylate anion (Figure 5.8,
A).

A

B

Figure 5.8: FT-IR spectrum of NIR GUMBOS 197 (A) and IR-780 iodide 196 (B)
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5.5 Preparation of nanoGUMBOS
NanoGUMBOS can be prepared via the ion diffusion method (Figure 5.9). A solution of
bulk GUMBOS is prepared in a volatile solvent that is miscible with water, usually acetone or
ethanol. 100 microliters of that solution is injected into five milliters of water (Figure 5.9, A).
This is then sonicated (Figure 5.9, B) using either a sonicating bath or a sonicating probe for a
predetermined length of time. The homogenous mixture is stored at room temperature for a
minimum of one day to let the nanoparticles “grow” (Figure 5.9, C).

Figure 5.9: Ion diffusion method for making nanoparticles
Preparation of IR-780-based nanoGUMBOS through the reprecipitation method using
the sonication probe produced nanoparticles that ranged from 30-50 nm in length (Figure 5.10).
Using the sonication bath, 100 nm nanoparticles were formed (Figure 5.11).

Figure 5.10: nanoGUMBOS prepared using sonication probe with 24 hour crystal growth
These nanoparticles were visualized using transmission electron microscopy (TEM). Aggregation
of the nanoparticles became problematic after prolonged growth periods. This could result
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from a number of factors including: interaction of the cationic dye with the TEM laser, partial
rearrangement of the DMA aryl ether, particles not being redistributed before TEM analysis,
and slow nanoparticle growth.

Figure 5.11: NanoGUMBOS prepared using sonication bath with 24 hour crystal growth
Optimization of these conditions, including nanoparticle growth at lower temperatures
is currently in progress.
5.6 Future Work
A synthetic route for installing an anionic terminus on to the prodrug model system
needs to be explored. Ideally, this would be in place at the outset and carried throughout the
synthesis to avoid competing alkylation with the phenyl group in the TaxolTM sidechain. Scheme
5.7 outlines a proposed route to installing an anionic terminus, which would start with a
halogen already installed in the para-position of 3,5-dimethylphenol (Scheme 5.7, 198).
Synthesis of compound 199 will then follow a series of steps analogous to the preparation of
the protected diol 181 in Chapter 4 (Scheme 4.21). With the diol suitably protected, the
halogen could then be displaced with methyl chloroformate10 to give the protected methyl
ester 201. The methyl ester is sturdy, and should be able to survive the remaining chemical
transformations.
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Scheme 5.7: Synthesis of the 2nd generation NIR GUMBO 203
Deprotection of the ether protecting group on the gem-dimethyl substituent ortho to
the prenyl ether and subsequent oxidation to the acid and coupling to the Taxol TM sidechain
alcohol will give us compound 202. This second generation model system would then be
treated with an aqueous solution of potassium hydroxide to cleave the methyl ester. The
resulting potassium salt will be converted to the ion pair with IR-780+I- through ion exchange
resin chromatography to give NIR GUMBO 203.
In summary, we have described the synthesis of a trimethyl lock-based prodrug delivery
model system that incorporated the TaxolTM amido alcohol sidechain as a model for the drug,
and utilized an aryl Claisen rearrangement as the molecular trigger. We investigated the
thermal rearrangement of the model system, and identified 1,1-dimethyl allyl ether as a rateaccelerating group for Claisen rearrangements. This group effectively lowers the temperature
required for rearrangement to more biologically feasible temperatures. We have also
demonstrated effective ionic pairing of prenyl aryl ethers to cationic NIR laser dye IR-780.
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5.7 Experimental Section
General Methods: All reactions were performed under a dry nitrogen atmosphere unless
otherwise noted. All chemicals and reagents were purchased from Sigma-Aldrich and Fisher and
were used without further purification. Flash chromatography was performed using 230-400
mesh silica gel (40-63 µm) from Sigma-Aldrich.

Reactions were followed by thin layer

chromatography (TLC) on pre-coated aluminum-backed 60 F254 silica plates from EMD
Chemicals, Inc. Compounds were visualized under UV fluorescence or by staining with KMnO 4.
1

H and

13

C NMR spectra were recorded at room temperature on a Bruker AV-400 or Bruker

Nanobay-400 and are reported in parts per million (ppm) on the δ scale relative to residual
CHCl3 or CH3OH in deuterated solvents or tetramethylsilane as an internal standard. Coupling
constants (J) are reported in Hertz (Hz). High resolution mass spectrometry (HRMS) was carried
out using an Agilent 6210 electrospray ionization-time-of-flight (ESI-TOF) mass spectrometer.
5.7.1 Procedures

Scheme 5.8: Synthesis of compound 184
Methyl 4-hydroxybenzoate (184).11 Concentrated H2SO4 (0.5 mL) was added to a suspension of
4-hydroxybenzoic acid (183) (500 mg, 3.62 mmol, 1.0 equiv.) in MeOH (3.3 mL), and the
solution was heated at reflux for 1 h. After cooling to rt, aq. 1M NaOH (~2-3 mL) was added to
neutralize the solution. The mixture was allowed to stand for 15 minutes to allow for maximum
precipitation. The mixture was poured into a beaker, where cool water (0 °C) for a total volume
of 85 mL. The colorless precipitate was collected by filtration was filtered and dried to give
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methyl 4-hydroxybenzoate (343 mg, 62%). Additional product was recovered by extracting the
aqueous solution with EtOAc (3 x 20 mL). The organic extracts were combined, dried over
MgSO4, filtered, and concentrated to give a combined yield of 413 mg (75%). Rf 0.15 (3:1
Hexanes-EtOAc). 1H-NMR (400 MHz, CD3OD) δ 3.84 (s, 3H, OMe), 6.82 (d, J = 8.6 Hz, 2H, Ar-H),
7.87 (d, J = 8.6 Hz, 2H, Ar-H);

13

C-NMR (100 MHz, CD3OD) δ 50.8, 114.7, 120.8, 131.3, 162.1,

167.3.

Scheme 5.9: Synthesis of compound 186
Aryl prenyl ether (185).12 A solution of LiOH (0.44 mg,1.85 mmol, 1.8 equiv.) in H2O (1.23 mL,
1.5 M) was added to a solution of 173c (222 mg, 1.01 mmol, 1.0 equiv.) in THF/H2O (3:1, 18 mL)
and was stirred at rt overnight. Water (4.5 mL) was added, and the solution concentrated to
remove the THF. The solution was acidified to pH 6 by the dropwise addition of 1 M HCl (10 mL)
and extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine (20
mL), dried over MgSO4, filtered and concentrated. The residue was purified on silica gel eluting
with 5:1 hexanes:EtOAc

1:1 Hexanes:EtOAc to give a colorless solid (104 mg, 50%). Rf 0.15

(3:1 Hexanes-EtOAc). 1H-NMR (400 MHz, CDCl3) δ 1.53 (s, 6H, CH3x2), 5.20 (d, J = 10.8 Hz, 1H,
HC=CH2), 5.23 (d, J = 17.5 Hz, 1H, HC=CH2), 6.14 (dd, J = 17.6, 10.9 Hz, 1H, CH=CH2), 7.02 (d, J =
8.8 Hz, 2H, Ar-H), 7.98 (d, J = 8.8 Hz, 2H, Ar-H); 13C-NMR (100 MHz, CDCl3) δ 27.2, 80.4, 114.1,
119.5, 122.0, 131.7, 143.8, 161.4, 172.2.
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Scheme 5.10: Preparation of IR-780+Cl- through ion exchange chromatography
IR-780+Cl- (196).13 A glass column (1 cm diameter) was packed with 1.25 g of Amberlyst A-26.
The resin was washed with water (12.5 mL). The solvent bed was then progressively
equilibrated with H2O-MeOH mixtures, starting with 75% H2O-25% and increasing the MeOH
content in 25% increments until reaching 100% MeOH. A 1% solution of HCl in MeOH was
passed through the resin until the eluents had the same pH as the acid solution (1.3 pH). The
resin was washed with MeOH until a constant pH was observed. A solution of IR-780+I- (0.08
mmol) in 5 mL of MeOH was passed slowly through the resin with no external pressure. The
resin was washed with MeOH until all dye had eluted off the resin. The eluent was collected
and concentrated to give IR-780+I- in 95% yield. 1H-NMR (400 MHz, MeOD) δ 1.06 (t, 6H, PrCH3), 1.73 (s, 12H, CMe2), 1.89 (sext., J = 7.1 Hz, 4H, CH2CH3), 1.96 (t, J = 5.6 Hz, 2H,
CH2CH2C=CCl), 2.73 (t, J = 6.0 Hz, 4H, CH2C=CCl), 4.17 (t, J = 7.0 Hz, 4H, CH2N), 6.31 (d, J = 14.1
Hz, 2H, =CH-C=N), 7.29 (t, J = 7.3 Hz, 2H, Ar-H), 7.35 (d, J = 7.8 Hz, 2H, Ar-H), 7.43 (t, J = 7.5 Hz,
2H, Ar-H), 7.53 (d, J = 7.3 Hz, 2H, Ar-H), 8.44 (d, J = 14.1 Hz, 2H, Ar-H);

13

C-NMR (100 MHz,

CDCl3) δ 10.3, 20.5, 25.9, 27.0, 45.3, 49.3, 101.0, 111.0, 122.1, 125.2, 126.5, 128.5, 141.2, 142.3,
144.1, 149.7, 173.0.
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Integration Data
Time (in h)

p-COOH

0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
5.5

0
0.6154
1.8544
3.2763
5.217
7.5215
11.7917
16.8133
31.8337
42.1926
74.0698

m-3,5-dimethyl
p-COOMe
Ar-Ha’-Integration
0
0
0.0877
0.0559
0.151
0.1243
0.3011
0.1924
0.4722
0.2654
0.6421
0.3455
0.8008
0.4126
0.973
0.5043
1.1925
0.65
1.476
0.754
1.7034
0.8542
1.9284
0.9807

p-OMe
0
0.1597
0.1243
0.1924
0.2654
0.3455
0.4126
0.5043
0.65
0.754
0.8542
0.9807

Reference peak set at 6 for compound 185, and 1 for compounds 173b, 173c, 168 and stayed
constant
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5.7.2 1H and 13C- NMR Spectra
Compound 184 (Scheme 5.1) – 1H-NMR spectrum
4-methoxycarboxyl phenol in CDCl3 at 400 MHz
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Compound 184 (Scheme 5.1) – 13C-NMR spectrum
4-methoxycarboxyl phenol in CDCl3 at 100 MHz
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Compound 185 (Scheme 5.1) – 1H-NMR spectrum
Prenyl p-COOH phenyl ether in CDCl3 at 400 MHz
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Compound 185 (Scheme 5.1) – 13C-NMR spectrum
Prenyl p-COOH phenyl ether in CDCl3 at 100 MHz
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Compound 196 (Scheme 5.5) – 1H-NMR spectrum
[IR-780]+Cl- in MeOD at 400 MHz
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Compound 196 (Scheme 5.5) – 13C-NMR spectrum
[IR-780]+Cl- in MeOD at 100 MHz
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Compound 197 (Scheme 5.6) – 1H-NMR spectrum
[IR-780]+[Prenyl p-COOH phenyl ether]- in CDCl3 at 400 MHz
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